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The genus Brucella consists of Gram-negative, facultative intracellular coccobacilli that 
can cause chronic infections in several mammals. Brucella spp. can exhibit a smooth or 
rough phenotype; smooth Brucella spp. contain a surface-exposed O-polysaccharide in 
their cell wall structure while the rough Brucella spp. are devoid of the O-polysaccharide. 
Acquired immunity against Brucella infection is primarily cell-mediated and involves both 
CD4+ T cells and CD8+ T cell responses. However, antibodies to the O-polysaccharide also 
play a role in enhancing the protection against infections by virulent Brucella species in 
some hosts.  B. abortus strain RB51 is a stable rough attenuated mutant which is used as a 
licensed live vaccine for bovine brucellosis in theUnited States and several other countries. 
Previous studies have shown that the wboA gene, which encodes a glycosyltransferase 
required for the synthesis of O-polysaccharide in Brucella, is disrupted in B. abortus RB51 
by an IS711 element.  Although low-levels of intra-cytoplasmic O-polysaccharide were 
produced when RB51 was complemented with a functional wboA gene (strain 
RB51WboA), it did not result in a smooth phenotype. This suggests that mutations in 
several genes of the O-polysaccharide biosynthesis pathway contribute to the rough 
phenotype of RB51. However, nucleotide sequence analysis has revealed that there are no 
other gene-disrupting mutations that could affect the smooth LPS synthesis in strain RB51.   
The first part of the study was undertaken to investigate whether overexpression of two 
other glycosyltransferases, WbkA and WbkE, in strain RB51 would result in the expression 
of O-polysaccharide and restore the smooth phenotype. No O-polysaccharide expression 




(strain RB51WbkA) leads to the development of extremely mucoid bacterial colonies that 
form clumps/strings in liquid culture. This mucoid phenotype is attributed to the production 
of exopolysaccharide(s) containing mannose, galactose, N-acetylglucosamine and N-
acetylgalactosamine. The clumping RB51WbkA strain exhibited increased adherence to 
polystyrene matrices; however, it was similar to strain RB51 in its attenuation characteristic 
and conferred a similar level of protection against virulent B. abortus 2308 as strain RB51. 
The second part of the study was carried out to determine whether increasing the amount 
of bactoprenol primed molecules in strain RB51WboA would lead to the expression of 
higher levels of O-polysaccharide and confer it a smooth phenotype. We generated strain 
RB51WboAKF by overexpressing wbkF gene, which encodes undecaprenyl-
glycosyltransferase involved in bactoprenol priming for subsequent O-polysaccharide 
polymerization, in strain RB51WboA. Strain RB51WboAKF expressed high levels of O-
polysaccharide and its Western blot reactivity profile with the O-polysaccharide-specific 
monoclonal antibody was similar to that of the smooth Brucella strains. Immunoelectron 
microscopy revealed that the O-polysaccharide was pre ent mostly on the bacterial cell 
surface. However, RB51WboAKF strain exhibited rough phenotypic characteristic in 
acriflavine agglutination test.  Although there was no difference between strains RB51 and 
RB51WboAKF in their ability to persist in spleens of BALB/c mice, strain RB51WboAKF 
was more resistant to the bactericidal effect of polymyxin B. Mice immunized with strain 
RB51WboAKF developed increased levels of smooth LPS-specific serum antibodies, 
primarily of IgG2a and IgG3 type, when compared with those immunized with strain 
RB51WboA. Levels of serum IL-12p70, IFN-γ and IL-10 were higher in mice immunized 
with strain RB51WboAKF when compared to the mice immunized with strain RB51. 
Splenocytes from the RB51WboAKF vaccinated group of mice secreted higher levels of 
antigen-specific IFN-γ, IL-10 and TNF-α when compared to those of the RB51 or 
RB51WboA vaccinated groups. Also, increased numbers of antigen-specific IFN-γ 
secreting CD4+ and CD8+ T lymphocytes were detected in RB51WboAKF immunized 
mice. Importantly, immunization of mice with strain RB51WboAKF conferred greater 
protection against virulent B. abortus 2308 and B. melitensis 16M than immunization with 




Human brucellosis is one of the most frequently encou tered zoonotic diseases worldwide. 
It is a major public health concern in several developing, Brucella-endemic countries. 
Occupational exposure and consumption of infected dairy and meat products are the main 
routes for human infection. B. abortus, B. melitensis, and B. suis are the most frequent 
causes of disease in humans. These Brucella spp. are considered as potential weapons of 
biowarfare and are categorized by the CDC as Category B select agents. Emergence of new 
foci of zoonotic Brucella spp. around the world has significantly changed the global map 
of human brucellosis. Currently, there is no brucellosis vaccine available for use in humans. 
Safety concerns preclude the use of live attenuated nimal vaccine strains for human 
vaccination. 
The final part of the study was conducted to test the ability of orally inoculated gamma-
irradiated strains B. neotomae and B. abortus RB51 in a prime-boost immunization 
approach to induce mucosal as well as systemic protecti n against virulent B. abortus 2308. 
Heterologous prime-boost vaccination regimens and homologous prime-boost vaccination 
of mice with B. neotomae led to the production of serum and mucosal antibodies specific 
to the smooth LPS. All oral vaccines induced antige-specific CD4+ and CD8+ T cells 
capable of secreting IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated 
with B. neotomae showed the highest level of resistance against virulent B. abortus 2308 
colonization in spleen and liver. Experiments with vaccination with different doses of B.
neotomae showed that all tested doses of 109, 1010 and 1011 CFU-equivalent conferred 
significant protection against the intra-peritoneal challenge. However, only the highest 
tested dose of 1011 CFU-equivalent of B. neotomae afforded protection against intranasal 
challenge.  
Overall, the present research discovered that gene wbkA is involved in 
exopolysachharide(s) production in Brucella spp. and adds to the growing evidence for the 
exopolysaccharide synthesis in Brucella. Also, our studies show that the vaccine efficacy 
of strain RB51 can be enhanced by inducing high levels of O-polysaccharide expression; 
the recombinant strain RB51WboAKF can be a more efficacious vaccine than its parent 




gamma-irradiated B. neotomae as an effective and safe oral vaccine to induce mucosal and 





Bacteria belonging to the genus Brucella are Gram-negative, facultative intracellular, non-
motile, non-encapsulated, non-spore forming aerobic co cobacilli that can cause 
brucellosis in several mammals, including humans. Brucella species are transmitted by 
direct contact with infected animal tissues and fluids or consumption of contaminated dairy 
and meat products. In natural animal hosts, Brucella spp. primarily target tissues of the 
reproductive tract and can cause abortion and infert lity [1]. Till date, several species of 
Brucella have been identified and are classified based on, primarily, their host preference. 
Except for B. canis and B. ovis, all other Brucella species known to date possess an O-
polysaccharide (O-PS) in their lipopolysaccharide (LPS) moiety and exhibit a smooth 
colony phenotype. Rough strains that are devoid of the O-PS in their LPS are generally 
attenuated than their smooth counterparts [2,3]. In the infected host, Brucella replicates 
within the phagosomes of macrophage-monocyte lineage cells. Despite the intricacy of 
microbicidal functions of professional phagocytes, Brucella possesses the ability to 
circumvent host defense mechanisms and ultimately acquire a replication-permissive niche 
by influencing the host intra-cellular vesicular pathway [4]. The ability of Brucella spp. to 
persist within host tissues is critical as natural tr nsmission of Brucella only occurs once 
or twice annually during mating and parturition [5]. Interestingly, Brucella species lack 
classical bacterial virulence factors such as exotoxins, capsules, flagella, fimbriae, 
plasmids, lysogenic bacteriophages, antigenic variation and endotoxic LPS [6]. Instead, 
Brucella expresses a set of virulence factors, including a non-classical LPS molecule, 
which contribute to the establishment of chronic infections [4, 7]. Chapter 1 of this 
dissertation includes a review of the virulence determinants of Brucella and how they 




According to the World Health Organization (WHO), brucellosis is one of the most 
frequently encountered zoonosis worldwide [8]. Countries of the Mediterranean basin, 
Middle East, Central Asia, South America and Africa have a high prevalence of brucellosis 
[8]. Occupational exposure and consumption of contamin ted food products are the main 
routes of human infection. Most of the naturally occurring human infections are caused by 
B. melitensis, B. abortus and B. suis.  A few human brucellosis cases are caused by B. canis 
that is associated with brucellosis in dogs [9]. Due to their highly infectious nature and ease 
of aerosol spread, B. melitensis, B. suis and B. abortus are considered as potential 
bioweapons and classified as Class B select agents by he Center for Disease Control 
(CDC) [9]. Infected humans exhibit flu-like symptoms including general malaise, anorexia, 
headache, myalgia, arthralgia, fever. If left untrea ed, the infection can lead to a chronic 
disease and in rare cases complications like endocar itis, meningitis and spondylitis can 
occur [9]. Successful treatment of human disease reli s on a prolonged therapy with a 
combination of antibiotics (usually an aminoglycoside or rifampicin and tetracycline); 
however, relapses are common [10,11]. There is no brucellosis vaccine available for use in 
humans.  
Humans are dead-end hosts of Brucella; a reduction in animal brucellosis prevalence will
result in a substantially reduced number of human infections. Through concerted 
comprehensive efforts, several countries including the United States, Canada and parts of 
Europe have succeeded in controlling brucellosis in domestic livestock and are considered 
to be ‘brucellosis-free’ [8]. However, there is a constant threat of Brucella re-introduction 
due to spillback from wild life reservoirs. Also, worldwide emergence of new foci of 
human brucellosis has made Brucella eradication difficult [12].  Human brucellosis 
remains a major public health concern in several developing countries that still suffer with 
a huge disease burden in animals and humans [13]. Due to differences in livestock 
production systems as well as economic and social constraints, control measures that are 
effective in developed countries may not be implementable in developing countries. For 
this reason, vaccination is considered to be the most c st-effective intervention to control 
disease spread and limit its severity [14]. Currently, live attenuated vaccines are used to 




used for vaccinating sheep and goats, and cattle, respectively [15,16]. However, these 
strains exhibit some abortifacient potential in pregnant animals and are virulent for humans 
[17]. A rough strain B. abortus RB51 is used as a licensed vaccine for cattle in the United 
States and several other countries. It is a stable, att nuated, spontaneous mutant of the 
virulent strain B. abortus 2308 [18]. Nevertheless, this vaccine is only 70% efficacious in 
cattle and its efficacy in pigs, sheep and goats is questionable [19-21]. Safety concerns 
preclude the use of these live attenuated strains for human use. A human vaccine would be 
valuable as a means of direct intervention in areas where natural infections are very high 
or in the event of deliberate misuse of Brucella as a bioweapon. Previously, numerous 
attempts were made to vaccinate humans with live att nuated strains and ‘non-living’ 
subcellular fractions in the former USSR, China andFrance [22-24]. However, the use of 
these vaccines was discontinued on account of safety issues and lack of substantial 
evidence of their efficacy from large, well-controlled clinical trials [25]. A concise history 
of human vaccination and strategies that need to be incorporated in any future efforts to 
develop a safe and effective vaccine against human brucellosis are discussed in Chapter 2. 
Despite the availability of live attenuated vaccines for ruminants, there is a need for 
developing a new generation of improved vaccines. A afe vaccine that can provide long-
lasting protection in multiple animal species would be ideal for controlling brucellosis. 
Several previous studies have demonstrated that exposure to an optimum dose of gamma-
rays can enhance the safety of the current live Brucella vaccine strains by abolishing the 
replicative ability of the bacteria [26-28]. Minimu exposure to gamma-rays creates 
sufficient number of breaks in the genome that makes th  bacteria unable to replicate but 
still contain a large portion of the genomic nuclei acid intact for transcriptional and 
translational activity [26-28]. This ensures the downstream effectiveness of elicited host 
immune responses against the expressed proteins of the pathogen. Gamma-irradiated 
vaccines are metabolically active [29]; metabolic activity is a potential pathogen-associated 
molecular pattern (PAMP) that is associated with microbial viability (vita-PAMP) and is 
exploited by the host defense system to differentiate viable pathogens from killed 
pathogens [30]. vita-PAMP signal allows the host defense system to scale the level of 




Hence, while possessing the safety profile of killed vaccines, gamma-irradiated vaccines 
are capable of inducing protection at levels comparable to live vaccination strategies [26-
28]. A review of the role of gamma-rays in the development of replication-deficient safer 
vaccines that stimulate effective protection is presented in Chapter 3. 
Cell-mediated immune responses play a major role in acquired immunity against Brucella. 
In particular, IFN-γ-secreting CD4+ and CD8+ T lymphocytes are crucial for controlling 
Brucella infection [32,33]. At least in certain animal species, O-PS-specific antibodies also 
participate in protection against B. melitensis, B. abortus and B. suis infection [34-37]. In 
contrast to smooth vaccines Rev 1 and S19, the rough vaccine strain RB51 does not induce 
detectable levels of anti-O-PS antibodies in the vaccinated hosts [18]. Previous studies have 
demonstrated that wboA gene, which encodes a glycosyltransferase required for O-PS 
synthesis in Brucella, is disrupted by an IS711 element in strain RB51 [38]. Absence of O-
PS-specific antibodies prevent the development of cross-reacting immune responses in the 
serodiagnostic assays that are used for distinguishing infected animals from vaccinated 
animals (DIVA strategy). However, the absence of O-PS and the rough LPS make strain 
RB51 more sensitive to complement-mediated lysis, limiting its persistence in the host and 
vaccine efficacy [39,40]. Complementation of RB51 with a functional wboA gene (strain 
RB51WboA) did not restore the smooth phenotype but resulted in low levels of 
cytoplasmic O-PS expression [41]. When compared with strain RB51, immunization of 
mice with RB51WboA resulted in a superior level of protection against virulent B. abortus 
2308 and B. melitensis 16M [41,42]. Several genes in the wbk and wbo genetic loci are 
shown to be essential for the O-PS synthesis in Brucella [2,3]. The objectives of the studies 
in Chapters 4 and 5 were to enhance the vaccine efficacy of strain RB51 through 
recombinant engineering to induce high levels of O-PS expression.  To achieve this, we 
overexpressed selected genes of the O-PS biosynthetic pathway in strain RB51 by 
transforming RB51 with a multi copy plasmid containing the specific Brucella gene under 
a strong synthetic promoter. We hypothesized that such recombinant vaccines would 
possess enhanced protective efficacy when compared with strain RB51 due to their ability 
to stimulate O-PS-specific antibodies in the vaccinated animals. Studies to determine 




would result in the synthesis of O-PS and confer it a smooth phenotype are described in 
Chapter 4. The studies in Chapter 5 were carried out to determine whether increasing the 
amount of bactoprenol priming precursor molecules in train RB51WboA would increase 
the level of O-PS expression and result in smooth phenotype of the recombinant bacteria. 
For this purpose, we overexpressed wbkF, which is involved in priming bactoprenol for O-
PS polymerization [2,3], in strain RB51WboA. Also, the immunogenicity and the 
protective efficacy of the constructed strain was evaluated in the mouse model of 
brucellosis. 
The studies in Chapter 6 were aimed at developing an or l vaccine against brucellosis for 
use in humans. Brucella infection is generally acquired through mucosal routes; however, 
human brucellosis is a systemic disease. Accordingly, it is important that an effective oral 
vaccine should induce both mucosal and systemic immunity. Oral vaccines have proved 
effective in providing protection against diseases like typhoid [43] and polio [44]. An 
attenuated Salmonella enterica serovar Typhi strain, which is used as a licensed oral
vaccine against typhoid fever in humans, requires 4 doses to be taken at prescribed alternate 
day intervals [45]. Using a similar empirical selection, experiments in Chapter 6 were 
conducted to identify the optimum prime-boost vaccine-dose approach that would afford 
the highest level of protection against parenteral as well as mucosal challenge with virulent 
Brucella. Most research pertaining to prime-boost approach has been directed towards the 
assessment of DNA vaccines, viruses or purified proteins as immunogens. However, it is 
well accepted that vaccines that mimic the antigenicity of live infectious organisms have 
greater likelihood to possess better protective efficacy as they would be able to stimulate 
all facets of the immune system. Therefore, we used gamma-irradiated strains B. abortus 
RB51 and B. neotomae in various prime-boost combinations and assessed the induction of 
mucosal and systemic immunity. Previous studies have demonstrated that intra-peritoneal 
(i.p) vaccination with gamma-irradiated RB51 or gamma-irradiated B. neotomae protects 
mice against i.p challenge with virulent Brucella species [28,29]. In general, parenteral 
vaccination strategies do not afford protection at mucosal surfaces [46]. We hypothesized 
that oral delivery of gamma-irradiated Brucella strains would prime the host immune 




protection at both sites. Inducing a robust mucosal immunity would enhance resistance to 
brucellosis by limiting bacterial invasion through the primary route of infection.  
The final Chapter 7 summarizes the conclusions of the present research and discusses their 
implications. Also, potential areas of future work are discussed. Overall, the present 
research provides evidence that vaccination with recombinant Brucella abortus RB51 
strain engineered to express increased levels of O-PS provides enhanced protection against 
virulent Brucella challenge. Also, it demonstrates the feasibility of using gamma-irradiated 
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CHAPTER 1. BRUCELLA AND ITS VIRULENCE DETERMINANTS 
Abstract 
Members of the bacterial genus Brucella are facultative intracellular pathogens that resid 
predominantly within macrophages of infected hosts. The capacity of Brucella to persist 
within the phagosomes of macrophages is critical to their ability to produce chronic 
infections in their mammalian hosts. Within macrophages, Brucella species regulate their 
intracellular trafficking to avoid degradation along the endocytic pathway. A precise 
sequence of programmed intracellular events allow Brucella to efficiently subvert host 
defense mechanisms and create a niche that permits replication while protecting them from 
microbicidal functions of host cells. This sophistica ed lifestyle of Brucella is strongly 
dependent on the expression of several bacterial factors that are crucial to its protracted 
survival within the host system. In this chapter, we review the virulence determinants of 
Brucella and how they contribute to its pathogenicity.  
 
Introduction 
Brucella genus belongs to the α-2 subclass of the Proteobacteria that also includes several 
other phylogenetically related plant pathogens, symbionts and intracellular animal 
pathogens such as Bartonella. Brucella spp. are Gram-negative, aerobic, non-motile, 
nonsporulating, facultative intracellular coccobacilli that primarily replicate in the 
monocyte-macrophage lineage of host cells. They are the causative agents of brucellosis, 




replicates in placental trophoblasts leading to frequent contagious abortions [1]. 
Transmission of Brucella occurs through direct contact with contaminated aborted fetal 
tissues or consumption of contaminated meat and dairy products. Human brucellosis is 
strictly a zoonotic disease; the incidence of human disease is dependent on the prevalence 
of animal brucellosis.  
The genus Brucella is classified into several species based on their host preference. Natural 
hosts for Brucella species are: cattle (B. abortus), sheep and goats (B. melitensis), swine 
(B. suis), dogs (B. canis), rams (B. ovis), desert wood rats (B. neotomae), seals (B. ceti), 
dolphins, porpoises and whales (B. pinnipedialis) and common voles (B. microti) [2]. More 
recently, Brucella has been isolated from baboons (B. papionis), Australian rodents, and 
an infected breast implant (B. inopinata) [3,4,5]. Due to their highly infectious nature and 
the ease of aerosol spread, B. melitensis, B. suis, and B. abortus are considered as potential 
biowarfare agents and are classified as Class B pathogens by the Centers of Disease Control 
(CDC).  
Brucella lacks the well-known classical bacterial virulence factors such as capsules, 
exotoxins, lysogenic bacteriophages, plasmids, flagel , fimbriae, antigenic variation and 
endotoxic LPS [6]. The virulence of Brucella relies on its ability to modulate its trafficking 
within host cells to avoid the formation of a degradative phagolysosome. Bacterial factors, 
such as lipopolysaccharide (LPS) [7], type IV secretion system (T4SS) [8], and the 
BvrR/BvrS two-component system [9] are essential for the intracellular lifestyle of 
Brucella and therefore, they are considered as virulence fators of these pathogens.  
Although these virulence determinants may not directly mediate clinical symptoms of 
brucellosis, they have been identified to be critical for Brucella to survive and replicate in 
the vacuolar phagocytic compartment of macrophages. Thi  chapter reviews the molecular 
mechanisms underlying intracellular trafficking of Brucella and the virulence factors that 





Invasion and intracellular trafficking of Brucella in phagocytic cells 
Brucella are mostly transmitted through mucosal routes, especially at the respiratory and 
the gastrointestinal surfaces. The bacteria are eventually taken up by phagocytic cells lying 
underneath the submucosa. Previous studies have shown t at macrophages ingest Brucella 
through ‘zipper-like’ phagocytosis [10]. Opsonized Brucella are internalized via 
complement or Fc receptors while non-opsonized smooth bacteria exploit lipid rafts and 
some other unidentified receptors to enter macrophages [11,12,13]. Mechanism of cell-
invasion is linked to bacterial fate; opsonized Brucella employ lipid raft-independent entry 
and are preferentially degraded in macrophages [13].
Upon internalization, surviving bacteria are found within Brucella-containing vacuoles 
(BCVs).  The bacteria in BCV modulates the vesicle trafficking to reach endoplasmic 
reticulum (ER)-derived vacuole which is the replicative niche for Brucella (Fig. 1.1). 
During the first few minutes after cellular invasion, BCV undergoes a series of transient 
interactions with components of the endosomal pathwy. Interaction with early endosomes 
is confirmed by the presence of early endosomal antige  1 (EEA 1), transferrin receptor 
and small GTP binding protein Rab5 in the BCV (Fig. 1.1) [14]. BCVs also interact with 
late endosomes and lysosomes. These interactions are transient and occur prior to the 
interactions of BCV with ER membranes and the formation of a replication-permissive 
compartment. Presence of CD63, Rab7-interacting lysosomal protein (RILP), lysosomal-
associated membrane protein 1 (LAMP-1) and small GTPase Rab7 in BCV is suggestive 
of its interaction with late endosomes/lysosomes (Fig. 1.1) [15]. At this point, unlike killed 
Brucella, live Brucella spp. limit interaction of their vacuoles with the lysosomes, possibly 
to avoid accumulating degradative contents to bactericidal levels [15]. These vacuole 
maturation steps take up to 12 hrs to be completed aft r which BCVs transform into ER-
derived replicative organelles. Sustained interaction of BCVs with ER leads to the 
progressive loss of LAMP-1 and acquisition of ER-specific markers including calreticulin 
(Fig. 1.1) [14,16,17].  
The formation of ER-derived replicative organelle depends on the interaction of BCV with 




initiated at ER-exit sites (ERES), where transport vesicle formation is mediated by the coat 
complex II (COPII). The organization and functionality of ERES domains are regulated by 
small GTPase Sar1 [18]. Subsequent protein transport requires the activity of ADP-
ribosylation factor 1 (ARF1) which recruits components of COPI to the ER membranes 
[19]. A previous study by Celli et al. demonstrates hat BCV interacts with ERES and 
disruption of ERES by inhibiting Sar1 activity impairs Brucella replication; however, 
inhibition of Arf1 activity had no effect on the ability of BCVs to mature into replicative 
organelles [17]. 
 
Virulence factors of Brucella 
Persistent infection is an adaptation that Brucella needs to evade the host defense system 
until transmission can occur. Brucella spp. rely on several virulence factors that contribu e 
to disarming the host macrophages and ensuring Brucella survival. Knowledge of these 
factors has significantly enhanced our understanding of how Brucella directs its 




LPS of Brucella is composed of three components: lipid A, a core oligosaccharide and an 
O-polysaccharide (O-PS). Lipid A forms the hydrophobic anchor of the LPS while O-PS 
extends into the extracellular environment. LPS is one of the major virulence factors of 
Brucella [7]. Based on the LPS structure, Brucella spp. can be separated into smooth and 
rough strains. Smooth strains possess O-PS in their LPS moiety while strains that are 
devoid of O-PS exhibit a rough phenotype. O-PS of Brucella confers serum and 
complement resistance and it is also involved in protecting Brucella against microbicidal 




their rough counterparts [20]. However, B. canis and B. ovis are rough species that are 
virulent in their natural hosts [20].  
 
Genetics of Brucella O-PS biosynthesis 
The biosynthetic pathway of smooth LPS of Brucella has not yet been fully characterized. 
However, several genes have been found to be essential for the synthesis of O-PS. These 
genes are located on two genetic loci, wbk and wbo, of Brucella chromosome I (Fig. 1.2) 
[21].  Region wbo contains two genes, wboA and wboB, encoding glycosyltransferases 
while region wbk contains genes involved in synthesis of perosamine (gmd and per), its 
formylation (wbkC) and polymerization (wbkA and wbkE), its translocation (wzm and wzt) 
as well as those for bactoprenol priming (wbkD and wbkF) (Fig. 1.2) [21]. wbk also contains 
genes encoding products that furnish the perosamine precursor, mannose [21]. Brucella O-
PS is first assembled onto bactoprenol phosphate on he cytoplasmic face of inner bacterial 
membrane, following which it is translocated across the inner membrane. This 
translocation event is mediated by an ATP-binding cassette (ABC) transporter system [20]. 
Mutations in genes that are required for the synthesis of perosamine or bactoprenol-P-P-
NAc-aminosugars also affect the synthesis of O-PS (Fig. 1.2) [20]. Using transposon 
mutagenesis, Gonzales et al. demonstrated that mutaions in 13 genes (wa** , wbkE, wbkA, 
gmd, per, wzm, wbkF, wbkD, prm, ManBcore, wboA, wboB and manB) conferred a rough 
phenotype to B. melitensis [20]. They also found that wboA and wboB genes are absent in 
B. ovis genome contributing to its rough phenotype [20,21]. B. canis, on the other hand, 
was found to have disruptions in wbkF (encodes undecaprenyl-glycosyltransferase) and 
wbkD (encodes epimerase/dehydratase) genes, both of which are required for O-PS 
synthesis [20,21].  
  
Function of smooth LPS during Brucella infection 
The LPS of Brucella is non-classical when compared with the classical LPS moiety of 
enterobacterial species. The endotoxin component of Brucella LPS, lipid A, has several 




Brucella lipid A contains a diaminoglucose backbone (rather an glucosamine) and long 
chain fatty acids C28 (instead of C18-C19) [22]. Due to the difference in lipid A 
composition, Brucella LPS is several hundred times less toxic than E. coli LPS [23]. It is 
a poor inducer of respiratory burst, reactive nitrogen intermediates as well as lysozyme 
[24,25]. Also, it is poorly recognized by the innate immune sensor Toll-like receptor (TLR) 
4 and it does not induce the secretion of pro-inflammatory cytokines by infected host cells, 
thereby evading host immune responses [23].  The presence of long-chain fatty acids in 
lipid A also contributes to the reduced activity of Brucella LPS in inducing inflammatory 
responses [26]. Also, smooth Brucella LPS impairs host cells from activating Brucella-
antigen-specific adaptive immune responses. It forms large clusters or macrodomains with 
MHC-II and interferes with antigen presentation to host CD4+ T cells [27]. 
Smooth Brucella LPS also plays a role in lipid-raft mediated entry into host cells. Brucella 
strains lacking O-PS enter macrophages in a lipid-raft independent manner and are targeted 
to lysosomes for degradation [28]. The BCVs containing O-PS deficient strains fuse more 
rapidly with lysosomes when compared with BCVs containing heat-killed smooth Brucella 
[28], indicating that O-PS is essential for the intracellular trafficking of Brucella. It is 
possible that Brucella is able to exploit a survival-permissive entry only when its O-PS 
interacts with particular receptor(s) associated with lipid-rafts or alternatively, the O-PS 
might modify the fusogenic properties of the BCV membrane [29].  
 
Brucella Type IV secretion system (T4SS) 
Type IV secretion systems (T4SS) are membrane-associ ted transporter complexes which 
are closely related to bacterial conjugation system. They are present in many Gram-
negative bacteria including Agrobacterium tumefaciens, Legionella pneumophila and 
Helicobacter pylori.  T4SSs mediate the secretion of multimeric protein toxins, monomeric 
proteins and nucleoprotein complexes.  Hence, they ar  extremely versatile (unlike other 
secretion systems) in the choice of the secreted substrate and also the target-cell types, 
which can be bacteria (same/different species), fungi, plants or mammalian cells [30-32]. 




mediate DNA uptake and subsequent release into the extracellular milieu. Moreover, T4SS 
is involved in the conjugative transfer of plasmid DNA and transposons into a variety of 
bacterial species. This genetic exchange helps the bacteria to adapt to the changes in the 
host during infection while the delivery of effectors into target cells aids in suppressing the 
host defense system thereby allowing the bacteria to replicate and persist.  
 
Architecture of Brucella T4SS 
T4SS of Brucella is encoded by virB operon which consists of 12 genes: virB1 to virB12. 
Brucella T4SS is not yet fully characterized; however, much has been inferred from the 
similarity of Brucella VirB proteins to components of T4SS in bacteria likeAgrobacterium 
tumefaciens [8]. Proteins VirB8, VirB9 and VirB10 interact with each other to form the 
core structure that spans the outer and inner membrane of bacterium [8,33-35]. VirB6 and 
VirB7 might act to stabilize the core structure [36,37] while the ATPase, which consists of 
VirB4 and VirB11, provides energy for the assembly of the T4SS as well as for the delivery 
of effector proteins [38,39]. VirB2 and VirB5 form the pilus while VirB3 mediates the 
assembly of the pilus [40]. The effectors are translocated to the eukaryotic target cell 
through the pilus. Previous studies have shown that virB1, virB7 and virB12 are not 
essential for the enhanced persistence of B. abortus [41-43]. The encoded proteins VirB1, 
VirB7 and VirB12 do not contribute to the structure of the core complex or the pilus in any 
bacteria containing the T4SS and might be dispensable for the function of T4SS [43,44].  
 
Function of T4SS during Brucella infection 
Brucella strains lacking a functional T4SS are attenuated in macrophages as well as in 
laboratory and natural host animals [8,45,46]. Brucella virB mutants are incapable of 
preventing the fusion of phagosomes with lysosomes and are gradually cleared from the 
host [47]. Although phagosomes containing wild-type Brucella do transiently fuse with 
early and late endosomes and lysosomes, they restrict this interaction to avoid the 
formation of phagolysosomes and subsequent degradation [15]. This transient fusion with 




phagosomes; acidification is essential for the induction of expression of the virB genes. It 
has been observed that wild-type Brucella are able to rescue the survival of virB mutants 
[48] indicating that T4SS-intact Brucella secrete effectors that are translocated into the 
cells containing virB mutants. 
 
Regulation of Brucella T4SS 
virB T4SS is induced in acidic pH and also in nutrient r s ricted conditions [49,50]. Three 
regulators are involved in the induction of T4SS under nutrient starvation. They include 
the stringent response regulator Rsh, integration hst factor (IHF) and the histidine 
utilization regulator HutC [51,52]. Also, two LuxR family regulators, VjbR (Vacuolar 
jacking Brucella regulator) and BabR (Brucella abortus regulator), modulate the 
expression of virB genes [53,54]. Both VjbR and BabR control the exprssion of genes 
involved in virulence, stress response, metabolism and replication; however, they act in the 
opposite manner [54-56]. It is possible that the activity of these regulators helps Brucella 
to adapt in nutrient-limitied conditions after host cell infection until the formation of an 
ER-derived replication-permissive vacuole [14]. At this stage, VjbR is turned off while 
BabR is activated [55]. BabR represses T4SS activity and enables Brucella to replicate in 
the ER-derived vacuole [14]. 
 
Effectors translocated by Brucella T4SS 
Unlike Bartonella, the genes encoding the effector molecules in Brucella are not co-located 
with the virB genes [57]. Thus, identification of effector proteins translocated through the 
T4SS in Brucella has been a formidable task. Till date, only a few effector proteins have 
been identified. 
The first two T4SS effectors identified were virB-coregulated effectors A and C (VceA and 
VceC) [58]. These effectors were identified in a screen for VjbR-activated promoters of 
genes that are co-regulated with virB genes. Translocation of VceA and VceC was found 
to be dependent on VirB as demonstrated by generatig fusions of the effectors to TEM-1 




infection which is consistent with the time of phagosomal acidification and induction of 
T4SS. Legionella pneumophila Dot/Icm system was also able to translocate B. suis VceC 
indicating that the secretion mechanisms are conserved to some extent [58]. A more recent 
study has shown that VceC induces ER stress and secretion of proinflammatory cytokines 
[59]. 
Translocation of four other effector proteins (BPE123, BPE005, BPE275 and BPE043) was 
found to be dependent on VirB T4SS [60]. They were identified by screening for proteins 
for eukaryotic-like domains or domains that participate in protein-protein interactions [60]. 
Their intracellular functions are still unknown. Also, Rab2-interacting conserved protein 
(RicA), another effector translocated by T4SS, was identified by a yeast two-hybrid 
screening assay for Brucella proteins that potentially interact with host proteins [61]. RicA 
binds preferentially to GDP-bound Rab2 and is involved in recruiting Rab2 GTPase to the 
Brucella-containing phagosome. The recruitment of Rab2 to BCV is considered crucial for 
the sustained interactions of Brucella with ER by intercepting secretory vesicles [61]. 
Hence, Rab2 is essential for the intracellular replication and trafficking of Brucella [62]. 
However, ricA deletion mutant is not attenuated in virulence even though blocking Rab2 
leads to inhibition of intracellular replication ofBrucella [61]. This indicates that several 
additional proteins might play a redundant role in the serial recruitment of eukaryotic 
factors during the maturation of the BCV.  
More recently, the translocation of 5 effector proteins (BspA, BspB, BspC, BspE, BspF) 
has been demonstrated to be dependent on VirB T4SS [63]. Among them, BspA, BspB and 
BspF inhibit the host protein secretion by impairing the vesicular cargo transport from ER 
to the Golgi apparatus [63]. Mutation in these three g nes (bspA, bspB and bspF) affect the 
ability to replicate and persist within host cells [63]. 
 
Quorum sensing in Brucella 
Quorum sensing (QS) is the regulation of gene expression in response to small diffusible 
chemical signaling molecules, autoinducers, which are produced and secreted by bacteria. 




density. The detection of a minimal threshold concentration of these signaling molecules 
leads to modulation in gene expression. This sensing system is used both by Gram-positive 
as well as Gram-negative bacteria to regulate diverse processes including virulence, 
biofilm formation, conjugation, and antibiotic production etc. In general, Gram-negative 
bacteria use N-acyl homoserine lactone (AHL) to communicate, and Gram-positive 
bacteria use processed oligo-peptides as autoinducig molecules [64]. The ability of the 
bacteria to communicate with each other allows them to coordinate gene expression and 
therefore the behavior of the overall population. 
AHL based QS requires an AHL synthase and a target t anscriptional regulator that can 
recognize the AHL molecules and alter the expression of target genes. The autoinducer in 
Brucella was identified to be N-dodecanoylhomoserine lactone (C12-HSL) in the 
supernatants of B. melitensis culture [56,65]. However, the concentration of C12-HSL in 
Brucella culture supernatant was found to be low. It might be that the in vivo AHL 
production is much higher than i  vitro production, or alternatively, the hydrophobic long-
chain AHLs interact with the Brucella membrane leading to a lowered concentration in the 
culture supernatant. Attempts to identify an AHL synthase in Brucella have not yielded 
any promising results.  
Two bonafide QS regulators in Brucella are VjbR and BabR [53,54]. They both contain an 
AHL binding domain as well as a C-terminal HTH (helix turn helix) DNA binding domain. 
vjbR mutants are attenuated and unable to reach their ER-derived replicative vacuole [14]. 
As discussed above, VjbR is required for vi B expression. Previous experiments have 
demonstrated that addition of exogenous C12-HSL impairs Brucella trafficking to its 
replicative vacuole. Also, C12-HSL decreases the production of VirB8 by repressing the 
transcription from virB promoter. C12-HSL-mediated repression of virB genes is through 
its inhibitory effect on VjbR [55,56]. In contrast, C12-HSL has an activating effect on BabR 
[55,56]. Previous transcriptomic studies and qRT-PCR analysis suggest that there is cross-
talk between VjbR and BabR; significant overlap exists between VjbR- and BabR-
regulated genes [55,56]. However, comparative studies indicate that the loss of VjbR has 
a more pronounced effect on Brucella virulence when compared to the loss of BabR 




The two-component BvrR/BvrS system in Brucella 
Most prokaryotic signal transduction units consist of wo components: a histidine kinase 
that senses the environmental alterations and a response regulator protein. The histidine 
protein kinase autophosphorylates at a conserved histidine residue creating a high energy 
phosphoryl group that subsequently phosphorylates a conserved aspartate residue in the 
response regulator protein. This phosphorylation induces activation of factors that interact 
with specific DNA sequences to affect gene expression. In this way, two-component 
systems control the response of bacteria to a number of stimuli that regulate important cell 
functions including response to stress and virulence [66]. 
BvrR/BvrS (Bvr: Brucella virulence related) is one of the best characterized two-
component system in Brucella. Mutants in this system are highly attenuated and sensitive 
to the bactericidal action of polycations including polymyxin and also to non-immune 
human and cattle sera. The bvrS mutant is unable to recruit the small GTPases that are 
required for polymerization of actin and subsequent cell invasion [67]. The BvrR/BvrS 
system also regulates intracellular trafficking of Brucella as the mutant strains are 
incapable of replicating in macrophages and epithelial cells; they are unable to avoid the 
formation of phagolysosomes and are cleared from the host in less than 12 days [68].  
Numerous genes are subject to BvrR/BvrS regulation: some examples include genes 
encoding specific outer membrane proteins (Omp3a and Omp3b), lipoproteins, 
glycosyltransferases, ABC-type transport system, genes required for biosynthesis of fatty 
acids and flagellum, genes involved in the Krebs cycle and metabolism of amino acids, 
fatty acids and nitrogen [9,69]. All these genes are differentially expressed in the bvrR 
mutant. Also, seven transcriptional regulators including VjbR are differentially regulated 
in the bvrR mutant. BvrR/BvrS system regulates the expression of VirB at the 
transcriptional level and also directly controls thevjbR expression [70]. Hence, BvrR/BvrS 
is a master system that interacts with other regulators to alter the expression of genes 
involved in synthesis of the cell envelope, metabolism and virulence-related genes and 




Other virulence factors that contribute to Brucella survival and replication 
Brucella resistance to the microbicidal activity of phagosomes 
Several virulence factors of Brucella are involved in enhancing the resistance to the 
microbicidal host defenses. Microbicidal function of professional phagocytes relies in part 
on the reactive oxygen species (ROS) which are generated either directly or indirectly by 
NOX2 NADPH oxidase. Superoxide is released within te phagosomal lumen when the 
active oxidase transfers the electrons from cytosolic NADPH to O2 [71]. Dismutation of 
superoxide can lead to the formation of H2O2 which in turn reacts with superoxide to 
generate hydroxyl radicals and singlet oxygen [72]. Similar to ROS, reactive nitrogen 
species (RNS) are also important microbicidal effectors. Within the phagosomal 
compartment, nitric oxide can undergo a spontaneous or catalytic conversion into RNS 
such as nitrogen dioxide, peroxynitrite, dinitrogen trioxide and nitrosothiols [73]. These 
RNS and ROS can interact with a variety of microbial targets like nucleic acids, protein 
tyrosine residues, thiols, and lipids [74] ultimately resulting in inhibition of microbial 
replication. 
Phagocytes also secrete a set of proteins that either prevent the growth of the pathogen or 
compromise the microbial membrane integrity. For example, scavengers can directly limit 
the availability of essential nutrients to prevent microbial growth. Also, phagosomal 
membranes can acquire various transporters. As an example, natural resistance-associated 
macrophage protein 1 (NRAMP1) can be recruited to the phagosomal membrane from late 
endosomes and lysosomes. NRAMP1 exerts a bacteriostatic effect on pathogens by 
exclusive extrusion of divalent cations from the phagosomal lumen [75]. Phagosomes can 
also disrupt the integrity of pathogens by the action of defensins, lysozymes, proteases and 
lipases. Defensins induce membrane permeabilization of bacteria by binding to negatively 
charged molecules on the pathogen surface and forming ion-permeable channels [76]. 
Despite the presence of these microbicidal host factors, Brucella spp. can survive inside 
host cells. They have evolved various strategies to counteract host defenses. Brucella spp. 




to cellular components. Among them, superoxide dismutases (SODs) are a family of 
metalloenzymes that can dismutate superoxide into H2O2 and O2 and protect Brucella from 
the oxidative burst of macrophages [77]. Two enzymes, catalase (encoded by katA) and the 
alkyl hydroperoxide reductase (encoded by ahpC and ahpD) have a role in protection from 
H2O2 [78,79]. Peroxiredoxin AhpC scavenges endogenous H2O2 that is generated by 
aerobic respiration while KatE detoxifies the supraphysiologic levels of H2O2 [78,79]. 
Brucella can also avoid oxidative damage indirectly. Cytochr me bd ubiquinol oxidase 
and cbb3-type cytochrome c oxidases prevent ROS toxicity by scavenging O2 [80]. They 
are involved in adaptation of Brucella to oxygen-limiting conditions [80]. Brucella also 
expresses exonuclease III, encoded by xthA, which removes the oxidative lesions from the 
bacterial DNA [81]. This base excision repair system has been found to protect Brucella 
from oxidative damage in vitro [81]. For resistance to nitrosative damage, Brucella 
expresses nitric oxide reductase (norD) which detoxifies NO and enhances intracellular 
bacterial survival [82]. 
Brucella is inherently more resistant to the action of microbicidal cationic peptides due to 
the structure of its non-canonical LPS. Brucella LPS is a poor inducer of respiratory burst, 
reactive nitrogen intermediates as well as lysozyme (as discussed earlier) [24,25]. It also 
protects the bacteria against a variety of cationic peptides such as defensins, lactoferrin, 
lysozyme, bactenecin-derived peptides [83]. This resistance is partly due to the reduced 
number of phosphate groups in the lipid A moiety which facilitate a close aggregation of 
LPS molecules via their hydrophobic fatty acids, thereby reducing the penetration by 
cationic peptides [7,83,84].  
Following entry in phagocytes, Brucella needs to adapt under nutrient-deprived 
intracellular environment to survive. This physiological adaptation is in part facilitated by 
the stringent response mediator Rsh [52]. Rsh deletion mutants exhibit altered cellular 
morphology and reduced survival under starvation coditions in vitro and in vivo [52]. 
Also, Rsh participates indirectly in the VirB-mediated formation of the ER-derived 
replicative niche for Brucella [52]. Under iron-deprived conditions, Brucella is capable of 




the survival of Brucella in the presence of erythritol under iron-limiting conditions in vitro 
[85]; however, the role of siderophores in virulenc is not clearly understood. 
Brucella spp. also inhibit apoptosis of the infected host macrophages [86] which is likely 
a strategy exploited by Brucella to survive intracellularly and evade host adaptive 
responses. The precise mechanism by which Brucella spp. inhibit host cell apoptosis is not 
clearly understood; previous studies provide valuable insights into possible mechanisms 
for inhibition of apoptosis. Brucella downregulates mitochondrion-associated proapoptotic 
genes [87] and upregulates the expression of anti-apoptotic factors [86]. Further, a recent 
study shows that Brucella infection results in calcium-dependent degradation of the 
protease calpain2, and subsequent prevention of caspase 3 (apoptotic effector) activation 
[88]. Brucella mutants lacking the O-PS fail to inhibit apoptosis [89] indicating that O-PS 
of Brucella plays a crucial role in infection-induced inhibition of apoptosis. 
 
Table 1.1 briefly summarizes the virulence factors of Brucella and their roles in enhancing 
the survival of Brucella. 
 
Concluding remarks 
Brucella spp. employ several strategies to deceive the host and survive in host cells for a 
considerable time. This is important as Brucella spp. have to persist within their hosts until 
transmission occurs which in natural hosts is primaily via aborted fetal tissues, sexual 
contact and shedding in milk. As some mammalian hosts f Brucella can only breed once 
or twice annually, the capacity of Brucella to successfully survive intracellularly is critical 
to their virulence [44]. Following cell invasion, Brucella spp. avoid the induction of an 
aggressive inflammatory response and subsequently, regulate the trafficking of their 
membrane-bound vacuole so as to avoid the fusion with lysosomes. Several virulence 
factors of Brucella participate to promote its intracellular trafficking and persistence within 
the host. Brucella also exploits some host defense mechanisms such as acidic pH and 
nutrient limitation for the induction of genes that modulate its intracellular cycle. Recent 




functional characterization would further enhance our understanding of the molecular 
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Table 1.1. Virulence determinants of Brucella and their functions. 
Virulence factor Gene Function Reference 
Alkyl hydroperoxide 
reductase 
ahpC and ahpD Scavenges endogenous H2O2 
that is generated by aerobic 
metabolism 
[79] 
Base excision repair xthA Protect Brucella from ROS 




bvfA Induced by phagosomal 
acidification and coregulated 
with virB operon suggesting 
a potential role in 
establishment of a replicative 
niche for Brucella 
[90] 
Catalase katA Protects from oxidative 





sodC Protects from oxidative burst 
of host macrophages 
[77] 
Cyclic β-1,2-glucans cgs - Cyclic β-
1,2-glucan 
synthetase  
Mediate Brucella entry 
through lipid-rafts and 
controls cellular trafficking 
by preventing the fusion of 
BCVs to lysosomes 
[91] 













Protects against cationic 
peptides, respiratory burst of 
macrophages, and 
complement activity. 
Prevents the induction of 
pro-inflammatory cytokines 
and impairs host adaptive 





norD Resistance to nitrosative 
damage 
[82] 
Type IV secretion 
system 
virB Effector translocation into 
host cells 
[58,60,63] 
Urease ure Catalyzes the hydrolysis of 
urea to ammonia facilitating  









Figure 1.1. A revised model of Brucella intracellular trafficking. Following entry, Brucella 
is found within BCVs. These BCVs traffic along the endocytic pathway, sequentially 
interacting with early and late endosomes and lysosomes. Early BCVs interact with early 
endosomes and transiently acquire EEA-1 and Rab5. They mature into intermediate BCVs 
that transiently acquire LAMP-1 and Rab 7 and interact with ERES. Such interactions are 
necessary for the formation of an ER-derived replicative organelle. Replicative BCVs 
exclude LAMP-1 and acquire ER markers such as calreticulin, calnexin and sec61β. BCVs: 
Brucella-containing vacuoles; EEA-1: early endosomal antige-1; Lamp-1: lysosomal-






Figure 1.2. Genetic organization of the O-polysacchride biosynthesis genes. The genes 
required for O-polysaccharide synthesis are located on two loci, wbk and wbo.  wbk region 
contains genes coding for enzymes necessary for N-formylperosamine synthesis 
(gmd, per, wbkC), O-PS glycosyltransferases (wbkE, wbkA), the ABC transporters 
(wzm,wzt), the enzymes that lead to bactoprenol priming (wbkD, wbkF), as well as groups 
of insertion sequences (ISs). wbo region contains genes coding for two O-PS 
glycosyltransferases (wboA and wboB). Mutations in genes marked in dark brown generate 




CHAPTER 2. DEVELOPING A VACCINE FOR HUMAN BRUCELLOSIS: WHY 
AREN’T WE THERE YET? 
Abstract 
Brucella species are facultative intracellular coccobacilli that cause one of the most 
frequently encountered zoonotic diseases worldwide. Most of the naturally occurring 
human infections are mainly caused by B. melitensis, B. abortus and B. suis. These species 
are classified as Center for Disease Control category B select agents. Brucellosis is 
endemic in the Mediterranean basin, the Middle East, Central Asia, Central America and 
parts of South America. If untreated, the infection ca  progress to a chronic phase that can 
last from a few weeks to several years. Rare complications like endocarditis, meningitis 
and spondylitis or death can occur. While treatment with a combination of antibiotics is 
usually effective, relapses are fairly common. There is no licensed vaccine available for 
use in humans. Safety concerns preclude the use of current live attenuated animal vaccines 
for human vaccination. This review focuses on the ne d for a human brucellosis vaccine 




Brucellosis is a chronic infectious disease that affects several mammals, including humans. 
The first evidence of brucellosis in humans dates back to AD 79 as determined by bone 




Cocco-bacillary forms, morphologically similar to the causative agent Brucella, were 
found in the remnants of buried carbonized cheese [2]. However, it was not until 1886 that 
Brucella was first isolated by Sir David Bruce from the spleen of a British soldier who had 
died of a febrile illness (Malta fever) on the Medit rranean island of Malta, not far away 
from Herculaneum [3]. The Roman name of Malta was ‘melita’ and hence the isolated 
organism was initially named Micrococcus melitensis (now Brucella melitensis). Later on 
in 1897, Bang’s bacillus (now Brucella abortus), the causative agent of cattle brucellosis, 
was discovered by L.F Benhard Bang. The close homolgy of these two species was 
demonstrated by Alice Evans of the Hygiene Laboratory of the U.S. Public Health Service 
(now National Institutes of Health) in 1918 and thewo species were regrouped under the 
genus Brucella in honor of David Bruce [4,5]. Since then, several Brucella species have 
been isolated from different mammalian hosts.  
Brucella species are small, non-motile, non-spore forming, aerobic, facultative 
intracellular Gram-negative coccobacilli. The species classification is mainly based on 
their host preferences: B. abortus (found in cattle and buffalo), B. melitensis (sheep and 
goats)  B. suis (pigs), B. canis (dogs), B. ovis (rams), B. neotomae (desert wood rats), B. 
cetaceae (whales, dolphins and porpoises), B. pinnipedialis ( seals and walruses), and B. 
microti (voles) [6,7]. More recently, Brucella was isolated from a human breast implant 
(B. inopinata) [8], Australian rodents [9] and from a baboon colony (B. papionis) [10]. In 
infected animals, Brucella primarily targets the tissues of the reproductive ract leading to 
contagious abortions and infertility. Most of the naturally occuring human infections are 
caused by B. melitensis, B. suis, B. abortus, and B. canis in decreasing order of virulence 
[11]. Marine mammal Brucella spp. have also been isolated from humans; however, thei  
infectivity and degree of virulence for humans is st ll largely unknown [8,10,12]. 
 
Need for a human brucellosis vaccine 
Brucellosis is one of the most frequently encountered zoonosis [13]. Humans get infected 
from consumption of contaminated animal products or from direct exposure to 




per cm3 of the tissue [14]. Many cases of human infection fr m unintentional, accidental 
exposure to animal vaccines have also been reported [15]. At the site of entry, the bacteria 
are ingested by resident phagocytes and carried to regi nal lymph nodes where they 
multiply leading to bacteremia. Brucella primarily colonizes the monocytes and the 
macrophages of the reticulo-endothelial system (RES) including spleen, liver and lymph 
nodes and the reproductive system [11]. Human brucellosis is frequently misdiagnosed and 
underreported due to the existence of non-specific flu-like symptoms. It initially presents 
as a febrile illness with symptoms including undulant fever, general malaise, anorexia, 
arthralgia, fatigue and headache [11].  Enteric sympto s like diarrhea, abdominal pain and 
ulceration of Peyer’s patches have been reported in cases associated with ingestion of 
Brucella [16,17]. Complications like spondylitis, arthritis, meningitis and encephalitis can 
ensue depending on the internal organ involved [11]. Infective endocarditis is a rare 
complication (1-2% of the cases) [18] that accounts for almost 80% of the deaths due to 
brucellosis [19,20]. 
Brucellosis has been eradicated from the livestock population in many parts of the world 
including the United States of America, Canada, Japan and Scandinavian and several other 
countries in Europe [13,20]. However, Brucella in wildlife reservoirs poses a constant 
threat to reemergence of the disease in food animals. As an example, B. abortus is prevalent 
in wildlife reservoirs including bison and elk populations in the Greater Yellowstone Area; 
almost 50% of the 4000 bison and high numbers of elks have been exposed or are infected 
with B. abortus [15]. Brucellosis is highly prevalent in the Mediterranean basin, the Middle 
East, Central Asia, Northern Africa, and Central and Southern parts of America [13,20]. 
Humans are dead-end, incidental hosts of Brucella and the disease incidence in humans is 
strongly dependent on the prevalence of brucellosis in animals. As animals are the only 
source of Brucella infection to humans, successful strategies to control the disease in 
animals would eliminate the risk of infection to humans. In fact, the control of brucellosis 
in domestic livestock by rigorous surveillance, vaccination and slaughter programs has 
resulted in a paralleled decrease in human brucellosis cases [21,22]. However, the 
developing nations still suffer under a huge disease burden of animal and human brucellosis 




eradication of the disease in developed countries may not be implementable in these nations 
for several reasons including differences in livestock production systems, social culture, 
and the lack of veterinary infrastructure and financi l resources. Currently, there is no safe 
and effective vaccine against Brucella infection in humans. Successful treatment of 
brucellosis relies on antibiotic regimens administered for a prolonged period of time. 
However, previous studies have shown that, despite uccessful therapeutic interventions, a 
significant number of clinically asymptomatic patients could still remain infected [24]. As 
Brucella resides in intracellular niches, relatively secluded from antibiotics, it is not 
surprising that relapses following antibiotic therapy are common [25,26].  
A vaccine would be invaluable for controlling human disease in Brucella-endemic regions 
and for protection of people at occupational hazard including animal handlers, farmers, 
veterinarians, abattoir workers and lab personnel. Brucellosis is also one of the most 
frequently reported laboratory-acquired infections [27]. An infectious dose of 10-100 
organisms has been found to be sufficient to establi h disease in hosts by the aerosol route 
[14]. Due to their highly infectious nature and theease of aerosol spread, B. melitensis, B. 
suis and B. abortus are considered as potential bioweapons by the CDC and listed as Class 
B select agents [28]. Also, Brucella is included in the National Institute of Allergy and 
Infectious Disease’s Strategic Plan for Biodefense Research [29]. In fact, B. suis was the 
first organism that was weaponized in 1954 by the United States Government in an attempt 
to develop its offensive biowarfare. However, the United States officially terminated the 
development of bioweapons in 1969. As of now, there is a renewed interest in developing 
a vaccine as a means of direct intervention to protect the military troops and the public in 
the event of bioterrorism.  Human brucellosis is rarely fatal; however, it is a notoriously 
debilitating disease that incapacitates a person [11] and causes substantial financial losses 
in terms of medical care for infected people [30]. A previous study has assessed that $477.7 
million dollars would be incurred in the event of an erosol exposure of 100,000 people to 
a bioterrorist attack [30]. This study provides economic justification for investing in 
preparedness measures, including vaccine development, to combat any deliberate misuse 




Currently used animal vaccines 
Currently, three live vaccines, B. abortus strains 19 and RB51 for cattle and B. melitensis 
Rev 1 for sheep and goats, are used to control brucellosis [31,32]. However, strain 19 and 
Rev 1 retain some pathogenicity while RB51 is only 70% effective in cattle and its efficacy 
in pigs, sheep and goats is questionable [33-36]. None of the vaccines induce a lifelong 
100% protection against the infection that is encoutered in heavily infected herds/flocks.  
 
B. abortus Strain 19 (S19) 
This strain was isolated from milk of a Jersey cow in the early twentieth century. It is an 
attenuated strain obtained spontaneously after the virulent B. abortus was maintained at 
room temperature for one year [37]. It exhibits a phenotypic sensitivity to erythritol owing 
to the deletion of a region of 702 bp encompassing erythritol catabolic genes [38]. This 
strain has been used worldwide and has been instrumental in achieving a significant 
reduction in the prevalence of brucellosis in cattle. The use of S19 was discontinued in 
United States after the introduction of the rough strain RB51 in the mid-1990s. This vaccine 
is still being used in several countries [39, 40]. One drawback of this vaccine is the 
induction of anti-O-polysaccharide (O-PS) antibodies in the vaccinated animals. These 
antibodies interfere in the diagnostic assays that are routinely used to detect infected 
animals. The persistence of these antibodies is dependent on the age of the vaccinated 
animal, the dose and the route of immunization. Vaccination of adult cattle with a standard 
dose of 3×1010 CFU-equivalent of S19 induces antibodies that persist for upto 10-11 
months post-vaccination [41,42]. Calfhood vaccination shortens the duration of antibody 
persistence; however, a lower level of protection is induced in calves than in adults [31]. 
This strain is also associated with low abortifacient (approximately 5%) potential when 
used for vaccinating pregnant animals [43,44]. When used in adults, it results in udder 
infections in 2% of the animals which also shed thebacteria in milk [45,46]. Less 




virulent for humans; several cases of human disease have been due to accidental 
inoculation of S19 vaccine [32,33,48]. 
 
B. melitensis Rev 1  
B melitensis Rev 1 is a live attenuated strain developed in 1957 that has been successful in 
preventing brucellosis in small ruminants [49]. It protects against both B. melitensis 
infection in sheep and goats and B. ovis infection in rams [49,50]. Controlled studies show 
that Rev 1 vaccination can induce high levels of immunity that can last longer than 4 years 
in goats and for at least 2.5 years in sheep [49]. In spite of being attenuated when compared 
with field strains, Rev 1 retains some virulence [51]. It is abortifacient and the abortion rate 
can be as high as 80% if the animals are vaccinated in their second to third month of 
pregnancy [49]. To avoid abortions, animals are vaccinated prior to the first gestation at 3-
7 months of age. Also, conjunctival administration can substantially reduce the abortion 
rate [52]. Rev 1 vaccine has been found to be of very low virulence in rams [53]. Being a 
smooth strain, vaccination with Rev 1 results in induction of antibodies against the O-PS 
that interfere with the serodiagnosis. Also, although rarely excreted in sheep milk, Rev 1 
can be secreted in goat milk for several weeks to months posing a hazard for the farmers 
[52]. Despite being attenuated in animals, Rev 1 is capable of infecting humans [54]. 
 
B. abortus RB51 
B. abortus strain RB51 was licensed for use in cattle by Animal and Plant Health Inspection 
Service (APHIS), U.S. Department of Agriculture (USDA), in February 1996 [55]. This 
vaccine is being currently used in a number of countries including the United States. It 
induces a good level of protection in cattle; however, its protective efficacy in swine, sheep 
and goats is still unclear [33-36]. B abortus RB51 is a genetically stable, live, attenuated, 
spontaneous mutant of B. abortus 2308 obtained after repeated in vitro passages in the 
presence of penicillin and rifampin [56]. The wboA gene, that encodes a 




element in RB51 [57]. Although RB51 synthesizes lowevels of M-like O-chain [58], it 
does not induce any measurable amounts of anti-O-PS antibodies that might interfere in 
smooth-LPS serological tests [59]. Also, it possesses low virulence and does not induce 
abortions in the vaccinated animals [60]. RB51 affords a similar level of protection as S19 
in cattle [61]; however, it is considered less virulent than S19 on the basis of results from 
animal testing. Calves are generally vaccinated subcutaneously (SC) at 4-12 months of age 
with a dose of 1-3.4×1010 organisms without adverse effects. A vaccine dose f 109 
organisms can be safely used to vaccinate pregnant cattle via SC route without the 
induction of abortions or placentitis [62]. Despite its efficacy in cattle, two major 
drawbacks preclude its use for vaccination of humans. Firstly, accidental exposure of 
humans to RB51 is known to cause local and systemic adverse reactions [55,63]; secondly, 
RB51 is resistant to rifampin which is an effective antibiotic for treating brucellosis [56]. 
Although RB51 is genetically stable, the exact nature of mutations affecting its attenuation 
characteristic is not known. Previous studies document that complementing strain RB51 
with a functional wboA gene does not restore the smooth phenotype suggesting that 
mutations in several genes might be contributing to its rough colony morphology and 
attenuation [64].  
 
History of vaccination of humans against brucellosis 
Previously, numerous attempts have been made to vaccinate humans against brucellosis. 
Formerly, a strain derived from Strain 19, Strain 19-BA, was used extensively during a 
period extending from 1940-1960 to immunize at least 3 million people in the former 
USSR [65]. People were vaccinated with 1×109 cells via skin scarification. It delivered 
partial protection that did not result in long-lasting immunity and frequent re-
immunizations were required. Local adverse reactions i cluding hyperaemia and 
induration were exhibited by 76% of the vaccinates while generalized symptoms like 
headache, lethargy and fever occurred in 3 to 7% of the immunized people [65,66]. Also, 
vaccination with 19-BA was associated with the apperance of variable degrees of 




in acute human brucellosis cases during 1952-1958 was attributed to the use of 19-BA 
vaccine [65,66].  
Other live attenuated strains like B. abortus VA19 and B. abortus 104M were used in the 
former USSR and China, respectively [67]. They were administered intradermally or in 
aerosolized forms [67]. Severe adverse reactions were associated with their improper use 
or use in sensitive individuals [67]. On account of sa ety issues, emphasis was shifted 
towards non-living vaccines. Vaccines based on subcellular fractions including a 
peptidoglycan fraction (PI) and an extracted protein-polysaccharide fraction (BCV- 
Brucella chemical vaccine) were used in France and Russia, respectively [68]. PI was a 
phenol-insoluble residue obtained from lipid-extraced B. melitensis M15 [69,70,71]. 
Subsequently, B. abortus S19 was used for developing PI. Two doses of PI at 2 week 
interval were administered SC to high-risk populations including laboratory workers [69]. 
The vaccine was non-toxic and less reactogenic. Protecti n in vaccinates lasted for about 
18-24 months [69,70]. Although PI was used as a vaccine against brucellosis for almost 
two decades, conclusive evidence of its efficacy from controlled clinical trials does not 
exist [72]. This vaccine is no longer in production. 
Similarly, an acetic acid extracted protein-polysaccharide fraction of cell wall was 
developed in USSR [73,74]. It was prepared from B. abortus strain 19-BA and was 
administered via intra-muscular (IM) route in humans [73,74]. Studies involving the use of 
75,000 vaccine doses in Kazakhstan indicated that the protective efficacy of BCV was 
similar to that of strain 19-BA [73,75]. However, BCV was shown to have lower 
reactogenicity than strain 19-BA [73,75]. The efficacy of this vaccine has not been 
rigorously tested under controlled clinical trials [75]. 
 
Immune responses against Brucella 
Immune response studies and gene expression patterns in mouse and macrophage cell lines 
during Brucella infection have contributed significantly to our current knowledge about 
immunity to Brucella. Both humoral [76-80] and cell-mediated responses [80,81] 




a major role in acquired resistance against Brucella infection [81]. Th1 type of immune 
response is considered essential for clearing Brucella from mice [81-83]. Interferon- γ
(IFN-γ) is an important cytokine for resistance to Brucella infection. It is secreted by T 
cells and natural killer (NK) cells and activates the bactericidal function of macrophages 
by promoting the production of reactive oxygen interm diates, enhancing the production 
of cytokines, and by inducing isotype switching to immunoglobulin (Ig)G2a and IgG3 
[81,84]. Consequently, IFN-γ knockout mice or mice lacking interferon regulatory factor 
-1 (IRF-1) are unable to control Brucella and succumb to infection within 6 weeks [84,85]. 
Tumor necrosis factor-α (TNF-α) also plays a similar role of enhancing the bacteri idal 
activity of macrophages [86]. Previous studies document the role of interleukin-12 (IL-12) 
in resistance against brucellosis; in a mouse model, depletion of IL-12 before Brucella 
infection exacerbated the infection and enhanced th chronicity of the disease [87].  
Both CD4+ and CD8+ T lymphocytes help to control Brucella infection as shown by 
specific T cell depletion experiments using T cell-specific monoclonal antibodies and also 
by using gene knock-out mice [80,81]. Importantly, both cell populations are sources of 
IFN-γ which helps to control the intracellular growth of Brucella [81]. Studies in human 
primary cells have helped to identify some aspects of immune responses that are restricted 
to humans. Gamma delta (γδ) T cells appear to play a role in brucellosis that is especially 
prominent in humans. A human-specific population of γδ T cells (V γ9δ2) can kill B. suis-
infected cells by releasing microbicidal peptides [88]. γδ T cells might also exert their 
protective effect in humans by release of IFN-γ and through cytotoxic activity [89]. Also, 
previous studies showed that human natural killer (NK) cells can mediate killing of B. suis-
infected cells in a contact-dependent manner [90]. While human NK cells play a role 
against Brucella infection, murine NK cells are not important in controlling brucellosis 
[91]. 
B. abortus infection also induces the production of IL-10 which inhibits the microbicidal 
function of macrophages and antagonizes the activity of IFN-γ [92,93]. CD4+ T cells have 
been identified as the major source of IL-10 during the early phase of Brucella infection. 
A recent study demonstrates that mice lacking IL-10 are better able to control Brucella 




LAMP1+ late endosomes and replicate intracellularly thereby limiting the establishment of 
chronic infection [94]. 
The significance of humoral immunity has been repeatedly demonstrated, both in murine 
model of brucellosis as well as in natural hosts [76-80]. IgG2a and IgG3 are the dominant 
antibody isotypes detected in infected mice and natural hosts, again emphasizing the 
prominent role of Th1 immunity against brucellosis [95]. Passive transfer of anti-LPS sera 
as well as B. abortus O-PS specific monoclonal antibodies protect mice against challenge 
with virulent Brucella species [76, 78-80]. These antibodies presumably play a direct role 
in opsonization; antibody-mediated opsonization enhances the phagocytic uptake and 
intracellular killing of Brucella [96]. 
 
Strategies for optimizing the design of a brucellosis vaccine for use in humans 
A major challenge for development of a vaccine against human brucellosis is the absence 
of well-established correlates of protection. However, extensive studies with mouse models 
have helped to identify definite indices of immune responses that are required for 
protection against Brucella. An ideal brucellosis vaccine should be avirulent and effective, 
and should be able to provide long-term protection, preferably with a single dose. 
 
Vaccine safety and protective response 
Historically, live attenuated vaccine candidates, including the vaccines currently in animal 
use, have delivered the most promising results against Brucella infection [97]. Live 
attenuated organisms mimic the infection caused by live pathogens and can deliver 
multiple antigens for processing and presentation by dendritic cells (DCs) and 
macrophages for stimulation of a robust immunity. However, lack of knowledge about the 
molecular basis of attenuation as well as safety risks preclude the use of currently used 
field vaccines in humans. Recent years have seen a co siderable amount of research on the 




disease [98-100]. This knowledge can be exploited to esign a safe and effective vaccine 
by making the organism innocuous while still able to traffic within host cells and interact 
with host components for induction of optimum protection. Inactivation of genes involved 
in virulence and survival have yielded several promising Brucella attenuated strains [101-
104]. However, it is crucial that prospective vaccine candidates should not possess any 
residual virulence. Such a vaccine design is often problematic as genetic mutations that 
severely affect virulence may attenuate the organisms to levels where they are unable to 
induce sufficient protection. Following a careful assessment of the residual virulence, the 
attenuated candidates are evaluated for vaccine efficacy using laboratory animal models. 
Previous studies have indicated that some level of persistence is essential for a vaccine to 
stimulate an adaptive immune response [105-108]. Attenuated strains that undergo rapid 
clearance are unable to produce sufficient protection. However, attenuated strains that 
exhibit incomplete clearance from the host may be of questionable safety and might induce 
symptoms of full-blown brucellosis. Only the vaccine candidates that meet the desired level 
of attenuation and immunogenicity in mice can be evaluated rigorously for safety and 
protective efficacy in non-human primates. It is alo important to take into account the 
genetic predispositions to potential side effects or that can influence vaccine 
immunogenicity. 
In the absence of identification of genes that can enhance persistence without 
compromising safety, several alternate strategies such as encapsulation can be employed. 
Encapsulation of highly attenuated organisms that are otherwise rapidly cleared can 
enhance the immune responses and protection against pathogens by providing gradual 
timed release of the vaccine (discussed later in section ‘Mucosal delivery of vaccines’). 
Alternatively, attenuated strains that exhibit optimal persistence can be further subjected 
to gamma-irradiation to enhance their safety by renderi g them incapable of reverting to 
virulence [109-113]. An optimal dose of gamma-rays can abolish the replicative ability of 
organisms by creating sufficient number of breaks in the genomic DNA. Gamma-ray 
attenuation of microbes leaves a large portion of the genomic nucleic acid intact for 
transcriptional and translational activity. This ensures the downstream effectiveness of the 




studies document that gamma-irradiated Brucella strains can induce potent protection [109, 
111-113]. Gamma-irradiated strains are metabolically ctive; microbial metabolism is a 
potential viability-associated PAMP (vita-PAMP) tha helps the host system to 
differentiate between live and killed microbes [114]. vita-PAMPs signal microbial viability 
that is identified by the innate immune system and consequently, the host system can 
perceive the level of threat and launch a proportionally potent adaptive immune response 
against the invading pathogen [114]. Killed vaccines lack vita-PAMPs and are only weakly 
immunogenic [115]. Hence, while being safe, gamma-ray-attenuated vaccines possess 
comparable efficacy to live vaccines.  
Another concept that assures a safe vaccine design is the ‘killed-but-metabolically-active’ 
(KBMA) approach. This approach has yielded several s fe, potential vaccines for 
pathogens such as Listeria monocytogenes, Salmonella Typhimurium, Leishmania 
infantum, and Bacillus anthracis [116-119]. According to the KBMA concept, bacterial 
strains are mutated in the nucleotide repair system to ake them exceedingly sensitive to 
DNA damage induced via ultraviolet (UV) light [116]. Consequently, these mutants can 
be inactivated using a synthetic psoralen that causes pyrimidine residues to cross-link on 
exposure to UV radiation. Organisms are unable to repai  this psoralen-induced DNA 
damage as they are mutated in the ABC excision endonuclease (excinuclease) complex that 
mediates nucleotide excision repair [120]. These vaccines are safe and induce protection 
in the vaccinated hosts [116-119]. 
With increasing awareness of vaccine-associated potential adverse effects, rigorous 
controlled studies need to be undertaken to gather convincing evidence of vaccine safety 
and enable vaccine acceptance. With this in mind, significant efforts have been focused on 
the development of subunit and DNA vaccines. These vaccines are well-defined, nonviable 
and unable to cause disease. However, subunit vaccines exhibit weak immunogenicity 
mostly as a result of the difficulty to target them to appropriate tissues or to mimic the 
intracellular trafficking pattern of live infectious pathogen and stimulate various facets of 
the host defense system. The immunogenicity of the subunit vaccines can be potentiated 
by inclusion of supplements that can enhance the overall vaccine efficacy. However, even 




be robust enough to provide protection against Brucella infection (CpG adjuvants are 
discussed in the next page).   
Alternatively, DNA vaccination can generate both humoral and CMI in the vaccinated 
subjects. DNA vaccines can induce major histocompatibility complex (MHC) class I-
restricted responses and mimic the effects of live att nuated vaccines [121]. This feature is 
advantageous when compared to conventional protein-based vaccines. Also, DNA 
vaccines do not possess the inherent risk of potential bacterial reversion as seen with live 
attenuated vaccines. DNA vaccines are biologically stable, their manufacturing is cost 
effective and simple and they do not require cold-chain maintenance as they can be 
transported in lyophilized form [121]. Previous studies have shown that DNA vaccines 
encoding protective antigens such as lumazine synthase (BLS), outer membrane protein 
(Omp) 31 and Cu, Zn superoxide dismutase (SOD) of Brucella provide protection against 
virulent Brucella challenge in mice [122-124]; the level of protection nduced is similar to 
live attenuated reference vaccines used in these studie . This protection is attributed to the 
production of antigen-specific humoral and CMI responses, primarily of Th1 type. DNA 
vaccine design also allows for the inclusion of multiple protective antigens. Immunization 
with a divalent vaccine encoding L7/L12 and Omp 16 or a trivalent vaccine encoding 
L7/L12, BCSP31 and SOD confers protection at comparable levels to that induced by 
licensed field vaccines [125,126]. 
One of the principal advantages of DNA vaccines is that they be easily tailored to induce 
desired immune responses. Several complementary strtegies to alter the qualitative and 
quantitative aspects of immune responses and enhance the potency of DNA vaccines have 
been developed. Genes encoding cytokines, chemokines and co-stimulatory molecules can 
be incorporated in DNA vaccines to amplify the induced immune responses as well as 
control the type of immunity. As an example, while a range of T-cell responses including 
Th1, Th2 and cytotoxic T lymphocytes (CTLs) are induced using granulocyte/macrophage 
colony-stimulating factor (GM-CSF), IL-12 primarily induces CTL responses [127]. Also, 
a combination of cytokines can be administered for the synergistic stimulation of T-cell 
polarized immunity. Previous studies document that a combination of GM-CSF, TNF-α 




number as well as function of DCs, while IL-12 and TNF-α upregulate the expression of 
IL-12 receptor and IFN-γ [129]. Also, genes for co-stimulatory molecules can be 
incorporated for maximizing the vaccine efficacy. A combination of IL-12 and B7-1 acts 
synergistically and enhances both the antigen-specific T helper cell proliferation and CTL 
responses [130,131]. Thus, cytokines and costimulatory DNA that can induce Th1-biased 
immune responses can be exploited for potentially enhancing the vaccine efficacy against 
brucellosis. 
Alternatively, adjuvants can be used to induce relevant cytokines and to upregulate the 
expression of co-stimulatory molecules leading to increased vaccine efficacy. In particular, 
CpG oligodeoxynucleotide (ODN) is considered as one of the most promising adjuvant for 
the development of improved vaccines against infectious diseases including brucellosis. It 
can be used as an adjuvant in both antigen-based conventional vaccines as well as DNA 
vaccines against brucellosis. ODNs are immunostimulatory DNA sequences containing 
unmethylated CpG dinucleotide motifs that can directly activate human B-cells to 
proliferate and differentiate into IgG producing B-cells [132]. They exert their effect as a 
polyclonal activator via TLR9. Overall, CpG ODNs induce a cytokine profile that is 
characteristic of Th1 type of immune response including higher production of IL-12 and 
IFN-γ [133].  They enhance CD4+ T cells, CD8+ T cells and antibody responses to a variety 
to pathogens including Brucella [134].  All the published protection studies with subunit 
and DNA vaccines were conducted in mouse models; whether these vaccines perform 
similarly in target host species remains to be tested. 
Before any of these strategies can be effectively translated into applicable vaccine 
technology, associated potential risks and long term thical implications should be 
carefully considered. As an example, one major drawback of using cytokine-encoding 
plasmids is that they can persist in the host for mnths or years. The overproduction of one 
type of effector cytokine can skew the balance of Th1 and Th2 immune responses, disrupt 
the immune homeostasis and alter the host’s susceptibility to various infections. As 
multicomponent vaccines become more common, the possibility for detrimental adverse 
effects will also increase. Rigorous preclinical studies are needed to adequately establish 




Induction of immunity at mucosal surfaces 
Most infectious agents infect humans via mucosal sites, principally the digestive and 
respiratory tracts. Therefore, mucosal immunity constitutes a very critical part of overall 
protective responses against the invading microbes. Vaccines that elicit robust immunity 
at mucosal sites would prevent colonization of mucosal surfaces and enhance resistance by 
limiting the entry of pathogens beyond the mucosa. However, most licensed vaccines are 
administered parenterally and target the systemic imune system. They either elicit only a 
weak mucosal response or altogether fail to induce protective mucosal immunity [135]. 
The understanding that mucosal vaccination is requid to fortify defenses at mucosal sites 
and protect against infections has renewed interest in the development of efficacious 
mucosal vaccines. Mucosal immunization can induce the expression of mucosal and 
systemic homing receptors in lymphocytes and can prime the host immune system for 
subsequent mucosal as well as systemic recall responses leading to enhanced protection at 
both sites. However, direct mucosal immunization is challenging; the vaccine dose that 
actually enters the body cannot be accurately assessed due to the difficulty of capturing 
and analyzing the functionality of mucosal antibodies as well as mucosal T cells [136]. 
Also, mucosal vaccines have to face a similar range of host innate defenses as mucosal 
pathogens do such as the degradative lytic enzymes, epithelial barriers and mucus 
secretions. Vaccines delivered via mucosal routes tend to become diluted in mucosal 
secretions limiting effective deposition onto mucosal epithelium [136]. Also, they can 
become stuck in mucus and subsequently degraded by proteases [136]. To overcome these 
limitations, relatively large doses are required to s imulate immune responses when 
compared to parenteral vaccination strategy [136].  
Despite the complications associated with mucosal vaccination, there are some mucosal 
vaccines that are approved for human use. Among those are the live attenuated poliovirus 
and Salmonella typhi oral vaccines that are both derived from pathogens that exploit M cell 
transport to invade the enteric lymphoid tissues [137- 40]. The effectiveness of these live 




mucosal surfaces, invading the organized mucosal lymphoid tissues and stimulating innate 
and adaptive immune responses against the target pathogen [136].  
Prevention of mucosal transmission should be a goal in developing an effective brucellosis 
vaccine as Brucella is mainly transmitted by mucosal routes. However, as human 
brucellosis is a systemic disease, an ideal vaccine should be able to induce both mucosal 
as well as systemic protection. The choice of vaccination route is partly dependent on the 
expected site of challenge. Human brucellosis is often acquired through aerosol route; 
protection against inhalational challenge should be considered while evaluating the vaccine 
efficacy of potential candidates for humans. Several Brucella investigators have 
demonstrated the generation of enhanced protection against intra-nasal (IN) challenge 
infection with virulent Brucella spp. in mice following IN and oral immunization with live 
attenuated Brucella vaccines [113,141-143].  These results are extremely promising; future 
studies need to focus on the strategies to overcome the physiological barriers at mucosal 
routes, specific targeting of antigen-presenting cells (APCs) at inductive sites for immune 
activation and modulating the kinetics of antigen delivery to promote long-lasting 
protection. One promising approach of mucosal vaccination involves entrapping antigens 
within synthetic polymeric particles designed to mimic immunogenic properties of natural 
pathogens. These carriers can protect the antigens from degradation, selectively target them 
to preferential sites of antigen uptake, and releas the antigens slowly over a prolonged 
period of time (discussed in ‘mucosal delivery of vaccines’).  
 
Mucosal delivery of vaccines  
Notable advances to improve the delivery of vaccines to mucosal inductive sites have 
focused on the use of particulate systems. These include carrier particles like poly (lactide 
co-glycolide) (PLG), liposomes, chitosan, virosomes, ISCOMs etc. for controlled-release 
of antigens and also for eliminating the need for boster immunizations [144,145]. 
Particulate carriers prepared from PLG are one of the most widely used delivery platforms 
for vaccines. They are biodegradable, biocompatible, and have previously been used as 




Particulate delivery systems potentiate vaccine efficacy through the efficient uptake of the 
antigen by the APCs and subsequent delivery to lymphoid tissues [148]. The encapsulated 
antigen can be released in a pattern to maximize the licited immune response by varying 
the release kinetics of the particles. Optimum rate of antigen release would result in 
extended antigen presentation to the host immune syst m [149] potentially allowing for a 
single-shot vaccine formulation to induce long-lasting effective immunity. 
One important determinant of efficient antigen uptake nd its cellular trafficking as well as 
immune stimulation is the size of the encapsulating particles. Particles of 20-200 nm induce 
a Th1-biased immune response following receptor-mediat  endocytosis while particles 
>0.5 µm stimulate humoral immunity following uptake by phagocytosis or pinocytosis 
[150]. Simultaneous administration of particles of distinct size distributions can be 
exploited to release the antigen in a pulsed pattern analogous to primary and booster 
immunizations. Following oral immunization, particles of 5 µm-10 µm are taken up by 
Peyer’s patches and remain detectable for about 35 days [151]. In contrast, particles of <5 
µm are found in draining lymph nodes and spleen [151]. Also, the surfaces of particles can 
be tailored to enhance particle diffusion through the mucosa as well as transcytosis by M 
cells [152]. Following mucosal entry, the infectious agents are delivered through the 
intestinal Peyer’s Patch Follicle-Associated Epithel um (FAE) and Nasal Associated 
Lymphoid Tissue (NALT) by the activity of M cells [153]. For efficient uptake, vaccine 
particles should mimic M cell-invasive pathogens. Particles that are small (<1 µm) and 
adherent to M cells are taken up efficiently and transported to Peyer’s patches. Ligands can 
be exploited for targeting particles to M cells. However, only a limited number of receptors 
and their ligands have been identified; most of them including pathogen recognition 
receptors (PRRs) are expressed by both M cells as well as by enterocytes. Previous studies 
have demonstrated that Ulex europaeus agglutinin 1 (UEA-1), a lectin specific for α-L-
fucose residues, selectively binds to the apical surface of murine M cells [153]. Coating 
particles with such ligands can increase the antige uptake and transport to mucosal 
inductive sites, thus enhancing the protective efficacy of vaccines [153]. Oral vaccination 
with killed Helicobacter pylori and UEA-1 resulted in the induction of protection against 




remains to be determined whether UEA-1 can be used to ffectively target human M cells 
[155]. 
One of the main advantages of particulate delivery fo  mucosal immunization is the 
protection of the antigen from degradation by extracellular proteolytic enzymes. This 
would help reduce the antigen dose that is required for immune activation especially 
following oral immunization. Also, various immunopotentiators such as cytokines can be 
codelivered with encapsulated antigens to selectively modulate and enhance the potency 
of elicited immune responses. Many of the cytokines have a short half-life in vivo and cause 
adverse effects if administered at high doses. Sustained release of cytokines following their 
encapsulation serves to overcome these limitations. 
Microparticle-delivery of Brucella holds potential to enhance the vaccine efficacy. 
Microencapsulation of Brucella antigens has been successful in inducing potent immunity 
in animal models [156-160]. Studies with Brucella have also demonstrated that 
microencapsulated delivery of live attenuated Brucella results in the induction of sustained 
antibody responses, a Th1-biased immunity and enhanced protection against challenge 
when compared to non-encapsulated counterparts [156,158,160].  
Hence, microencapsulation is an attractive alternative that can optimally exploit controlled-
sustained release and preferential targeting for the development of a protective human 
brucellosis vaccine. 
 
Differentiating vaccinated humans from infected humans 
The differentiation of infected humans from vaccinated ones can be challenging; however, 
it is advantageous for any future potential human vccine to possess this capability. 
Diagnostic methods for brucellosis are mainly based on serology and detect antibodies to 
the O-PS of smooth LPS. Vaccination of hosts with rough strains prevents the development 
of smooth LPS-specific antibodies; however, absence of O-PS makes the rough strains 
more susceptible to complement-mediated lysis, limiting their persistence in the host and 
vaccine efficacy [97]. At least in some animal species, these anti-O-PS antibodies play a 




[78-80]. In many cases, Brucella strains affected in their ability to produce smooth LPS are 
unable to induce enhanced protection when compared with live smooth strains. Previous 
studies have shown that inducing O-PS expression in strain RB51 by complementing it 
with a functional wboA gene enhances its protective efficacy against virulent B. abortus 
and B. melitensis challenge [64,161]. Efforts to induce O-PS expression in rough strains 
that exhibit optimum persistence might yield a safe vaccine with enhanced efficacy. Also, 
smooth strains attenuated in virulence can be assessed for their safety and vaccine efficacy. 
Vaccine safety can also be enhanced by subjecting the engineered strains to gamma-rays 
to render them non-replicative. However, the use of O-PS expressing Brucella strains as 
vaccines will require the development of alternate diagnostic tests for distinguishing 
infected hosts from vaccinated ones. 
Previous studies have shown that several strategies can minimize the intensity and the 
duration of the antibody responses against smooth LPS. These include reducing the vaccine 
dose, vaccination via conjunctival route and vaccinating young hosts; however, these 
approaches do not completely eliminate the possibility of serologic interference. Another 
way is to create genetic markers by either heterologous expression of GFP or by deletion 
of specific genes in vaccine strains to allow for the differentiation of vaccinated hosts from 
infected hosts. Previous studies show that expression of a heterologous gene in Brucella 
vaccine strain provides a marker to differentiate th  vaccine from the wild-type Brucella 
spp. [162]. The authors modified the O-PS of Brucella to produce a distinct immunogenic 
epitope that does not react with the antibodies from naturally infected animals [162]. Such 
novel approaches will permit the use of smooth LPS intact vaccines for stimulating robust 
immune responses leading to a long-lasting protection.  
 
Conclusions 
An efficiently attenuated Brucella strain with improved stability and safety is required for 
use as a human vaccine. However, the rational design of such a vaccine is impeded by our 
current lack of understanding of the precise immune correlates of protection against 




mechanisms and mimic natural pathogens, without induci g disease. Numerous strategies 
can be exploited to enhance the safety and immunogenicity of the vaccine, influence the 
quality of the elicited immune response and circumvent any inhibitory immune 
mechanisms. Important challenges lie ahead: we would have to rely on animal models to 
examine the efficacy of vaccine candidates as clinical challenge in humans would face 
ethical objections. In the coming years, it is likely that a combination of several of the 
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CHAPTER 3. GAMMA IRRADIATION: REPURPOSING AN OLD TOOL FOR 
DEVELOPING SAFER VACCINES AGAINST INTRACELLULAR PATHOGENS 
Abstract 
Successful vaccination strategies attempt to mimic natural infection for induction of long 
lasting immunity against infectious diseases. An effective vaccine should stimulate both 
antibody-mediated and cell-mediated immune responses that are required to eliminate the 
pathogen from the body. Observations till date indicate that vaccines containing live 
organisms are far superior to the killed ones in inducing protective immunity. Live vaccines 
induce a broad, robust cell-mediated immune response a d a long-lasting immunological 
memory. In fact, only live vaccine are effective against some infectious diseases such as 
tuberculosis and brucellosis, which are caused by intracellular bacterial pathogens. 
However, the replication potential of organisms in live vaccines poses a safety risk, at least 
to some individuals in a population. Exposure to ionizing radiation has been used to 
generate non-replicative but metabolically active microorganisms. While possessing the 
safety profile of killed vaccines, irradiated vaccines retain sufficient metabolic activity to 
initiate potent immune responses similar to that of live vaccines. This review focuses on 
gamma-irradiation and its applicability as a promising technique for development of safer 





Vaccination is the most efficient medical interventio  employed till to date to reduce 
infectious disease burden in animals and humans [1]. Since the advent of vaccination, 
inactivation and attenuation of pathogens have been th  most widely used strategies for 
development of vaccines. Undoubtedly, live attenuated vaccines are more immunogenic 
and induce longer lasting protective responses than vaccines based on inactivated forms. 
However, there are inherent safety risks associated with the use of live vaccines; they often 
retain some pathogenicity and can also revert back to being fully virulent. Empirical 
attenuation, in instances where the molecular basis of attenuation is not known, is often 
unreliable. Even in cases of rational attenuation, the live attenuated vaccines can cause 
serious adverse effects, especially in immunocomproised subjects [2]. In contrast, 
inactivated vaccines, although reliably safe, induce a weaker immunity that often does not 
translate to long-lasting protection. Developing vaccines that are efficacious and yet 
possess the safety profile of killed vaccines is highly desirable. 
Ionizing radiation, such as X-rays and gamma-rays, can cause damage to cellular 
components, and at sufficiently high enough doses can cause cell death.  Gamma-rays have 
higher energy than X-rays.  In aqueous conditions of bi logical materials, ionizing 
radiation causes formation of reactive oxygen species (ROS) from water, and ROS cause 
the damaging effects on DNA, proteins, and other cellular components. Exposure to 
gamma-rays (gamma-irradiation) is a widely used technique for inactivation of pathogens 
in food to avoid spoilage [3], sterilization of pharmaceuticals [4,5], medical/research 
supplies and tissue/biological based products [6]. The Center for Biologics Evaluation and 
Research of the United States Food and Drug Administration has approved gamma-
irradiation for sterilization of plastic containers and diluents used in vaccine 
manufacturing. Using ionizing radiation for developing vaccines dates back to 1936, when 
Moore and Kersten reported the use of X-rays to inact v te Shigella dysenteriae [7].  
Remarkably, studies conducted in 1950s with X-ray iradiation led to the development of 
a commercial vaccine (Dictol) against Dictyocaulus viviparous, a nematode parasite of 




such that their development halted at the fourth larval stage and they did not form adult 
worms. Vaccination with the irradiated larvae induced host immunity and conferred 
protection to cattle [8]. Since then, gamma-rays and other ionizing radiations have been 
used for the development of viral, bacterial and parasitic vaccines [9-15]; however, the 
specific benefits of irradiation in the development of safer vaccines for intracellular 
pathogens are yet to be fully explored. Thirty six years ago, gamma-irradiation as a 
technique for vaccine inactivation was illustrated in a murine model of Rickettsia [16,17]. 
The findings established that irradiated scrub typhus rickettsiae induced protection in mice 
which was superior to that of formalin-killed vaccine. Subsequently, many studies have 
demonstrated the use of gamma-rays for development of effective and safer vaccines. The 
focus of this chapter is limited to discussing the benefits of gamma-irradiation as a 
technique for developing safer vaccines, especially for intracellular pathogens.  
 
Immune sensing of pathogen metabolic activity 
The mammalian immune system has innate and adaptive components; together they 
orchestrate to protect the host against microbial infections. Innate immune responses 
influence the development of subsequent adaptive immunity to the pathogens through 
recruitment and activation of antigen presenting cells (APCs). 
APCs express pattern-recognition receptors (PRRs) which can bind with distinct microbial 
components that are unique to microorganisms, often referred to as pathogen-associated 
molecular patterns (PAMPs). The best known PRRs are Toll-like receptors (TLRs), but a 
number of other cell surface and intracellular receptors are also involved in sensing the 
presence of PAMPs. [18,19]. The rapid and effective sensing of PAMPs stimulates the host 
immune responses via activation of complex signaling pathways leading to an 
inflammatory response that subsequently assists in pathogen clearance [20]. Both live and 
killed vaccines contain PAMPs (Table 3.1).  However, live attenuated vaccines like typhoid 
or tuberculosis vaccine induce a potent immune respon e that leads to long-lasting 
protection when compared with vaccines that are basd on killed organisms (Table 3.1). 




and launch a more robust immune response against them. A recent study has demonstrated 
that the host immune mechanisms can make a fine distinct on between live and dead 
microorganisms by sensing their viability itself [21]. 
The host immune system perceives a vaccine as being‘live’ or ‘viable’ only if the vaccine 
contains viability-associated PAMPs (vita-PAMPs) which are present in live microbes. In 
case of bacteria, bacterial messenger RNA (mRNA) are an example of vita-PAMPs 
associated with live bacteria [21]. Products of microbial metabolism such as bacterial 
pyrophosphates and second messengers such as cyclic di-GMP are other potential vita-
PAMPs that help the host system to differentiate betwe n live and killed microbes [22]. 
Recognition of vita-PAMPs leads to inflammasome activ tion and pyroptosis. Previous 
reports have documented that replication-unfit ‘killed-but-metabolically-active’ (KBMA) 
bacteria are able to mount a robust immune response indicating that bacterial metabolic 
activity by itself may be sufficient to produce vita-PAMPs [23].  
Several previous studies reported that gamma-ray attenuated bacteria and parasites retain 
their metabolic activity, though they lose their ability to replicate [11-13,24]. Gamma-
irradiation leads to the generation of ROS that cause random double-strand disruptions in 
the DNA [25,26]. The extent of the resulting DNA dam ge is dependent on the genome 
size of the organism and is inversely related to the dose of the gamma-rays [27,28]. 
Exposure of vaccine organism to a minimum dose of gamma-radiation that causes 
sufficient DNA fragmentation and abrogation of its replication capacity is an attractive 
strategy for developing effective vaccines. Sufficient DNA fragmentation can overwhelm 
the DNA repair machinery of the bacteria and abolish their ability to replicate but leave an 
ample portion of the genome still intact to permit the organism to be metabolically active 
and express genes de novo and consequently, synthesize proteins [11,13]. This would help 
facilitate the recognition, processing and presentation of the antigenic repertoire by the host 
defense system leading to the induction of protectiv  immunity at levels comparable to live 
vaccines.  In addition to irradiation, other approaches based on genetic manipulation of the 
organism were used for developing non-replicative but metabolically active vaccines [29-
32]. Such vaccines were also demonstrated to be effective in inducing robust immune 




of metabolic activity by the vaccine organisms is crucial for induction of effective 
immunity. Future studies should focus on demonstrating the role of vita-PAMP recognition 
in immunity induced by gamma-irradiated vaccines. 
 
Maintaining structural, functional and epitope integrity 
Unlike inactivation by heat or chemical treatment, gamma-irradiated organisms remain 
structurally intact.  Gamma-irradiation at a dose ud in vaccine preparation does not cause 
denaturation of structures and proteins. Structural integrity of the functional domains of the 
microbe is crucial for effective antigen processing and the development of immunity 
against natural infections. For example, gamma-ray in ctivation of pathogenic viruses like 
Lassa, Marburg and Ebola, renders the microbes non-infectious without affecting their 
immunological activity [33]. Gamma-irradiated viruses retain the ability to induce 
cytotoxic T cells [34-36]. These findings suggest that the irradiated virus can infect target 
host cells, allowing natural and efficient uptake of antigens by APCs and major 
histocompatibility complex I (MHC I) presentation of viral antigens for the induction of 
cell-mediated immunity. Chemical inactivation methods, on the contrary, cause extensive 
cross-linking of the microbial proteins [37], thereby compromising the epitope structure as 
well as functionality. Gamma-irradiated Brucella do not lose their structural integrity even 
after 48 hours of infection of macrophage cells [13] indicating that gamma-rays have no 
residual adverse effect on the microbe structure, for at least upto 2 days post-infection. 
Gamma-irradiated organisms also remain functionally intact. For example, gamma-
irradiated Listeria retains the ability to escape into the cytosolic compartment and induce 
robust immunity [12]. This is only possible if the gamma-irradiated Listeria expresses 
listeriolysin O which mediates its escape into the cytosol. Similarly, gamma-irradiated 
Brucella is able to direct its intracellular trafficking ina way to avoid degradation within 
phagolysosomes [13]. This indicates that, while inside the macrophages, gamma-irradiated 
Brucella can express proteins that are necessary for its modulation of the endocytic 
pathway and its survival. Gamma-irradiated Toxoplasma gondii is capable of infecting 




synthesize proteins and even nucleic acids [38]. Hence, gamma-irradiated organisms are 
able to express effectors that allow them to mimic the infection pattern of live pathogens 
and influence the effectiveness of the elicited immune responses. This intact transcriptional 
and translational activity confers enhanced immunoge icity to the gamma-irradiated 
vaccines.  
 
Inducing protective immune responses 
Gamma-irradiated vaccines are capable of eliciting protection in vaccinated hosts (Table 
3.2). Attenuation by gamma-rays has been used for the development of a cross-protective 
experimental vaccine against influenza. The most comm nly used influenza vaccines are 
trivalent split or subunit vaccines that are strain-matched to the seasonal circulating strains. 
These vaccines rely on the induction of strain-specific neutralizing antibodies. In contrast 
to the strain-matched influenza vaccines, natural influenza infections induce 
heterosubtypic immunity. Protection against heterosubtypic strains has been attributed 
mainly to the development of cross-protective cytotoxic T cells against the virus-infected 
cells. Generally, whole virus based vaccines are more immunogenic against influenza than 
subunit or split-product vaccines which frequently require adjuvants and/or multiple 
immunization regimens. Whole virus based vaccines activate the innate immune system 
through TLR-7 which leads to Th1-biased favorable immune responses. Polley et. al. first 
demonstrated the induction of serum neutralizing antibodies and protection against 
homotypic strains by intra-peritoneal (i.p.) vaccinat on with a gamma-irradiated H1N1 
virus [39]. Subsequently, many reports confirmed the ability of gamma-irradiated viruses 
to afford homologous protection [40,41]. The cross-protective potential of gamma-
irradiated influenza vaccines was first demonstrated by Mullbacher et. al. [36]. These cross 
protective responses are believed to be mainly directed against the internal proteins, such 
as the nucleoprotein, which are conserved among the influ nza A strains [42]. Interestingly, 
equivalent doses of formaldehyde treated or ultraviolet (UV) irradiated whole inactivated 
virus preparations failed to induce cross-protective cytotoxic T cell responses [43]. 




H1N1 virus afforded protection against a lethal H5N1 avian influenza virus challenge and 
other heterosubtypic influenza A infections [44]. Gamma Vaccines Pty Ltd, Australia, is 
currently working towards the development of a universal gamma-irradiated influenza 
vaccine (GammaFluTM) that would target both seasonal as well as pandemic markets. 
Unlike with the live-attenuated vaccines, there is no risk of reassortment with the newly 
emerging strains and reverting to a virulent form with gamma-irradiated influenza virus 
vaccines. 
Radiation attenuation has also contributed significantly to the efforts of developing a 
vaccine against malaria. Since the 1970s, researchers have studied vaccination by the bite 
of mosquitoes containing radiation-attenuated sporozoites of Plasmodium falciparum in 
their salivary glands [45-48]. A recent study reported that this type of vaccination induced 
protection in more than 90% of the human volunteers [49]. 
 
Conclusions and future directions:  
Till date, vaccination strategies, particularly against intracellular microorganisms, have 
delivered limited success. Regarding vaccine research, the bottleneck is likely to lie in the 
extensive regulatory restrictions which prevent theranslation of promising vaccine 
research from preclinical trials to the relevant subjects on account of safety or efficacy 
concerns. This translational block can be overcome by using techniques which render the 
vaccinal microorganisms permanently non-replicative but still capable of inducing high 
levels of immunity. Subjecting the vaccine to an optimum dose of gamma-irradiation 
assures non-reversion to virulence and, consequently, the research is more likely to ease 
into the phase of clinical investigation to establish the vaccine efficacy. In contrast to 
rational attenuation, gamma-irradiation is an easily applicable method for broadly 
inactivating a large batch of vaccine preparation. It is likely that using gamma-irradiation 
will allow the development of a more effective and safer alternative to the classic-
attenuated and killed-pathogen vaccine, especially for chronic infections caused by 
intracellular microorganisms. Gamma-irradiation canalso be used for the rapid production 




and Ebola virus. The process of gamma-irradiation also eliminates the purification steps 
and other cumbersome procedural drawbacks associated wi h inactivation methods that 
employ chemicals. Moreover, it is a relatively inexp nsive process that can be an attractive 
and indispensable alternative for nations with limited resources. However, further research 
is needed to establish the shelf-life and thermal stability of irradiated vaccines. Gamma-
irradiation can also be combined with vaccine adjuvants and targeted molecular strategies, 
such as deleterious gene mutations or inclusion of additional genes, in order to obtain the 
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Table 3.1. Differences between killed, gamma-irradiated and live vaccines. 
 Killed vaccines Gamma-irradiated 
vaccines 
Live vaccines 
PAMPs        
vita-PAMPs X     
Replication X X   
Reversion to 
virulence 
X X   
Gene expression X     
Immunogenicity weaker stronger stronger 
Duration of 
immunity 
short lasting long lasting long lasting 
Type of immunity mostly antibody 
mediated 
antibody and cell 
mediated 
antibody and cell 
mediated 
Adjuvant required not required not required 










Table 3.2. Induction of antigen-specific immune responses and protection by gamma-
irradiated vaccines in the indicated host species.  









































Brucella spp.  
[13] 










a 2-3 log 
reduction in 
bacterial load 




























































































































































































50,000 Mice Neutralizing 
antibodies 
More than 















CHAPTER 4. OVEREXPRESSION OF BRUCELLA PUTATIVE 
GLYCOSYLTRANSFERASE WBKA IN B. ABORTUS RB51 LEADS TO 
PRODUCTION OF EXOPOLYSACCHARIDE 
Abstract 
Brucella spp. are Gram-negative, facultative intracellular b cteria that cause brucellosis in 
mammals. Brucella strains containing the O-polysaccharide in their cll wall structure 
exhibit a smooth phenotype whereas the strains devoi  of the polysaccharide show rough 
phenotype.  B. abortus strain RB51 is a stable rough attenuated mutant which is used as a 
licensed live vaccine for bovine brucellosis. Previous studies have shown that the wboA 
gene, which encodes a glycosyltransferase required fo  the synthesis of O-polysaccharide, 
is disrupted in B. abortus RB51 by an IS711 element.  Although complementation of strain 
RB51 with a functional wboA gene results in O-polysaccharide synthesis in the cytoplasm, 
it does not result in a smooth phenotype. The aim of this study was to determine if 
overexpression of Brucella WbkA or WbkE, putative glycosyltransferases essential for O-
polysaccharide synthesis, in strain RB51 would result in the O-polysaccharide synthesis 
and smooth phenotype. Here, we demonstrate that overexpression of wbkA or wbkE gene 
in RB51 did not result in the O-polysaccharide exprssion as shown by Western blotting 
with specific antibodies. However, wbkA, but not wbkE, overexpression led to the 
development of a clumping phenotype and the production of exopolysaccharide(s) 
containing mannose, galactose, N-acetylglucosamine and N-acetylgalactosamine. 




polystyrene plates.  The recombinant strain was similar to strain RB51 in its attenuation 
characteristic and in its ability to induce protective immunity against virulent B. abortus 
challenge in mice.   
 
Introduction 
Members of the genus Brucella are Gram-negative, facultative intracellular coccobacilli 
that can cause chronic infections in several mammals, including humans. Based on the 
structure of the lipopolysaccharide (LPS) molecule and the colony morphology, Brucella 
spp. can be separated into smooth and rough phenotypes. Smooth colony morphology of 
Brucella strains is determined by the presence of LPS containi g the O-polysaccharide (O-
PS) in their cell wall structure. Brucella spp. with LPS that is devoid of the O-PS display 
rough colony morphology. Based on the reactive specificities of antibodies, the O-PS of 
Brucella smooth LPS is defined to contain A (for Abortus), M (for Melitensis) and C (for 
Common) epitopes [1,2].  Brucella O-PS is a linear homopolymer of 4,6-dideoxy-4-
formamido-α-D-mannopyranosyl (perosamine) subunits connected in α-1,2 linkage in A-
dominant smooth Brucella strains, with every fifth residue connected in α-1,3 linkage in 
M-dominant smooth Brucella strains [3,4]. The O-PS is an immunodominant antige, and 
infected animals usually develop robust antibodies to this antigen.  Detection of anti-O-PS 
antibodies in the body fluids is the basis for several brucellosis diagnostic assays. At least 
in some animal species, anti-O-PS antibodies play a role in conferring enhanced protection 
against infections by B. abortus, B. suis and B. melitensis [5-7]. The O-PS also acts as a 
virulence factor by protecting the bacteria against complement-mediated lysis and the 
intracellular bactericidal milieu of phagocytic cells [8]. Consequently, the smooth Brucella 
strains are generally more virulent than their rough counterparts, which are typically 
attenuated [9]. B. abortus RB51, a laboratory derived stable rough attenuated strain, is used 
as a licensed live vaccine in the control of bovine brucellosis in the US and several other 
countries. Strain RB51 does not produce detectable levels of O-PS, and animals vaccinated 
with this strain do not develop anti-O-PS antibodies [10]. However, presence of low levels 




The complete biosynthetic pathway of Brucella smooth LPS is yet to be determined. 
However, several genes are known to be essential for the biosynthesis of the O-PS [12-14]. 
These genes are located in two loci, wbo and wbk, on the Brucella chromosome [13].  
Genes encoding four putative glycosyltransferases, wboA, wboB, wbkA, and wbkE, were 
identified to be involved in the polymerization of perosamine subunits leading to O-PS 
production [12-14].  The precise role of these four enzymes in O-PS synthesis is not yet 
established. In B. abortus RB51, the wboA gene is disrupted by an IS711 element [15]. 
Sequence analysis of the wbo and wbk loci of strain RB51 did not reveal any other gene-
disrupting mutations [16].  Complementation of strain RB51 with a functional wboA gene 
(RB51WboA) did not restore smooth phenotype, but result d in the production of low 
levels of O-PS which remained in the cytoplasm [17]. In mouse models, strain RB51WboA 
vaccination induced low titers of anti-O-PS antibodies and conferred superior protection 
against virulent B. abortus and B. melitensis challenge [17,18]. 
The initial objective of this study was to determine if overexpression of wbkA or wbkE in 
strain RB51 would lead to production of detectable levels of O-PS.  We cloned each gene 
in a multi-copy plasmid under a strong synthetic promoter and used the resulting plasmids 
to transform strain RB51. Although we did not detect any O-PS production by the 
recombinant strains, unexpectedly, the overexpression of wbkA, but not wbkE, in strain 
RB51 led to the development of hypermucoid colonies and the production of 
exopolysaccharide(s) (EPS) containing mannose, galactose, N-acetylglucosamine and N-
acetylgalactosamine. The EPS producing strain was similar to strain RB51 in its attenuation 
and vaccine efficacy characteristics. 
 
Materials and methods 
Bacterial strains 
B. abortus strains RB51 and 2308 were from our culture collection.  B. neotomae and 




RB51WboA was described previously [17]. Escherichia coli strain DH5α (Invitrogen, 
Carlsbad, CA) was used for the preparation of the necessary plasmid constructs. All 
bacteria were grown in tryptic soy broth (TSB) or on tryptic soy agar (TSA) at 37°C. 
Ampicillin at 100 µg/ml was used for growing bacteria harboring plasmids. All 
experiments with virulent Brucella were performed in a BSL-3 facility approved for the 
select agents work.  
 
 Generation of recombinant strains RB51WbkA and RB51WbkE 
The wbkA and wbkE genes were amplified by PCR using custom-designed primer-pairs 
and the genomic DNA of B. abortus 2308 as template.  For the wbkA gene, the forward 
primer (5’-TTTTCCATGGCTCCCTACGAATACATTTGCA-3’) and the reverse primer 
(5’-TTTTTCTAGATTAATAGGTCATGAGCTTAGATTC-3’) contained Nco I and Xba I 
restriction sites, respectively, at the 5’ ends.  Similarly, for the wbkE gene, the forward 
primer (5’-AAGCTTATGCCGCATCTGTATTGGAGA-3’) and the reverse primer (5’-
GGATCCTCACTGCATCAGCGACGTATA-3’) contained Hind III and Bam HI 
restriction sites, respectively, at the 5’ ends.  The amplified fragments were first cloned in 
pGEM-T Easy plasmid (Promega, Madison, WI) and sequenced to confirm the integrity of 
their nucleotide sequences. The inserts were subseqently excised from the pGEM-T 
plasmids using the restriction enzymes specific to the respective restriction sites engineered 
into the primers and cloned in the same sites of pBB4Trc plasmid. The resulting plasmids, 
pBB4TrcWbkA and pBB4TrcWbkE, were electroporated into strain RB51 as per 
previously described procedure [19] to generate strains RB51WbkA and RB51WbkE, 
respectively.   
 
Sample preparation for electron microscopy 
Freshly grown cultures of strains RB51 and RB51WbkA were mixed with an equal volume 
of stock buffer (0.1 M cacodylate buffer, pH 6.8) and incubated at room temperature for 




primary fixative solution (2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M stock 
buffer, pH 6.8). After 1 hr of incubation, the cells were washed 2 times by centrifugation 
with the stock buffer, followed by a final washing with water. Secondary fixation of the 
bacteria was performed for 1 hr in a solution containing 1% osmium oxide and 1.5% 
potassium ferricyanide. 
 
Scanning electron microscopy 
After the secondary fixation, the bacterial cells were washed 2 times with water and filtered 
using a nucleopore membrane (25mm diameter, 0.2 mm pore size, Corning corp., 45 Nagog 
Park, Acton, MA). The bacterial cells were dehydrated using increasing concentrations of 
ethanol and the samples were mounted using a double-side carbon tape and sputter coated 
with platinum (Pt) for 60 secs prior to imaging. Images were obtained using FEI NOVA 
nanoSEM (FEI Company, Portland OR) with 5kV accelerating voltage. 
 
Transmission electron microscopy 
After the secondary fixation, the bacterial cells were washed 2 times with water and 
pelleted by centrifugation. Melted (45°C) agarose (1.5% w/v) was added to the tube and 
the bacterial cells were gently dispersed while keeping the tube in warm water. The 
dispersed bacterial cells and agarose mixture was cooled and extracted from the tube using 
10% ethanol. Samples were then sliced and dehydrated using increasing concentrations of 
ethanol. Propylene oxide (PO) was used for a final ri se. Infiltration was carried out with 
1/3 Spurr’s resin (3 parts PO : 1 part resin) overnight, followed by further infiltration with 
1/1 Spurr’s resin (1 part PO : 1 part resin), 3/1 Spurr’s resin (1 part PO : 3 parts resin) 
overnight, and finally with 100% Spurr’s resin for 6 hrs in a rotator. The cells were then 
embedded in a fresh Spurr’s resin and polymerized for 2 days at 60oC. Samples were 
viewed under the FEI/Philips CM-10 transmission electron microscope (FEI Company, 





SDS-PAGE and Western blotting 
To detect O-PS expression and compare the protein profiles of RB51 and its recombinant 
strains, SDS-PAGE and Western blot analyses were performed as previously described 
[20]. As controls, antigen extracts of the strains RB51, RB51WboA and B. neotomae were 
used. Briefly, antigen extracts of strains RB51, RB51WboA, RB51WbkA, RB51WbkE and 
B. neotomae were separated on a 12.5% denaturing polyacrylamide gel by electrophoresis 
and stained with Coomassie Brilliant Blue.  For Western blotting, the separated antigens 
were transferred onto a nitrocellulose membrane which was subsequently blocked with 5% 
skim milk and reacted with an appropriately diluted rat monoclonal antibody specific to 
Brucella O-PS [10]. The bound primary antibody was detected by reacting with horseradish 
peroxidase labelled-secondary antibody (KPL, Gaithersbur, MD), and developing the 
enzyme reaction using a colorimetric substrate (TMB substrate, KPL, Gaithersburg, MD).  
 
Exopolysaccharide (EPS) staining 
Recombinant strain RB51WbkA and the strain RB51 were grown for 24 hrs at 37°C in 
TSB with ampicillin and TSB alone, respectively. The bacteria were fixed with 4% 
paraformaldehyde (PFA) for 20 mins and used for staining. 
 
Calcofluor white staining 
For detection of polysaccharides, the fixed cells were washed three times with phosphate-
buffered saline (PBS) (pH 8.5) and resuspended in 100 µl of the same buffer. 10 µl of the 
cell preparation was placed on a slide and one dropof calcofluor white stain (Fluorescent 
whitener 28, Sigma) was added to the cells. A coverslip was placed over the sample and 
the cells were visualized immediately using a Nikon A1R confocal laser scanning 





Lectin staining of EPS 
Fluorescently labelled lectins (Vector laboratories Inc, Burlingame, California), 
conjugated with tetramethylrhodamine isothiocyanate (TRITC), with different sugar 
specificities (Table 4.1) were used to characterize the EPS composition. Fixed RB51 and 
RB51WbkA bacterial cells were stained with TRITC-labelled lectins (20 µg/ml in PBS). 
4',6-diamidino-2-phenylindole (DAPI) was used to counterstain the bacterial cells. After 
an incubation for 30 mins in the dark at room temperature, the cells were washed three 
times with PBS, resuspended in 100 µl of the same buffer, and examined immediately 
using a Nikon A1R confocal laser scanning microscope with a 60X 1.4 NA oil immersion 
objective. 
 
Competitive inhibition assay 
The sugars D-(+)-galactose, D-(+)-mannose, N-acetyl-D-galactosamine and N-acetyl-D-
glucosamine (all from Sigma) were used to evaluate the carbohydrate binding specificities 
of the selected lectins (see Table 4.1). The sugars at a final concentration of 3 mg/ml or 
100 mg/ml were mixed with solutions containing specific lectins at a concentration of 20 
µg/ml. The mixtures were incubated for 30 mins in dark at room temperature to allow the 
sugars to bind with specific lectins. Each sugar plus lectin mixture was then used for 
staining the bacterial cells as described above.    
 
Microtiter plate attachment assay 
The attachment assay was performed as previously decrib d [21], with few changes. 
Briefly, strain RB51WbkA was freshly grown overnight in 10 ml of TSB with antibiotic at 
37°C. As controls, strain RB51 and Pseudomonas were grown overnight in 10 ml of TSB 
at 37°C. 100 µl of the overnight cultures was transferred to 10 ml of TSB, mixed thoroughly 
by vortexing, and a 200 µl of each resuspended culture was transferred to 8 wells in a 96-




20 hrs. Then, the liquid medium was removed and the a tached cells were washed with 
sterile PBS (pH 7.4). Plates were air dried for 45 mins and each well was stained with 150 
µl of 1% crystal violet solution (GRAM’S solution, Merck) in water for 45 mins. The wells 
were then rinsed with water, air dried, and the bound stain was released by adding 200 µl 
of 95% ethanol. 100 µl from each well was transferred to a new microtiter plate and the 
intensity of the color was determined by reading the absorbance at 595 nm in a 
spectrophotometer (Molecular devices, Sunnyvale, CA). 
 
Survival of strain RB51WbkA in mice 
Female BALB/c mice of 4 to 6 weeks of age were used. Groups of 9 mice were inoculated 
with 2×108 CFU-equivalent of strains RB51 or RB51WbkA. At days 1, 7 and 21 post 
inoculation (p.i.), 3 mice from each group were euthanized by CO2 asphyxiation followed 
by cervical dislocation. The spleens were collected aseptically and the Brucella CFUs per 
spleen were determined as previously described [10]. Briefly, the spleens were 
homogenized in TSB and ten-fold serial dilutions of the homogenates were plated on TSA 
plates for RB51 and TSA plates containing ampicillin for RB51WbkA. The bacterial CFUs 
were enumerated. 
 
Mice immunizations  
Groups of 4 female BALB/c mice of 4 to 6 weeks of age were used for the study. Mice 
were purchased from a commercial source (Harlan Laboratories, USA), and housed in 
cages with microisolator tops at 4 mice per cage.  Feed and water were provided ad libitum.   
Housing conditions included standard 12 hrs light/dark cycle, controlled humidity (55%) 
and room temperature (22oC).  After 1 week of acclimatization, mice were administered 
with vaccine or control formulation.  
Mice were immunized by intraperitoneal (i.p.) inoculation at day 0 with 2×108 CFU-
equivalent of RB51 or RB51WbkA. Mice inoculated with saline served as control. Blood 




weeks and 6 weeks p.i. The serum was separated from the clotted blood and stored at -
20°C until further use for the detection of antigen-specific antibodies by indirect enzyme-
linked immunosorbent assay (ELISA). 
 
Indirect ELISA 
Indirect ELISA was used to determine the levels of serum immunoglobulin G (IgG), as 
well as IgG1, IgG2a, IgG2b and IgG3 isotypes with specificity to whole antigens of RB51 
and RB51WbkA. Prior to coating the plates for ELISA, RB51 and RB51WbkA were heat-
killed by incubating at 65°C for 1 hr. The antigens were diluted in carbonate buffer, pH 
9.6, to a final concentration of 1×108 CFU-equivalent/ml. The wells of polystyrene plates 
(Nunc-Immunoplate with maxisorp surface) were coated with the diluted antigens (100 
µl/well). Following overnight incubation at 4°C, the plates were washed four times in wash 
buffer (TBS at pH 7.4, 0.05% Tween 20) and blocked with 5% skim milk in TBS. After 1 
hr of incubation at 37°C, mouse sera at 1 in 100 dilution in blocking buffer were added to 
the wells (50 µl/well). Each serum sample was tested in duplicate wells. Following 
incubation at room temperature for 4 hrs, the plates w re washed four times in wash buffer 
and appropriately diluted horseradish peroxidase-lab led anti-mouse isotype specific 
conjugates (Southern Biotechnology Associates Inc, Birmingham, Alabama) were added 
to the wells (50 µl/well). After further 1 hr incubation at room temperature, the plates were 
washed four times, and 100 µl of substrate solution (TMB Microwell peroxidase substrate; 
KPL, Gaithersburg, MD) was added to each well. After 20 mins, the enzyme reaction was 
stopped by adding 100 µl of stop solution (0.185 M sulfuric acid) and the absorbance at 
450 nm was recorded using microplate reader (Molecular devices, Sunnyvale, CA). 
 
Protection experiment 
Protection experiments were performed at Virginia Tech in an ABSL-3 facility that was 
approved for work with select agents.  Female BALB/c mice of 4-6 weeks of age (Harlan 




cages with high-efficiency particulate arresting-filtered air. Feed and water were provided 
ad libitum. Housing conditions included standard 12 hrs light/dark cycle, controlled 
humidity (55%) and room temperature (22oC).  After 1 week of acclimatization, mice were 
administered with vaccine or control formulation.  
Groups of four mice were vaccinated by i.p. inoculation with 2×109 CFU-equivalent of 
RB51 or RB51WbkA. A group of mice inoculated with saline alone served as a control. 7 
weeks p.i, each mouse was challenged by i.p. inoculation with 3×104 CFU-equivalent of 
B. abortus 2308. 2 weeks post-challenge, the mice were euthanized and the bacterial 
burden in their spleens was enumerated as previously de cribed [10]. 
 
Statistical analyses 
Absorbance values of ELISA were analyzed for differences among the groups by 
performing analysis of variance with post hoc Bonferroni and Tukey for pair-wise 
comparison using SPSS version 21.0 (SPSS Inc., an IBM company, USA). For protection 
study, Student -test modified for unequal variances between groups wa  performed to 
compare the log transformed bacterial loads in spleens of mice from each vaccinated group 
with the respective saline group. P values of <0.01 were considered significant. 
 
Ethics statement 
The protocols of the mice experiments performed in th s study were approved by the 
Institutional Animal Care and Use Committees at Purdue University (Approval # 
1112000488) and Virginia Tech (Approval # CVM-10-048). The animal studies were 
conducted in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. Blood was collected from 
the retro-orbital plexus from mice under anesthesia. For anesthetizing mice, regulated 
concentration of anesthetic mixture (oxygen and isoflurane) was administered via a 
commercially available rodent anesthesia machine (Vtamac, Inc., Rossville, Indiana).  




(Bausch & Lomb, Tampa, Florida) was placed on the eye to reduce pain. Mice infected 
with virulent B. abortus 2308 do not develop clinical disease or exhibit any signs of 
suffering for the duration of the experiments conducted in this study. Therefore, no humane 
endpoints were utilized for the mice in this study. 
 
Results 
B. abortus RB51 overexpressing wbkA gene displays a clumping phenotype 
The colonies of strain RB51WbkA exhibited an excessively mucoid phenotype on agar 
plates and when grown in liquid culture, the bacteria formed strings and clumps (Fig. 4.1B). 
Strains RB51 (Fig. 4.1A) and RB51WbkE (data not shown), on the other hand, displayed 
uniform dispersion in liquid culture. As a result of the strikingly distinctive phenotype of 
strain RB51WbkA, several colonies were analyzed by RB51-specific PCR [15] and all of 
them were confirmed to be derived from strain RB51 (data not shown). One colony was 
selected for further studies. 
Scanning and transmission electron microscopy were performed to examine the 
morphology of the bacteria. Strain RB51 culture contained well-defined coccobacilli, with 
relatively little or no visible extracellular material (Fig. 4.2A). In contrast, the recombinant 
strain RB51WbkA displayed formation of aggregates (Fig. 4.2B, left panel) containing 
bacterial cells and extraneous matrix material (Fig. 4.2B, left panel) characteristic of EPS. 
The recombinant bacterial cells also displayed altered cell walls (Fig. 4.2B). 
 
Overexpression of wbkA in the strain RB51 does not result in O-PS synthesis 
The antigen extracts of strain RB51WbkA did not react with Bru-38, a Brucella O-PS-
specific monoclonal antibody, indicating the absence of O-PS expression (Fig. 4.3A, lane 
3). As expected, strain RB51WboA and B. neotomae reacted with the antibody (Fig. 4.3A, 




lane 2). Strain RB51WbkE also did not react with the O-PS specific monoclonal antibody 
(Fig. 4.3A, lane 4). 
SDS-PAGE analysis did not reveal any apparent qualitative differences in the protein 
profiles between strains RB51 and RB51WbkA (Fig. 4.3B)   
 
RB51WbkA bacterial clumps contain EPS 
Bacterial extracellular matrices are frequently comp sed of polysaccharides. Therefore, a 
general EPS dye, calcofluor white, was used to determin  the presence of EPS in the 
aggregate-forming strain RB51WbkA. As shown in Fig. 4.4B, a bright fluorescence was 
exhibited by strain RB51WbkA, indicating the presenc  of an extracellular polysaccharide 
composed of (1-4)- and/or (1-3)-β-D-linked glucan residues. The dye failed to bind with 
strain RB51 (Fig. 4.4A). The bacterial cells of strain RB51WbkA also bound with 
mannose-specific-TRITC-labelled LCA (Fig. 4.5B), mannose-specific-TRITC-labelled 
PSA (data not shown), galactose-specific-TRITC-label ed GSL I (data not shown), N-
acetylglucosamine-specific-TRITC-labelled succinylated WGA (data not shown) and N-
acetylgalactosamine-specific-TRITC-labelled SJA (Fig. 4.6B). However, strain 
RB51WbkA did not demonstrate any apparent binding to the lectins PHA-E and PHA-L 
(data not shown), which have specificity for complex polysaccharide structures. The 
bacterial cells of strain RB51 exhibited very weak fluorescence with mannose-specific-
TRITC-labelled LCA (Fig. 4.5A) and PSA lectins (data not shown) when compared to 
strain RB51WbkA. Also, strain RB51 did not show any apparent binding with any of the 
other lectins tested, including TRITC-labelled SJA (Fig. 4.6A).  
 
EPS produced by RB51WbkA contains mannose, galactose, N-acetylglucosamine and N-
acetylgalactosamine 
In order to verify the specific lectin-binding pattern of strain RB51WbkA, competitive 
inhibition assay was carried out using 5 selected lectins (TRITC conjugated LCA, PSA, 




lectins to the EPS components was accomplished by using their respective target primary 
sugars (Table 4.1). The inhibition of lectin binding was evaluated microscopically by 
comparing the binding characteristic as well as the fluorescence intensity of strain 
RB51WbkA in presence and absence of the target carbohydrate. The observed binding 
pattern of the TRITC-labelled LCA and SJA are shown (Fig. 4.5 and 4.6, respectively). 
Original binding pattern of the TRITC-labelled LCA and SJA to the EPS(s) of the strain 
RB51WbkA in the absence of target carbohydrate is shown in Fig. 4.5B and 4.6B, 
respectively. Binding of the TRITC-labelled lectins to the EPS(s) was completely 
abrogated when the lectins were incubated with their target sugars at a concentration of 
100 mg/ml (Fig. 4.5D and 4.6D). At carbohydrate concentrations of 3 mg/ml, the binding 
of TRITC-labelled LCA (Fig. 4.5C), PSA (data not shown), WGA (data not shown) and 
GSL I (data not shown) to the bacterial strain RB51WbkA was greatly reduced when 
compared with the binding pattern in the absence of the target sugars (Fig. 4.5B). However, 
at 3 mg/ml, N-acetylgalactosamine only slightly inhibited the binding of TRITC-labelled 
SJA lectin to the EPS(s) produced by strain RB51WbkA (Fig. 4.6C).  
 
RB51WbkA displays increased adhesion property 
We assessed the ability of strain RB51WbkA to adhere to a 96-well polystyrene plate when 
compared to strain RB51. Pseudomonas spp. was used as a positive control for this 
adherence assay. Strain RB51WbkA displayed significantly increased adherence to 
polystyrene wells when compared to strain RB51 (Fig. 4.7).  
 
Bacterial persistence in mice spleens 
Bacterial persistence of strain RB51WbkA in mouse spl ens was determined and compared 
with that of strain RB51. As shown in Fig. 4.8, similar numbers of bacteria were present in 
the spleens of mice at days 1, 7 and 21 after inoculation with strains RB51WbkA and RB51. 
This result suggests that overexpression of wbkA did not affect the clearance of the 




Induction of antigen-specific antibody responses 
Serum samples collected from the groups of mice immunized with strains RB51 and 
RB51WbkA were analyzed in comparison with the sera obtained from the saline-
inoculated group of mice (Fig. 4.9 and 4.10). Analysis with IgG-specific conjugate 
revealed that significantly higher level of RB51-specific IgG was present at 6 weeks p.i. in 
mice vaccinated with RB51 and RB51WbkA when compared with saline-inoculated mice 
(Fig. 4.9). Moreover, mice vaccinated with RB51 and RB51WbkA developed significantly 
higher levels of IgG2a, IgG2b and IgG3 isotypes specific to RB51 at 3 and 6 weeks p.i. 
when compared with saline-inoculated controls (Fig. 4.9). However, only vaccination with 
strain RB51WbkA resulted in a significant increase in RB51-specific IgG1 antibody at 6 
weeks p.i. (Fig. 4.9). 
Significantly increased levels of RB51WbkA-specific IgG, IgG2a and IgG3 antibodies 
were detected in serum of mice vaccinated with strains RB51 and RB51WbkA at 3 and 6 
weeks p.i. than in saline-inoculated mice (Fig. 4.10). Moreover, mice vaccinated with 
RB51WbkA developed significantly higher levels of RB51WbkA-specific IgG at 3 and 6 
weeks p.i., as well as RB51WbkA-specific IgG2a at 6 weeks p.i., when compared with 
RB51 vaccinated group of mice (Fig. 4.10). Only vaccination of mice with RB51WbkA 
resulted in significantly increased levels of RB51WbkA-specific IgG1 at 3 and 6 weeks 
p.i. when compared with the saline-inoculated mice (Fig. 4.10). Assay with IgG2b-specific 
conjugate revealed that RB51WbkA-specific IgG2b antibody was present at significantly 
higher levels in RB51 and RB51WbkA vaccinated groups of mice at 6 weeks p.i. when 
compared to saline-inoculated controls. However, at 3 weeks p.i., only the mice vaccinated 
with strain RB51WbkA developed significantly higher l vels of RB51WbkA-specific 
IgG2b antibody than the saline-inoculated group (Fig. 4.10).  
 
Protection against challenge with virulent B abortus 2308 
Mice vaccinated with RB51 and RB51WbkA had significantly reduced number of virulent 




4.11). However, there was no statistical difference i  the splenic bacterial loads between 
the two vaccinated groups of mice. 
 
Discussion 
In this study, we unexpectedly discovered that overexpression of wbkA in strain RB51 
confers an extreme mucoid and clumping phenotype that is associated with the production 
of EPS. It is known that wbkA, which encodes a putative glycosyltransferase, is ssential 
for the O-PS and smooth LPS synthesis in B. abortus and B. melitensis [14].  However, the 
present study is the first to demonstrate the role of this gene product in EPS production in 
a Brucella strain.  Till date, production of EPS was reported in certain recombinant gene-
knockout or gene-overexpression strains of B. melitensis [22-25]. B. melitensis strain 
deficient in transcriptional regulator VjbR, which is involved in quorum sensing, was 
shown to produce EPS-like substance [23].  Overexpression of AiiD, an enzyme that 
degrades quorum sensing molecule acylhomoserine lactone (AHL), also leads to 
production of EPS in B. melitensis [24].  Interestingly, overexpression of MucR, an 
orthologue of a Sinorhizobium meliloti transcriptional regulator of its succinoglycan EPS, 
in B. melitensis resulted in clumping phenotype which is associated with EPS production 
[22].  A study also showed that EPS production occurs in virB mutants of B. melitensis 
[25].  Interestingly, overexpression of WbkA in strain VTRA1, a B. abortus wboA mutant 
[26], also resulted in the development of mucoid colonies that formed strings in liquid 
culture (result not shown). However, overexpression of WbkA in B. abortus 2308 resulted 
in mucoid colonies on solid media but the bacteria did not form strings in liquid culture 
(result not shown), suggesting the presence of some regulatory mechanism in the O-PS and 
EPS synthetic pathways.   Currently, it is not clearly known if Brucella produces EPS in 
response to any natural environmental conditions or during the course of infection in 
mammalian hosts.   However, above mentioned studies document the genetic competence 
of B. melitensis to produce EPS. Evidence for clumping phenotype and EPS production in 
B. melitensis under certain hypertonic culture conditions [22], and in B. abortus under 




Brucella belongs to the class Alphaproteobacteria; several members of the class 
Alphaproteobacteria are known to produce EPS(s) during their life-cycle [28,29]. For 
example, Sinorhizobium meliloti produces an EPS, succinoglycan, which is essential for 
the expression of its full virulence including formation and invasion of nodules [28,30]. 
Interestingly, a family of glycosyltransferases was shown to be required for the synthesis 
of succinoglycan by Sinorhizobium spp [31]. Similarly, Agrobacterium strains also 
produce an EPS which is structurally identical to the succinoglycan EPS; however, it has 
been found to be dispensable for the formation of cr wn gall tumors by Agrobacterium 
tumefaciens [30].  The EPS produced by RB51WbkA increased the bacterial adherence to 
plastic matrix, but it did not have an effect on the bacteria’s susceptibility to polymyxin B 
killing and persistence in mice.  This suggests that t e EPS did not prevent the rough LPS 
in the cell wall of RB51WbkA from external chemicals nor it was able to alter the 
attenuation characteristic of the bacteria.  
The structure of EPS produced by RB51WbkA still needs to be determined. However, the 
qualitative results of our lectin binding studies indicate the presence of mannose, galactose, 
N-acetylglucosamine and N-acetylgalactosamine in the EPS.  This EPS composition is 
similar to that reported for B. melitensis [24], where mannose was detected to be the 
primary sugar in the EPS.  Several of our attempts to purify the EPS from RB51WbkA 
were unsuccessful.  This could have been because of th molecular nature of the complexes 
between EPS and rough LPS of RB51.  Any future studies should take this into 
consideration for developing strategies for purification of EPS from RB51WbkA.   
Two-component systems have been found to regulate the EPS formation in many plant 
pathogenic bacteria, including Sinorhizobium meliloti [32,33]. These systems can sense the 
specific bacterial requirements during pathogenesis and can subsequently regulate the 
production of EPS. Global regulatory mechanisms, such as the two-component systems, 
quorum sensing (QS), also fine-tune the synthesis and secretion of EPS, leading to an 
increase in synthesis during nutritional stress and ecrease in EPS synthesis during 
growth of cells under nutrient sufficient environment. A previous study has demonstrated 
the formation of clumps in liquid culture by a vjbR mutant strain of B. melitensis [23]. 




explanation of this phenomenon is that the bacteria a e unable to regulate the vjbR-
dependent AHL-mediated repression of genes which are involved in clumping [23]. VjbR 
was found to regulate the EPS synthesis and/or export, and also the production of several 
outer membrane proteins (OMPs) [23].  Another study documented the induction of a 
similar clumping phenotype by Brucella overexpressing AHL-acylase aiiD [24]. The 
authors hypothesize that the overexpression of aiiD leads to the degradation of all of the 
intrinsically synthesized AHLs, resulting in unbound VjbR regulators which activate the 
expression of genes involved in clumping [24]. wbkA was found to be a QS-target using 
proteomic and microarray analysis [34]. It is interesting that WbkA is the only 
glycosyltransferase identified as a target of QS-regulators in the study. Further studies need 
to be undertaken to investigate the role of the QS-regulators in modulating the expression 
of wbkA under specific environmental conditions and the effect of gene-interplay on the 
level of the EPS production. 
Mice immunized with strain RB51WbkA appeared to develop antibodies to the EPS, as 
significantly higher levels of IgG antibodies were d tected to be specific to RB51WbkA 
than RB51.  IgG1 and IgG2a were the prominent isotypes that contributed to this 
difference.  Nevertheless, both RB51 and RB51WbkA vaccines induced the same level of 
protective response against the virulent B. abortus challenge, suggesting the minimal, if 
any, role of EPS in modulating immune responses in mice. 
In conclusion, our studies demonstrate that the overexpression of wbkA in RB51 results in 
the production of EPS that confers increased adherenc  property to the polystyrene 
surfaces. This EPS was found to contain mannose, galactose, N-acetylglucosamine and N-
acetylgalactosamine. This finding adds to the growing evidence for the EPS synthesis in 
Brucella.  EPS has previously been shown to aid some bacteri  to survive in a hostile 
environment, evade the immune mechanism of the host, and adhere to the host cells 
[35,36]. Further studies to identify the role of EPS in affecting the bacterial fitness under 
different environmental conditions would help delinate the precise contribution of EPS to 
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Table 4.1. Carbohydrate-binding specificities of lectins employed in this study for the 
staining of EPS(s) produced by the recombinant strain RB51WbkA. 




























































Figure 4.1. Observation of the clumping phenotype of the recombinant strain B. abortus 
RB51WbkA. (A) B. abortus RB51; (B) strain B. abortus RB51 overexpressing the wbkA 
gene. 
 
Figure 4.2. Electron microscopic images of strain RB51WbkA. Scanning electron 
micrographs (left panels; ×30,000) and transmission electron micrographs (right panels; 
×15,000) of the strains (A)  B. abortus RB51 and (B) B. abortus RB51WbkA. The 
recombinant strain RB51WbkA displays a clumping phenotype and produces EPS(s). 
Scanning electron micrograph show the clumping phenotype of the recombinant strain 






Figure 4.3. (A) Western blot analysis to detect O-PS expression by the strain RB51WbkA 
and (B) Coomassie Brilliant Blue staining of the polyacrylamide gel to detect difference in 
the protein profiles of strain RB51 and strain RB51WbkA.  Whole antigens of the strain 
RB51, recombinant strain RB51WbkA, RB51WbkE, RB51WboA and B. neotomae were 
separated by 12.5% SDS-PAGE and analyzed by (A) Western blotting with O-PS specific 
monoclonal antibody, Bru-38. Lane 1: molecular weight marker (MW) in kilodaltons 
(kDa); lane 2: strain RB51; lane 3: recombinant strain RB51WbkA; lane 4: recombinant 
strain RB51WbkE; lane 5: recombinant strain RB51WboA; lane 6: strain B. neotomae. 
Whole antigens of the strain RB51, RB51WbkA and RB51WbkE were analyzed for any 
differences in the expressed protein profiles by (B) Coomassie Brilliant Blue staining of 






Figure 4.4. Confocal microscopy of the EPS(s) produce  by the recombinant strain 
RB51WbkA.  Interactions between the calcofluor white stain andthe aggregates formed 
by the strain RB51WbkA were visualized using confocal laser scanning microscopy. (A) 
Strain RB51; (B) strain RB51WbkA. Selected differential interference contrast (DIC) 
images (left panel) and fluorescent images (middle panel) merged are shown (right panel). 







Figure 4.5. Confocal laser scanning microscopy showing the interactions between the 
fluorescently labelled LCA lectin and the (A) strain RB51; (B, C & D) strain RB51WbkA.  
Panel A and B show the bacterial cells stained with TRITC-labelled LCA lectin (red) in 
the absence of the target carbohydrate. Panel C & D show the bacterial cells of the strain 
RB51WbkA stained with TRITC-labelled LCA lectin preincubated with (C) 3mg/ml 
mannose and (D) 100 mg/ml mannose, prior to staining. DAPI (blue) was used to stain the 
bacterial nuclei. Selected differential interferenc contrast (DIC) images (left panel) and 
fluorescent images (middle panels) merged are shown (right panel). All images were 






Figure 4.6. Confocal laser scanning microscopy showing the interactions between the 
fluorescently labelled SJA lectin and the (A) strain RB51; (B, C & D) strain RB51WbkA.  
Panel A and B show the bacterial cells stained withTRITC-labelled SJA lectin (red) in the 
absence of the target carbohydrate. Panel C & D show t e bacterial cells of the strain 
RB51WbkA stained with TRITC-labelled SJA lectin preincubated with (C) 3mg/ml N-
acetylgalactosamine and (D) 100 mg/ml N-acetylgalactosamine, prior to staining. DAPI 
(blue) was used to stain the bacterial nuclei. Select d differential interference contrast 
(DIC) images (left panel) and fluorescent images (middle panels) merged are shown (right 
panel). All images were acquired using the same settings and adjusted for display using the 





Figure 4.7. Quantification of the microtiter plate adhesion assay of the recombinant strain 
RB51WbkA. The surface attachment of the strain RB51, recombinant strain RB51WbkA 
and Pseudomonas spp. is shown. Quantification of the microtiter plate dhesion is done by 
staining the adherent bacterial cells with crystal vio et, subsequent solubilization of the 
crystal violet stain in ethanol and spectrophotometric determination of absorbance at 595 
nm. Results are shown as mean ± standard deviation of absorbance of eight independent 








Figure 4.8. Determination of bacterial persistence in spleens of mice immunized with 
recombinant strain RB51WbkA. Mice spleens were collected at day 1, day 7 and day 21 
after vaccination with live RB51 and live recombinant RB51WbkA. The Brucella CFUs in 
their spleens were determined. Results are shown as me n ± standard deviation (n=3) of 
the log CFU of Brucella recovered from spleens. Overexpression of wbkA in RB51 does 





Figure 4.9. Detection of RB51-specific antibodies in serum of mice vaccinated with live 
recombinant RB51WbkA. Mice were vaccinated with live RB51, live recombinant 
RB51WbkA, or inoculated with saline. Serum samples w re collected at 3 and 6 weeks 
after vaccination, and were diluted 1 in 100 and assayed for the presence of total antigen-
specific IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect ELISA. Results are 
shown as mean ± standard deviation (n=4) of absorbance of the color developed. 
*Significantly different from the corresponding saline group at week 3 (P < 0.01). 






Figure 4.10. Detection of RB51WbkA-specific antibodies in serum of mice vaccinated with 
live recombinant RB51WbkA. Mice were vaccinated with live RB51, live recombinant 
RB51WbkA, or inoculated with saline. Serum samples were collected at 3 and 6 weeks 
after vaccination, and were diluted 1 in 100 and assayed for the presence of total antigen-
specific IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect ELISA. Results are 
shown as mean ± standard deviation (n=4) of absorbance of the color developed. 
*Significantly different from the corresponding saline group at week 3 (P < 0.01). 






Figure 4.11. Detection of the protective efficacy of RB51WbkA against challenge with the 
virulent strain B. abortus 2308. Mice vaccinated with live RB51, live recombinant 
RB51WbkA and saline-inoculated mice were challenged by i.p. inoculation of 3×104 CFU-
equivalent of virulent strain 2308.  2 weeks post-challenge, the mice were euthanized and 
the Brucella CFUs in their spleens were determined. Results are hown as mean ± standard 
deviation (n=5) of the log CFU of Brucella recovered from spleens. *Significantly different 





CHAPTER 5. OVEREXPRESSION OF WBKF GENE IN BRUCELLA ABORTUS 
RB51WBOA LEADS TO O-POLYSACCHARIDE EXPRESSION AND ENHANCED 
PROTECTION AGAINST BRUCELLA ABORTUS 2308 AND BRUCELLA 
MELITENSIS 16M IN A MURINE BRUCELLOSIS MODEL 
Abstract 
Brucella abortus strain RB51 is an attenuated, stable, rough mutant derived in the 
laboratory from the virulent strain B. abortus 2308. Animals vaccinated with strain RB51 
do not produce antibodies to the O-polysaccharide (O-PS) of the smooth 
lipopolysaccharide (LPS). Previous studies have shown that the wboA gene, which encodes 
a glycosyltransferase required for the synthesis of the O-PS, is disrupted in strain RB51 by 
an IS711 element. Complementation of strain RB51 with a functional wboA gene (strain 
RB51WboA) results in low levels of cytoplasmic O-PS synthesis, but it does not confer a 
smooth phenotype.  In this study, we asked if increasing the amount of bactoprenol priming 
precursors in strain RB51WboA would result in smooth LPS synthesis. To achieve this, 
we overexpressed the wbkF gene, which encodes undecaprenyl-glycosyltransferase 
involved in bactoprenol priming for O-PS polymerizat on, in strain RB51WboA to 
generate strain RB51WboAKF. In comparison with strain RB51WboA, strain 
RB51WboAKF expressed higher levels of O-PS. Immuno-electron microscopy revealed 
that the expressed O-PS was present in the cell wal of RB51WboAKF. However, 
RB51WboAKF strain exhibited rough phenotypic characteristic in acriflavine 
agglutination test. Mice immunized with strain RB51WboAKF developed increased levels 




compared with those immunized with strain RB51WboA. Splenocytes from the 
RB51WboAKF vaccinated group of mice secreted higher levels of antigen-specific IFN-γ, 
IL-10 and TNF-α when compared to those of the RB51 or RB51WboA vaccin ted groups. 
Also, increased numbers of antigen-specific IFN-γ secreting CD4+ and CD8+ T 
lymphocytes were detected in RB51WboAKF vaccinated mice. Immunization of mice with 
strain RB51WboAKF conferred enhanced protection against virulent B. abortus 2308 and 
B. melitensis 16M when compared with the RB51 and RB51WboA immunized groups of 
mice.  These results suggest that, in addition to wb A gene, mutations affecting expression 
of several other genes involved in the synthesis of O-PS and smooth LPS contribute to the 
rough phenotype of strain RB51.  Our results also suggest that strain RB51WboAKF could 
be a more efficacious vaccine than its parent strain in natural hosts.   
 
Introduction 
Bacteria belonging to the genus Brucella are Gram-negative, facultative intracellular 
coccobacilli that cause one of the most frequently encountered zoonosis worldwide known 
as brucellosis. Brucella spp. infect a wide variety of mammals and can cause abortions in 
natural hosts and undulant fever in humans. They can exhibit smooth or rough colony 
morphology depending on the structure of their lipopolysaccharide (LPS). Except for B.
canis and B. ovis, all other Brucella species known to date possess a surface-exposed O-
polysaccharide (O-PS) in their LPS moiety and exhibit a smooth phenotype. Rough strains 
are devoid of the O-PS in their LPS and are generally attenuated than their smooth 
counterparts [1-5]. O-PS is a linear homopolymer of 4,6-dideoxy-4-formamido-α-D-
mannopyranosyl (perosamine) subunits. These subunits are connected in α-1,2 linkage in 
A-dominant strains, with every fifth residue connected in α-1,3 linkage in M-dominant 
Brucella strains [6,7]. O-PS protects the smooth Brucella spp. from host defense 
mechanisms including complement-mediated lysis and the phagocytic microbicidal 
functions [1,8]. Acquired immunity against brucellosis is primarily cell-mediated and IFN-
γ producing CD4+ and CD8+ T cells play a major role in protection against Brucella [9]. 




virulent B. abortus 2308, B. melitensis and B. suis [10-13]. Currently, B. abortus strain 
RB51 is used as a licensed cattle vaccine in United States and several other countries [4]. 
It is a laboratory-derived rough, stable mutant of virulent B. abortus 2308 [4]. It can express 
low levels of M-like O-PS; however, it does not induce detectable levels of antibodies to 
the O-PS in vaccinated animals [4,14].  
The complete smooth LPS biosynthetic pathway is still not fully understood. The genes 
that are essential for the O-PS biosynthesis are located on two genetic loci, wboA and wbkA, 
of Brucella genome [15]. Previous studies have demonstrated that an IS711 element 
disrupts the wboA gene, which encodes a glycosyltransferase required fo  the synthesis of 
O-PS in Brucella, in strain RB51 [16]. Complementing strain RB51 with a functional wboA 
gene (strain RB51WboA) resulted in the expression of low levels of intra-cytoplasmic O-
PS; however, it did not restore the smooth phenotype [17]. Interestingly, when compared 
with strain RB51, immunization of mice with RB51WboA resulted in superior level of 
protection against virulent B. abortus 2308 and B. melitensis 16M strain [17,18]. Recent 
nucleotide sequence analysis of genes in the wbo and wbk loci did not reveal any other 
apparent mutation that could affect the O-PS synthesis in strain RB51 [19].  
 The objective of this study was to determine if increasing the amount of bactoprenol 
priming precursors in strain RB51WboA would result in smooth LPS synthesis and 
enhanced protection against virulent Brucella challenge. Gene wbkF, encoding putative 
undecaprenyl-glycosyltransferase, was identified to be essential for O-PS synthesis in 
Brucella [15]. We cloned the wbkF gene under a strong promoter in a multi-copy plasmid 
vector harboring the wboA gene and transformed strain RB51 with the resulting plasmid 
pBBR/wboAKF to generate strain RB51WboAKF. Our results indicate that strain 
RB51WboAKF produces smooth LPS but does not exhibit smooth colony phenotype or 
increased virulence.  We also demonstrate that vaccin tion with strain RB51WboAKF 






Materials and methods 
Bacterial strains 
 B. abortus strains RB51, RB51WboA and 2308, and B. melitensis strain 16M were from 
our culture collection. The required plasmid constructs were prepared using Escherichia 
coli strain DH5α (Invitrogen, Carlsbad, CA). Tryptic soy broth (TSB) and tryptic soy agar 
(TSA) were used as growth media for all bacterial strains. The growth medium was 
supplemented with chloramphenicol at 30 µg/ml for selection of bacteria harboring the 
plasmids. All protection experiments with virulent Brucella were performed in a BSL-3 
facility approved for the select agents work. 
 
Generation of recombinant strains RB51WbkF, RB51WboAKF and RB51WboAKD 
Genes wbkF and wbkD were amplified using custom-designed primer-pairs by PCR. B. 
abortus 2308 genomic DNA was used as template. Forward primer (5’-
TTTTGGTACCGGGCGTATGGTTGCGG) and reverse primer (5’-
TTTTCTCGAGCGCTTCAGGAAGCTATGACC) containing Kpn I and Xho I restriction 
sites, respectively, were used to amplify wbkD. Similarly, forward primer (5’-
TTTTGGTACCGAGCTTTGACATTATCCGTG) and reverse primer (5’-
TTTTCTCGAGGTCATAGCTTCCTGAAG) containing Kpn I and Xho I restriction sites, 
respectively, were used to amplify wbkF. The amplified fragments were cloned in pGEM-
T Easy plasmid (Promega, Madison, WI) and the integrity of the nucleotide sequences was 
confirmed by sequence analysis. The inserts were subsequently excised from the pGEM-T 
plasmids using the restriction enzymes specific to the respective restriction sites engineered 
into the primers. wbkF was subsequently cloned in the same sites of pBBR1Trc and 
pBBR/wboA [20,21]. wbkD was cloned in the same sites of pBBR1Trc [20,21]. The 
resulting plasmids, pBB1WbkF (wbkF), pBB1/wboAKF (wboA and wbkF) and 




described procedure [22] to generate strains RB51WbKF, RB51WboAKF and 
RB51WboAKD, respectively.   
 
SDS-PAGE and Western blotting 
SDS-PAGE and Western blot analyses were carried out as previous described [2]. Briefly, 
antigen extracts of RB51, RB51WboA, RB51WboAKF, RB51WboAKD and B. neotomae 
were separated electrophoretically on a 12.5% denaturi g polyacrylamide gel. The gel was 
subsequently stained with Coomassie Brilliant Blue. For Western blotting, the separated 
antigens were transferred onto a nitrocellulose membrane. Following membrane blocking 
in 5% skim milk for 3 hrs, the membrane was reacted with appropriately diluted Brucella 
O-PS specific rat monoclonal antibody, Bru-38 [4]. Horseradish peroxidase labelled-
secondary antibody (KPL, Gaithersburg, MD) followed by the development of the 
enzymatic reaction by a colorimetric substrate (TMB substrate, KPL, Gaithersburg, MD) 
were used to detect the binding of the primary antibody.  
 
Immuno-electron microscopy 
 Freshly grown cultures of B. neotomae and strains RB51 and RB51WboAKF were used. 
The bacterial cells were fixed in 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M 
sodium phosphate buffer.  They were then pelleted in 2% agarose (Sigma-Aldrich), 
dehydrated with a graded ethanol series to 85% ethanol and infiltrated with LR White resin. 
Polymerization was done overnight at 53°C in flat emb dding molds (Ted Pella, Inc.). 
Sections were cut on a Reichert-Jung Ultracut E ultramicrotome and collected on 100 mesh 
formvar-coated nickel grids. Grids were incubated on 50 mM glycine for 30 mins and then 
on blocking solution (0.1 M sodium phosphate buffer containing 0.5% Aurion BSA-c™, 
1% normal goat serum, and 0.2% Tween 20) for 1 hr. Primary antibody incubation was 
done overnight at 4°C with a 1:100 dilution of the rabbit anti-B. neotomae LPS antibody 
in blocking solution. Grids were rinsed seven times and incubated on goat anti-rabbit 




were washed six times and stained with 2% uranyl acetate. Images were acquired on a FEI 
Tecnai G2 20 electron microscope equipped with a LaB6 source and operating at 100 kV. 
 
Extraction of LPS  
Total LPS was extracted from live B. neotomae, RB51, RB51WboA and RB51WboAKF 
by butanol-water method as previously described [23,24]. Briefly, freshly grown bacterial 
cultures were pelleted by centrifugation and suspended in 0.85% NaCl at a concentration 
of 0.25 g wet weight/ml. An equal volume of water saturated butanol was added with 
constant mixing for 15 mins at 4ºC. The aqueous phase was collected by centrifugation at 
35,000×g for 20 mins. The LPS was precipitated using 4 volumes of cold methanol. The 
precipitate was dissolved in 0.1 M Tris buffer (pH 8) containing 2% SDS and 2% beta-
mercaptoethanol and heated for 5 mins at 100ºC followed by incubation with proteinase K 
at 56ºC. LPS was finally precipitated by cold methanol and dissolved in water. Purity of 
the extracted LPS was confirmed by SDS-PAGE followed by silver staining of the gel. The 
extracted B. neotomae smooth LPS was used as antigen in indirect ELISA. 
 
LPS analysis 
A 12.5% and a 15% denaturing polyacrylamide gel was used for Western blot analysis and 
silver staining, respectively. The extracted LPSs were separated electrophoretically in 
sodium dodecyl sulfate-polyacrylamide gel. For Western blotting, the separated LPSs were 
transferred onto a nitrocellulose membrane. Following membrane blocking in 5% skim 
milk for 3 hrs, the membrane was reacted with approriately diluted B. neotomae LPS-
specific antibody. Horseradish peroxidase labelled-s condary antibody (KPL, 
Gaithersburg, MD) followed by the development of the enzymatic reaction by a 
colorimetric substrate (TMB substrate, KPL, Gaithersburg, MD) was used to detect the 
binding of the primary antibody. Silver staining of the polyacrylamide gel was performed 





Polymyxin B sensitivity assay 
Polymyxin B (PmB) sensitivity assay was performed as described previously [1,25]. 
Briefly, RB51, RB51WboAKF and B. neotomae were grown to log phase, in TSB for RB51 
and B. neotomae and in TSB supplemented with 30 µg/ml chloramphenicol for 
RB51WboAKF. The bacterial cultures were pelleted by centrifugation at 4,200×g, 
resuspended in 10 mM phosphate buffer (pH 7.2) at approximately 1×104 CFU/ml, and 
incubated for 1 hr with different concentrations of p lymyxin B. Following incubation, the 
cell suspensions were diluted 1:10 and 1:100 in 10 mM phosphate buffer and 50 µl was 
plated on TSA plates. The plates were incubated at 37°C for 5 days and the bacterial 
colonies on each plate were counted.  Average results of three assays were expressed as 
percentages of the Brucella surviving in the absence of polymyxin incubation. 
 
Vaccine preparation 
B. abortus RB51, RB51WboA and RB51WboAKF were grown in liquid media to mid log 
phase, and aliquots of 1 ml were prepared and stored at -80ºC until further use. The number 
of bacteria in the aliquots was enumerated by performing ten-fold serial dilutions and 
plating them on TSA plates for RB51 and TSA plates supplemented with 30 µg/ml 
chloramphenicol for RB51WboA and RB51WboAKF. The plates were incubated at 37°C 
for 3-4 days and the bacterial CFUs were counted. 
 
Persistence in mouse organs 
Female BALB/c mice of 4 to 6 weeks of age were used for the studies. Mice were 
purchased from a commercial source (Harlan Laboratories, USA), and housed in cages 
with microisolator tops at 4 mice per cage.  Feed an water were provided ad libitum.   
Housing conditions included standard 12 hrs light/dark cycle, controlled humidity (55%) 
and room temperature (22oC).  Mice were allowed to acclimatize to the new environment 




Groups of twelve mice each were inoculated by intra-peritoneal (i.p.) route with 2×108 
CFU of live RB51 or RB51WboAKF. Three mice from each group were euthanized by 
CO2 asphyxiation followed by cervical dislocation on days 1, 7, 21 and 28 post-
immunization (p.i.) and their spleens, livers, and lungs were aseptically collected. The 
Brucella CFUs in the organs were enumerated as previously described [4]. Briefly, the 
tissues were homogenized with a tissue micer and were s rially diluted 10-fold in TSB. 
Fifty µl from each serial dilution was plated on TSA plates for RB51 and on TSA plates 
containing 30 µg/ml chloramphenicol for RB51WboAKF. The plates were incubated for 
up to 5 days at 37ºC. The bacterial CFUs were enumerated. 
 
Mice immunizations 
Groups of 4 mice each were immunized by i.p. inoculation with 2×108 CFU of live RB51, 
RB51WboA or RB51WboAKF. A group was inoculated with saline only as a control. At 
3 and 6 weeks p.i., blood from anesthetized mice was collected by puncture of retro-orbital 
plexus. The sera was separated from the clotted blood and was stored at -20°C until further 
use for antibody-mediated immune response analysis b  indirect ELISA. Also, at 6 weeks 
p.i., the mice were anesthetized by CO2 asphyxiation followed by cervical dislocation and 
their spleens were aseptically collected. The splenocytes were harvested from the spleens 
and used for the analysis of cell-mediated immune responses. 
 
Indirect ELISA 
Levels of RB51-specific and B. neotomae LPS-specific serum immunoglobulin M (IgM), 
IgG, as well as IgG1, IgG2a, IgG2b and IgG3 isotypes were determined using indirect 
ELISA [17,24,26]. RB51 was heat-killed by incubation at 65°C for 1 hr. The antigens were 
diluted in carbonate buffer (pH 9.6), to a final con entration of 1×109 CFU-equivalent of 
killed RB51/ml and 1 in 10 for B. neotomae LPS. These diluted antigens were plated in the 
wells (100 µl/well) of polystyrene plates (Nunc-Immunoplate with maxisorp surface). The 




buffer (TBS at pH 7.4, 0.05% Tween 20) and incubated for 1 hr at 37°C with blocking 
buffer (5% skim milk in TBS). Diluted mouse sera (1:200 in blocking buffer) were added 
in duplicates to the wells (50 µl/well). After 4 hrs, the plates were again washed with wash 
buffer. Appropriately diluted anti-mouse horseradish peroxidase labelled isotype specific 
conjugates (Southern Biotechnology Associates Inc, Birmingham, Alabama) were added 
to the wells (50 µl/well). Following 1 hr of incubation at room temperature, the plates were 
washed with wash buffer to remove any unbound antibody. Substrate solution (TMB 
Microwell peroxidase substrate; KPL, Gaithersburg, MD) was added to each well (100 
µl/well). The plates were incubated for 20 mins in the dark and the enzyme reaction was 
stopped by 100 µl of stop solution (0.185 M sulfuric acid). Finally, a microplate reader 
(Molecular devices, Sunnyvale, CA) was used to record the absorbance at 450 nm. 
 
Culture of splenocytes 
Single cell suspension of the splenocytes was prepared s per previously described 
procedure [24]. The erythrocytes were lysed using ACK lysis buffer and the splenocytes 
were cultured in triplicates in 96-well flat-bottomed culture plates, 5×105 cells/well for the 
quantification of cytokines and 106 cells/well for the analysis of antigen-specific IFN-γ 
secreting CD4+ and CD8+ T cells. The splenocytes were cultured in the presence of 
different stimulants: 107 CFU-equivalents of RB51 and RB51WboAKF. Cells stimulated 
with 2.5 µg/ml of concanavalin A (ConA) and plain media were used as controls.  
 
Quantification of cytokines 
The splenocytes were cultured with different stimulants and controls (as described above 
in culture of splenocytes) for 5 days in a humidified incubator with 5% CO2 at 37°C and 
their supernatants were collected. The concentrations of the cytokines IL-2, GM-CSF, IFN-
γ, TNF-α, IL-4, IL-5, IL-10 and IL-12p70 were determined using Bio-RAD Bio-Plex 





Flow cytometric analysis of antigen-specific IFN-γ secreting CD4+ and CD8+ T cells 
A previously described procedure was followed for int acellular IFN-γ staining [24,27]. 
The splenocytes were cultured with different stimulants and controls (as described above 
in culture of splenocytes) for 8 hrs in a humidified ncubator with 5% CO2 at 37°C. Brefelin 
A (Golgistop; Pharmingen) was added to the wells and the plates were incubated for 
another 8 hrs. Cells from each treatment were suspended in FACS buffer (PBS containing 
1% BSA and 0.2% sodium azide). They were incubated for 30 mins in ice with 
appropriately diluted FITC-conjugated anti-mouse CD8 antibody (BD Pharmigen, 
clone53-6.7) and APC-conjugated anti-mouse CD4 antibody (BD Pharmigen, clone L3T4-
RM 4.5). Following three washes with FACS buffer, the cells were stained for intracellular 
IFN-γ with PE-conjugated rat anti-mouse IFN-γ antibody using the cytofix/cytoperm 
(Pharmingen) using manufacturer’s instructions. As an isotype control, cells stained with 
PE-conjugated rat IgG1 antibody were used. The cells were acquired on BD FACS Canto 
II™ Flow cytometer (BD Biosciences, CA, USA). The data were analyzed using BD 
FACSDIVA version 6 software (BD Biosciences, CA, USA) and the proportion of 
CD4+ and CD8+ T cells that secreted IFN-γ was determined. 
 
Quantification of serum cytokines 
Groups of three mice each were infected with 2×108 CFU of live RB51 or RB51WboAKF. 
A group of mice inoculated with saline alone served as the negative control. Mice from all 
the groups were bled by retro-orbital puncture at days 1, 7 and 28 p.i. The serum was 
separated from the clotted blood and concentrations of the cytokines IL-2, GM-CSF, IFN-
γ, TNF-α, IL-4, IL-5, IL-10 and IL-12p70 were determined using Bio-RAD Bio-Plex 






Groups of six mice each were infected with 2×108 CFU of live RB51 or RB51WboAKF. 
A group of mice inoculated with saline was used as control. Two mice from each group 
were euthanized at days 1, 7 and 28 p.i. and their spleens were aseptically collected. The 
spleens were then weighed, and immersed in 10% neutral-buffered formalin, embedded, 
sectioned, mounted on microscopic slides, and stained with hematoxylin and eosin. The 
stained slides were digitized using an Aperio Digital Slide Scanner (Leica) and slides were 
analyzed by a board-certified pathologist (Grant N. Burcham). They were annotated using 
the ScanScope software (Leica). 
 
Protection experiments 
Protection experiments were performed at Virginia Tech in an ABSL-3 facility that was 
approved for work with select agents.  Female BALB/c mice of 4-6 weeks of age (Harlan 
Laboratories, USA) were used for the studies.  Mice were housed in individually ventilated 
cages with high-efficiency particulate arresting-filtered air.  Feed and water were provided 
ad libitum. Housing conditions included standard 12 hrs light/dark cycle, controlled 
humidity (55%) and room temperature (22oC).  After 1 week of acclimatization, mice were 
administered with vaccine or control formulation.  
Groups of ten mice each were vaccinated by i.p. inoculation with 2×108 CFU of live RB51, 
RB51WboA or RB51WboAKF. Ten mice inoculated with saline alone served as a control. 
Six weeks p.i, five mice in each group were challenged by i.p. inoculation with 5×104 CFU 
of B. abortus 2308 and the remaining five mice in each group were challenged with 5×104 
CFU of B. melitensis 16M. Two weeks post-challenge, the mice were euthanized and the 






Statistical analysis was performed using GraphPad Prism software. ELISA absorbance 
values, cytokine concentrations and flow cytometry data were analyzed for differences 
among groups by performing one-way analysis of variance (ANOVA) followed by 
Bonferroni test. The protection data was analyzed using student -test modified for unequal 
variances between groups. 
 
Ethics statement 
The protocols of the mice experiments performed in th s study were approved by the 
Institutional Animal Care and Use Committees at Purdue University (Approval # 
1112000488) and Virginia Tech (Approval # CVM-10-048).  The animal studies were 
conducted in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. Blood was collected from 
the retro-orbital plexus from mice under anesthesia. For anesthetizing mice, regulated 
concentration of anesthetic mixture (oxygen and isoflurane) was administered via a 
commercially available rodent anesthesia machine (Vtamac, Inc., Rossville, Indiana).  
Following blood collection, a drop of proparacaine hydrochloride ophthalmic solution 
(Bausch & Lomb, Tampa, Florida) was placed on the eye to reduce pain. Mice infected 
with virulent B. abortus 2308 do not develop clinical disease or exhibit any signs of 
suffering for the duration of the experiments conducted in this study. Therefore, no humane 
endpoints were utilized for the mice in this study. 
Results 
O-Polysaccharide expression by strain RB51WboA overexpressing the wbkF gene 
Strain RB51 was electroporated with plasmid pBB1/wboAKF, containing the functional 




plasmid-harboring recombinant colonies were selected for determination of O-PS 
expression. Western blot analysis with Bru-38 showed that all five RB51WboAKF 
colonies contained smooth LPS (Fig. 5.1A). The reactivity profile of the RB51WboAKF 
recombinants was similar to that of B. neotomae. In contrast, strain RB51WboAKD had a 
similar reactivity pattern as that of strain RB51WboA (data not shown). In strain 
RB51WboA, Bru-38 reacted with a few bands in the 45 kDa range, which was similar to 
previous descriptions [17] (Fig. 5.1A). As expected, RB51 did not show any reactivity with 
Bru-38 [4] (Fig. 5.1A).  Strain RB51WbkF also did not react with Bru-38 (data not shown). 
One of the RB51WboAKF recombinants was selected for all the further studies.  
SDS-PAGE followed by Coomassie Brilliant Blue staining was used to visualize any 
differences in the protein profiles of the strains RB51 and RB51WboAKF. There was no 
apparent qualitative difference in the protein profiles of the two strains (Fig. 5.1B). 
Immuno-electron microscopy was carried out to determine the location of the expressed 
O-PS in bacterial cells. Immuno-electron microscopy f thin sections of RB51WboAKF 
revealed the presence of O-PS mostly on the surface of bacterial cells (Fig. 5.2C). As 
expected, no O-PS was detected in strain RB51 (Fig.5.2B) while the presence of O-PS in 
strain B. neotomae was predominantly detected on the cell surface (Fig. 5.2A). 
Indirect ELISA with whole bacterial cells as antigen was performed to determine the level 
of O-PS expression on the surface of bacterial cells.  As expected, RB51 and RB51WboA 
whole cells did not react with smooth LPS-specific antibody (Fig. 5.3). In contrast, both 
strain RB51WboAKF and B. neotomae exhibited a higher level of reactivity with anti-
smooth LPS antibody when compared with RB51 and RB51WboA strains; however, B. 
neotomae reacted with all tested dilutions of the smooth LPS-specific antibody at 
significantly higher levels when compared with strain RB51WboAKF (Fig. 5.3). 
 
LPS analysis 
In order to assess the degree of roughness of strain RB51WboAKF, the electrophoretic 
profile of the LPSs were examined by Western blotting and silver staining (Fig. 5.4A and 




extended from 75kDa to 25kDa (Fig. 5.4A). In contrast, LPS from RB51 and RB51WboA 
did not show any reactivity with smooth LPS-specific antibody (Fig. 5.4A). LPS from B. 
neotomae exhibited positive reactivity with anti-smooth LPS antibody and a smear that 
extended from >100kDa to <20kDa was visible on Western blotting (Fig. 5.4A).  
On silver staining of the polyacrylamide gel, a major low-molecular weight band of the 
same size (<10kDA) was visible in the LPSs of all the four strains indicating that all the 
strains exhibit a complete core (Fig. 5.4B). Additionally, a high-molecular weight band 
(≈23kDA) and a low-molecular weight band (≈11kDA) were present in the LPS profiles 
of B. neotomae and RB51WboAKF but absent in RB51 and RB51WboA (Fig. 5.4B). A 
band of intermediate size (≈18kDA) was present in the LPSs of strains RB51, 
RB51WboAKF and RB51WboA but absent in LPS of B. neotomae (Fig. 5.4B). 
 
Sensitivity to the bactericidal effect of polymyxin B 
PmB at concentrations ranging from 2 µg/ml to 50 µg/ml was used to test the ability of 
strain RB51WboAKF to resist bactericidal killing. Strain RB51WboAKF was less 
sensitive to the bactericidal effect of PmB when compared to strain RB51 at concentrations 
≥ 10 µg/ml (Fig. 5.5). The difference was more apparent at higher concentrations (20-50 
µg/ml) of PmB (Fig. 5.5). As expected, tested concentrations of PmB had the least effect 
on B. neotomae which exhibited enhanced survival percentage when compared to the 
strains RB51 and RB51WboAKF (Fig. 5.5). 
 
Persistence of strain RB51 and RB51WboAKF in mice. 
Persistence of strains RB51 and RB51WboAKF in mice organs was compared in order to 
assess the attenuation characteristic of strain RB51WboAKF. There was no difference in 
the persistence pattern of RB51 and RB51WboAKF in spleens, livers and lungs of the 
vaccinated mice at days 1, 7, 21 and 28 p.i. (Fig. 5.6). Both the strains were cleared from 
the mice livers and lungs and persisted at very low levels in spleens of mice at day 28 p.i. 




Induction of specific antigen-antibody responses in mice 
Specific antigen-antibody responses induced in vaccin ted mice were determined by 
indirect ELISA. Higher levels of LPS-specific total IgG antibodies were detected in the 
serum of mice vaccinated with RB51WboA and RB51WboAKF when compared with 
RB51 vaccinated and saline-inoculated mice (Fig. 5.7). LPS-specific IgG levels were 
significantly higher in RB51WboAKF vaccinated mice when compared with those 
vaccinated with RB51WboA (Fig. 5.7). Mice vaccinated with RB51WboAKF also had 
significantly higher levels of LPS-specific IgM, IgG2a, IgG2b and IgG3 at 3 and 6 weeks 
p.i. and LPS-specific IgG1 at 3 weeks p.i. when compared with RB51 vaccinated and 
saline-inoculated mice group (Fig. 5.7). In contrast, significantly higher levels of LPS-
specific IgG2a and IgG3 antibodies were detected in mice vaccinated with RB51WboA 
only at 6 weeks p.i. when compared with the RB51 vaccinated and unvaccinated groups of 
mice (Fig. 5.7). The levels of LPS-specific IgG2a and IgG3 were significantly higher in 
the serum of RB51WboAKF vaccinated mice than those vaccinated with RB51WboA (Fig. 
5.7).  
All the vaccinated groups of mice (RB51, RB51WboA and RB51WboAKF) had 
significantly higher levels of RB51-specific IgG, IgM, IgG2a, IgG2b and IgG3 when 
compared with the saline inoculated controls (Fig. 5.8). Only the levels of RB51-specific 
IgG2a were significantly higher in the serum of RB51WboAKF vaccinated mice when 
compared with RB51WboA vaccinated group of mice (Fig. 5.8). 
 
Histology of spleens 
RB51WboAKF vaccinated mice had higher spleen weights (453.33 ± 20.54 mg)  at day 7 
p.i. when compared to RB51 vaccinated mice (403.33 ± 26.25 mg) (P < 0.05). Splenic 
histology in saline-inoculated and RB51 vaccinated mice was considered normal at day 7 
p.i. (Fig. 5.9A and B). In contrast, markedly increas d extramedullary hematopoiesis (EH) 
was observed in RB51WboAKF vaccinated mice at day 7 p.i. (Fig. 5.9C). At day 28, a 




RB51WboAKF vaccinated mice spleens when compared with the spleens of RB51 
vaccinated mice.  
 
Analysis of serum cytokines 
Vaccination of mice with RB51 and RB51WboAKF resulted in significantly higher levels 
of IL-12 and IFN-γ at day 1 and TNF-α at day 7 p.i. when compared with the saline-
inoculated mice (Fig. 5.10). The level of IL-12 and IFN-γ was significantly higher at day 
1 p.i. in the serum of WboAKF immunized mice than those immunized with RB51 (Fig. 
5.10). Moreover, significantly increased levels of GM-CSF at day 27 p.i. and IL-10 at days 
1 and 7 p.i. were detected in the serum of mice vaccin ted with RB51WboAKF when 
compared with RB51 vaccinated and saline inoculated mice groups (Fig. 5.10). The 
concentrations of IL-4 and IL-5 were below the limit of detection in the vaccinated groups 
of mice as well as the saline-inoculated group (data not shown). 
 
Induction of specific cell-mediated responses in mice 
Specific cell-mediated responses were analyzed at 6 weeks p.i. in the vaccinated mice by 
determining the number of IFN-γ secreting CD4+ and CD8+ T cells as well as by 
quantifying cytokines secreted by splenocytes upon in vitro stimulation with specific 
antigens. 
Upon in vitro stimulation with RB51 and RB51WboAKF, higher proportions of IFN-γ 
secreting CD4+ and CD8+ T cells were detected in all the vaccinated groups of mice but 
not the saline-inoculated group when compared with the corresponding unstimulated 
controls (Fig. 5.11A and B). When stimulated with RB51WboAKF, significantly higher 
proportions of IFN- γ secreting CD4+ and CD8+ T cells were detected in RB51WboAKF 
vaccinated mice when compared to the other vaccinated groups of mice (Fig. 5.11). 
Upon in vitro stimulation with RB51 and RB51WboAKF, splenocytes of all groups of 
vaccinated mice, but not the saline-inoculated group, secreted significantly increased levels 




(Fig. 5.12). In contrast, concentrations of IL-4 and IL-5 in the culture supernatants of all 
groups of mice were below the detection limit and not different from the corresponding 
unstimulated controls (data not shown). Stimulation with RB51WboAKF resulted in the 
secretion of significantly higher levels of IFN-γ and IL-10 by the splenocytes of 
RB51WboAKF vaccinated group of mice than the other vaccinated mice groups (Fig. 
5.12). Also, upon in vitro stimulation with RB51 and RB51WboAKF, significantly higher 
levels of TNF-α were detected in the culture supernatants of mice vaccinated with 
RB51WboAKF and RB51WboA, but not the saline-inoculated group, when compared with 
their unstimulated controls; the level of TNF-α was significantly higher in the 
RB51WboAKF vaccinated mice group when compared with other vaccinated groups of 
mice (Fig. 5.12). In contrast, only stimulation with RB51 resulted in the secretion of higher 
levels of TNF-α by splenocytes of RB51 vaccinated mice when compared to the 
corresponding unstimulated control (Fig. 5.12). In vitro stimulation with RB51 resulted in 
the secretion of higher levels of IL-2 by splenocytes of RB51 and RB51WboAKF 
vaccinated groups of mice, but not the saline-inoculated group, when compared with the 
corresponding unstimulated controls (Fig. 5.12); however, higher levels of IL-2 were only 
detected in the culture supernatants of mice vaccinted with RB51WboAKF, after in vitro 
stimulation with RB51WboAKF, when compared to the corresponding unstimulated 
control (Fig. 5.12). 
 
Enhanced protection against virulent challenge infection 
To assess the protection afforded by different vaccine strains in a mouse model of 
brucellosis, bacterial CFUs were calculated in the vaccinated groups of mice two weeks 
post-challenge with virulent Brucella species. Vaccination with RB51, RB51WboA and 
RB51WboAKF resulted in significant reduction of the splenic bacterial load following 
challenge with virulent B. abortus 2308 and B. melitensis 16M when compared with the 
saline inoculated group of mice (Fig. 5.13A and B). Following challenge with virulent B. 




the highest reduction in the splenic bacterial load when compared with RB51 and 
RB51WboA vaccinated groups (Fig. 5.13). 
 
Discussion 
The studies in this paper demonstrate that overexpression of wbkF in strain RB51WboA 
leads to the expression of O-PS similar to the smooth Brucella strains and enhanced 
protection against B. abortus 2308 and B. melitensis 16 M. Our immunoelectron study as 
well as indirect ELISA using whole live bacterial cells as antigens suggests that the 
synthesized O-PS by the strain RB51WboAKF is present mostly on the bacterial cell 
surface (Fig. 5.2 and 5.3). However, strain RB51WboAKF still exhibited rough strain 
characteristics as evidenced by agglutination with acriflavin. Also, silver stained profile of 
the extracted LPS from strain RB51WboAKF was partly similar to that of both rough and 
smooth strains (Fig. 5.4B). A previous study has described a strain of B. melitensis (strain 
EP) which simultaneously exhibits smooth and rough characteristics [28]. This type of 
‘smooth-rough’ phenotype of strain EP was attributed to the presence of fewer O-PS chains 
and higher amounts of rough-LPS when compared to the s rain 16M [28]. Similarly, 
reduced level of reaction of RB51WboAKF bacterial ce ls with smooth LPS-specific 
antibody when compared with B. neotomae indicates that fewer O-PS chains are expressed 
on RB51WboAKF cell surface. Fewer surface-expressed O-PS chains can also explain the 
enhanced sensitivity of strain RB51WboAKF to the bactericidal effect of polymyxin when 
compared to B. neotomae (Fig. 5.5). In case of RB51WboA, absence of positive reactivity 
with anti-smooth LPS antibody is expected as the O-PS is only expressed in the cytoplasm 
of the bacteria [17]. 
The complete biosynthetic pathway of Brucealla O-PS is yet to be determined. However, 
a pathway for it has been proposed based on the prediction of protein functions from 
comparisons with homologous proteins in other microorganisms and identification of 
rough Brucella phenotypes [2,15,29-32]. In the purported biosynthetic pathway of smooth 
LPS, WbkD and WbkF catalyzed steps lead to bactopren l priming for N-




strains with mutations in wbkF or wbkD genes cannot produce O-PS [29]. wbkD encodes 
an epimerase/dehydratase that takes part in the synthesis of N-acetylquinovosamine 
[29,33] that has been found in the smooth LPS [3,7,34].  Previously, it has been proposed 
that N-acetylquinovosamine might act as a substrate for WbkF (undecaprenyl-
glycosyltransferase) for the synthesis of bactoprenol primed N-acetylaminosugar [29]. In 
our study, overexpression of wbkD in strain RB51WboA did not change the level of O-PS 
expression when compared to that expressed by RB51WboA (data not shown). This finding 
suggests that a mere increase in the level of WbkD expression or quinivosamine does not 
affect O-PS expression. In contrast, increasing the lev l of WbkF in RB51WboA leads to 
enhanced O-PS expression (Fig. 5.1A) suggesting that overexpression of wbkF furnishes 
higher amounts of bactoprenol primed moieties for O-PS polymerization by wboA and 
other glycosyltransferases. As expected, overexpression of wbkF alone in RB51 did not 
lead to O-PS expression (data not shown) indicating that wboA encoded glycosyltransferase 
is required for O-PS polymerization. 
The attenuation characteristic of strain RB51WboAKF did not differ from the parent strain 
RB51. Based on the increased resistance to polymyxin B treatment, we had expected that 
strain RB51WboAKF would persist longer in mice organs than strain RB51.  The lack of 
any increase in the virulence characteristic of strain RB51WboAKF suggests that the 
attenuation of strain RB51 is because of mutations n multiple yet to be identified genes.  
Vaccination of mice with strain RB51WboAKF resulted in the induction of increased 
IgG2a and IgG3 subisotype antibodies specific to the smooth LPS than other vaccinated 
and non-vaccinated groups (Fig 5.7). This indicates that a Th1 type of immune response 
was induced by RB51WboAKF vaccine. Previous studies have validated the contribution 
of Th1 immunity in protection against intracellular bacterial infections including 
brucellosis. Detection of significantly higher conce tration of IFN-γ in the culture 
supernatants of antigen-specific splenocytes as well as significantly higher proportions of 
antigen-specific IFN-γ secreting CD4+ and CD8+ T cells in the RB51WboAKF vaccinated 
group of mice also indicates the induction of Th1 type of immunity. The presence of 




Significantly enhanced TNF-α secretion might also play a role in the induction f 
splenomegaly and EH in RB51WboAKF vaccinated mice spleens. Pro-inflammatory 
cytokines such as TNF-α help in the recruitment of inflammatory cells leading to 
splenomegaly during Brucella infection [35]. Cytokines such as TNF-α and GM-CSF also 
increase myelopoiesis by supporting the growth and maturation of myeloid progenitors 
[36]. This enhanced production of mature myeloid cells helps in clearing pathogens from 
body [37].  
RB51WboAKF vaccine conferred significantly higher protection against virulent Brucella 
species than strain RB51 and RB51WboA (Fig. 5.13). Both, T cell-mediated responses as 
well as O-PS specific antibodies, play a role in providing enhanced protection against 
brucellosis [9,13,29]. IFN-γ secreting T cells are implicated as the main effectors that 
provide acquired resistance against Brucella infection [9]. Previous studies show that 
antibodies to the O-PS including IgM, IgG2a, IgG2b and IgG3 can also mediate protection 
in mice [12,26,38,39]. The enhanced protection afforded by RB51WboAKF might be 
attributed to the anti-O-PS antibodies and/or to the enhanced cell-mediated immune 
responses. Further studies involving adoptive transfer experiments of O-PS-specific 
antibodies and/or immune T cells can characterize their specific contribution to the 
protective efficacy of RB51WboAKF.  
In conclusion, our results suggest that RB51 carries mutations in several genes required for 
the synthesis of smooth LPS. Also, our study demonstrates that RB51WboAKF strain, 
while maintaining the attenuation characteristic of strain RB51, is more immunogenic and 
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Figure 5.1. (A) Western blot analysis to detect O-polysaccharide expression by the strain 
RB51WboAKF and (B) Coomassie Brilliant Blue staining of the polyacrylamide gel to 
detect difference in the protein profiles of RB51, B. neotomae, RB51WboA and 
RB51WboAKF. Whole antigens of the strain RB51, recombinant strain RB51WboA, 
RB51WboAKF and B. neotomae were separated by 12.5% SDS-PAGE and analyzed by 
(A) Western blotting with O-polysaccharide specific monoclonal antibody, Bru-38. Lane 
1: strain B. neotomae; lane 2: recombinant strain RB51WboA; lane 3-7: recombinant strain 
RB51WboAKF; lane 8: strain RB51. Whole antigens of the strain B. neotomae, 
RB51WboA, RB51WboAKF and RB51 were analyzed for anydifferences in the expressed 





Figure 5.2. Detection of Brucella O-polysaccharide expression in strain RB51WboAKF by 
immunoelectron microscopy. Thin sections of (A) B. neotomae, (B) RB51 and (C) 
RB51WboAKF were reacted with anti-B. neotomae LPS followed by gold-labeled goat 
anti-rabbit IgG. The black arrows in panel A and C indicate the gold-labeled particles. Bars 






Figure 5.3. ELISA detection of O-polysaccharide expr ssion on the cell surface of strain 
RB51WboAKF. RB51, RB51WboA, RB51WboAKF and B. neotomae whole cells (108 
CFU/well) were reacted with specific dilutions of anti-B. neotomae LPS antibody. The 
results are shown as mean ± standard deviation of the optical density (OD) at 450 nm of 
the color developed. Asterisks indicate statistically significant differences from strain 







Figure 5.4. (A) Western blot analysis and (B) silver staining of the polyacrylamide gel to 
detect the differences in the LPS profiles of strains RB51, B. neotomae, RB51WboA and 
RB51WbkA. LPSs extracted from strain RB51, RB51WboA, RB51WboAKF and B. 
neotomae were separated by SDS-PAGE and analyzed by (A) Western blotting; Lane 1: 
strain B. neotomae; lane 2: recombinant strain RB51WboA; lane 3: recombinant strain 
RB51WboAKF; lane 4: strain RB51, and (B) silver staining; Lane 1: strain B. neotomae; 







Figure 5.5. Determination of the bactericidal effect of polymyxin on strains RB51, 
RB51WboAKF and B. neotomae. Polymyxin-sensitivity assay was performed as described 
in Materials and methods. Average results from three assays are expressed as percentage 
of the bacteria surviving in the absence of polymyxin. Asterisks indicate statistically 





Figure 5.6. Determination of bacterial persistence of strain RB51WboAKF in mice. Mice 
spleens, livers and lungs were collected at days 1, 7, 21 and 28 after vaccination with live 
RB51 and live RB51WboAKF. The Brucella CFUs in these organs were determined as 
described in Materials and methods. Results are shown as mean ± standard deviation (n=3) 








Figure 5.7. Detection of B. neotomae LPS-specific antibodies in serum of mice vaccinated 
with live recombinant RB51WboAKF. Mice were vaccinated with live RB51, 
RB51WboA, RB51WboAKF, or inoculated with saline. Serum samples were collected at 
3 and 6 weeks after vaccination, were diluted 1 in 200 and assayed for the presence of B. 
neotomae LPS-specific IgM, IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect 
ELISA. Results are shown as mean ± standard deviation (n=4) of absorbance of the color 
developed. Asterisks indicate statistically significant differences from the corresponding 





Figure 5.8. Detection of RB51-specific antibodies in the serum of mice vaccinated with 
live recombinant RB51WboAKF. Mice were vaccinated with live RB51, RB51WboA, 
RB51WboAKF, or inoculated with saline. Serum samples w re collected at 3 and 6 weeks 
after vaccination, were diluted 1 in 200 and assayed for the presence of RB51-specific IgM, 
IgG, IgG1, IgG2a, IgG2b and IgG3 antibodies by indirect ELISA. Results are shown as 
mean ± standard deviation (n=4) of absorbance of the color developed. Asterisks indicate 
statistically significant differences from the corresponding saline group. *, P < 0.05; **, P 





Figure 5.9. Spleen histology in BALB/c (A) saline-inoculated mice and mice infected intra-
peritoneally with 108 CFU-equivalent of live (B) RB51 and (C) RB51WboAKF. The mice 
were sacrificed 7 days post-vaccination and a portion of the spleen was fixed in formalin, 
processed and stained with hematoxylin and eosin. Pictures were taken with a 10X 







Figure 5.10. Detection of specific cytokines in theserum of RB51WboAKF vaccinated 
mice. Mice were immunized intra-peritoneally with 108 CFU-equivalent of live RB51, 
RB51WboAKF, or inoculated with saline. Values are shown as mean ± standard deviation 
(n=4). Asterisks indicate statistically significant differences from the corresponding saline 






Figure 5.11. Flow cytometric analysis showing the percentage of interferon-γ secreting (A) 
CD4+ and (B) CD8+ T cells in the spleens of mice immunized with live recombinant 




RB51, RB51WboA, RB51WboAKF, or inoculated with saline. The mice splenocytes were 
stimulated with media (unstimulated), heat-killed strains RB51 and RB51WboAKF and 
the percentages of IFN-γ secreting (A) CD4+ and (B) CD8+ T cells were analyzed by flow 
cytometry. (C) Representative figure of the flow cytometric analysis.  Values are shown as 
mean ± standard deviation (n=4). Asterisks indicate statistically significant differences 






Figure 5.12. Detection of specific cytokines produced by splenocytes of mice vaccinated 
with live recombinant RB51WboAKF. Mice were vaccinated intra-peritoneally with 108 
CFU-equivalent of live RB51, RB51WboA, RB51WboAKF and saline-inoculated mice 
after in vitro stimulation with media (unstimulated), heat-killed RB51 and RB51WboAKF. 
Values are shown as mean ± standard deviation (n=4). Asterisks indicate statistically 
significant differences from the corresponding unstimulated control. *, P < 0.05; **, P < 





Figure 5.13. Determination of the protective efficacy of strain RB51WboAKF against 
virulent strains B. abortus 2308 and B. melitensis 16M challenge. Mice vaccinated intra-
peritoneally with live RB51, RB51WboA, RB51WboAKF and saline-inoculated mice 
were challenged by i.p. inoculation of 3×104 CFU of virulent strains (A) B. abortus 2308 
and (B) B. melitensis 16M. 2 weeks post-challenge, the mice were euthanized and the 
Brucella CFU in their spleens were determined. Results are shown as mean ± standard 
deviation (n=5) of the log CFU of Brucella recovered from spleens. Asterisks indicate 
statistically significant differences from the corresponding saline group. *, P < 0.05; **, P 






CHAPTER 6. ORAL IMMUNIZATION OF MICE WITH GAMMA-IRRADIATED 
BRUCELLA NEOTOMAE INDUCES PROTECTION AGAINST INTRAPERITONEAL 
AND INTRANASAL CHALLENGE WITH VIRULENT BRUCELLA ABORTUS 2308 
Abstract 
Brucella spp. are Gram-negative, facultative intracellular coccobacilli that cause one of the 
most frequently encountered zoonosis worldwide. Humans naturally acquire infection 
through consumption of contaminated dairy and meat products and through direct exposure 
to aborted animal tissues and fluids. No vaccine against brucellosis is available for use in 
humans. In this study, we tested the ability of orally inoculated gamma-irradiated B. 
neotomae and B. abortus RB51 in a prime-boost immunization approach to induce antigen-
specific humoral and cell mediated immunity and protection against challenge with virulent 
B. abortus 2308. Heterologous prime-boost vaccination with B. abortus RB51 and B. 
neotomae and homologous prime-boost vaccination of mice with B. neotomae led to the 
production of serum and mucosal antibodies specific to the smooth LPS. The elicited serum 
antibodies included the isotypes of IgM, IgG1, IgG2a, IgG2b and IgG3. All oral 
vaccination regimens induced antigen-specific CD4+ and CD8+ T cells capable of secreting 
IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated with B. neotomae 
showed the highest level of resistance against virulent B. abortus 2308 colonization in 
spleen and liver. Experiments with different doses of B. neotomae showed that all tested 
doses of 109, 1010 and 1011 CFU-equivalent conferred significant protection against the 





required for affording protection against intranasal challenge as shown by the reduced 
bacterial colonization in spleens and lungs. Taken together, these results demonstrate the 
feasibility of using gamma-irradiated B. neotomae as an effective and safe oral vaccine to 
induce protection against respiratory and systemic infections with virulent Brucella. 
 
Introduction 
Brucella species, Gram-negative, facultative intracellular coccobacilli, are the causative 
agents of brucellosis, a chronic bacterial infection n a variety of mammals, including 
humans. B. melitensis, B. abortus and B. suis are the most frequent causes of human 
infections [1]. These Brucella species are also categorized in the class B list of select agents 
by the CDC due to their highly infectious nature and their potential use in bio-warfare.  In 
natural animal hosts and wildlife reservoirs, brucellosis commonly results in abortion and 
infertility. Chronically infected animals also shed the bacteria in milk.  Human brucellosis 
is truly a zoonotic disease. Humans usually get infected by consuming unpasteurized 
contaminated milk or dairy products, or by getting exposed to infected animal tissues or 
secretions. Few human infections are also documented to occur through accidental 
exposure to live bacteria in the laboratory or inoculation of live vaccine strains used for 
controlling animal brucellosis in the field.  Human brucellosis can manifest in a variety of 
clinical symptoms, starting from a subclinical infection to a protracted febrile illness which 
can progress to lethal endocarditis [1,2]. Treatment of brucellosis requires prolonged 
therapy with a mixture of antibiotics; even then relapses of infection are often noticed. 
There is no vaccine available for use in humans against brucellosis. 
A safe and effective human vaccine would benefit as a prophylactic measure to protect 
personnel at high risk of occupational exposure to pathogenic Brucella, especially in 
Brucella endemic regions. Cell-mediated immunity plays a major role in enhancing the 
resistance against brucellosis in animals. Antigen-specific CD4+ and CD8+ T lymphocytes 
that secrete Th1-type cytokines such as IFN-γ and TNF-α are important in immunity 
against Brucella infection [3-5]. In some animal species, antibodies to the O-




infections by B. abortus, B. melitensis and B. suis [6-8]. Only live vaccines are shown to 
be effective in providing long term protection against brucellosis in animals. Attenuated 
strains such as B. abortus S19 and RB51, and B. melitensis Rev1 are used as parenteral 
vaccines to immunize cattle, and sheep and goats, respectively. None of the live vaccines 
licensed for use in domestic animals are considered safe for human application [9,10].    
Gamma-irradiated bacteria cannot replicate but remain etabolically active, and they can 
be a safer alternative to live bacteria for immunization purposes. We previously showed 
that parenteral immunization of mice with gamma-irrdiated B. abortus RB51 or B. 
neotomae induces protection against challenge with virulent Brucella spp. [11,12].  As 
parenteral route of vaccination is seldom favored due to its invasive delivery and is unlikely 
to be a preferred route of immunization against brucellosis in humans, in this study we 
examined the feasibility of oral vaccination with gamma-irradiated B. neotomae and B. 
abortus RB51 in a prime-boost approach to induce protection against systemic and mucosal 
challenge infections.  
We show that oral immunization with gamma-irradiated B. neotomae in a homologous 
prime-boost regimen results in production of antigen-specific antibody, cell-mediated and 
mucosal immune responses and increased resistance to intra-peritoneal and intranasal 
challenge with B. abortus 2308.  
 
Materials and methods 
Bacterial strains 
B. neotomae strain 5K33 was obtained from the American Type Culture Collection, 
Manassas, VA. B. abortus vaccine strain RB51 and B. abortus virulent strain 2308 were 
from our culture collection. B. neotomae and RB51 were grown in tryptic soy broth (TSB) 
or tryptic soy agar (TSA) at 37°C. All experiments with B. neotomae were performed in a 
Biosafety level (BSL)-2 facility using BSL-3 practies. All experiments with virulent B. 





B. neotomae and B. abortus RB51 were grown in TSB to mid log phase, and aliquots 
containing approximately 1×1012 colony forming units (CFU)/ml were exposed to 350 
krads of gamma irradiation using a 60Co source irradiator (Gammacell 220 irradiator). The 
irradiated aliquots were plated on TSA to confirm the inability of the bacteria to replicate. 
The irradiated bacteria were stored at 4ºC until use.
 
Quantification of irradiated B. neotomae in mice spleens and mesenteric lymph nodes by 
real-time PCR 
A group of 8 female BALB/c mice were orally administered with 1×1011 CFU-equivalent 
of gamma-irradiated B. neotomae.  On days 1 and 3 post-vaccination, 4 mice from the 
group were euthanized and their spleens and mesenteric lymph nodes were collected 
aseptically.  The organs were homogenized in PBS and DNA from the homogenates were 
extracted using a commercial kit (DNeasy Blood and Tissue Kit, Qiagen Inc.).  
Quantification of B. neotomae DNA in the samples was accomplished using real-time PCR 
as previously described [11]. 
 
Immunization of mice 
Groups of 4 female BALB/c mice of 4 to 6 weeks of age were used for the study. Mice 
were purchased from a commercial source (Harlan Laboratories, USA), and housed in 
cages with microisolator tops at 4 mice per cage.  Feed and water were provided ad libitum.   
Housing conditions included standard 12 hrs light/dark cycle, controlled humidity (55%) 
and room temperature (22oC).  After 1 week of acclimatization, mice were administered 
with vaccine or control formulation.  
The gamma-irradiated bacteria were pelleted, washed with sterile phosphate-buffered 
saline (PBS) and adjusted to 5×1011 CFU-equivalent/ml. In some designated experiments, 




cells/ml.  A total of 200 µl of the vaccine suspensio  was used to vaccinate mice 15 mins 
after oral administration of 100 µl of sterile 10% sodium bicarbonate via a disposable 
feeding needle attached to a 1-ml syringe.  
 
Comparison of different prime-boost immunization strategies 
Mice were vaccinated by oral inoculation of 1×1011 CFU-equivalent of gamma-irradiated 
RB51 and/or gamma-irradiated B. neotomae in a prime-boost immunization regimen as 
shown in Table 6.1. Priming dose was administered at day 0. Booster immunizations with 
the same dose as the priming dose were given on days 3, 7 and day 10. A group of mice 
inoculated with saline was used as a negative control. 
 
Comparison of different vaccine doses of the B. neotomae vaccine 
Mice were vaccinated by three oral inoculations, on days 0, 3 and 10, with either 1×109 
CFU-equivalent or 1×1010 CFU-equivalent or 1×1011 CFU-equivalent of gamma-irradiated 
B. neotomae. A group of mice inoculated with saline was used as a negative control. 
 
Collection of blood and intestinal secretions  
Blood was collected by puncturing the retro-orbital plexus of the anesthetized mice at one 
and two weeks post-immunization (p.i) (1 and 2 weeks after the last booster immunization, 
respectively). The serum was separated and used for detection of antigen-specific 
antibodies by enzyme-linked immunosorbent assay (ELISA). At 2 weeks p.i., CO2 
asphyxiation followed by cervical dislocation was used to euthanize all the mice. The small 
intestines were separated and the intestinal contents were collected by flushing with 3 ml 
of PBS and centrifuged to remove the particulate matter. The supernatants were transferred 
to clean tubes and were used for the analysis of antigen-specific antibody responses by 
ELISA. Spleens of the euthanized mice were collected aseptically and used for analysis of 




Preparation of B. neotomae LPS antigen 
Butanol-water extraction was used to obtain total LPS from live bacteria as previously 
described [13,14]. Briefly, 10g of wet pellet obtained by centrifugation of live B. neotomae 
organisms was resuspended in PBS at a concentration of 0.25 g wet weight/ml followed by 
addition of an equal volume of water saturated butanol. The aqueous phase was collected 
by centrifugation at 35,000×g for 15 mins. 4 volumes of cold methanol was added to 
precipitate the LPS. The precipitate was dissolved in 0.1M Tris buffer (pH 8) containing 
2% SDS and 2% mercaptoethanol and heated for 5 minsat 100ºC. Following another 
incubation with proteinase K for 3 hrs at 60ºC, cold methanol was added to precipitate LPS. 
The precipitate was dissolved in water. SDS-PAGE of the polyacrylamide gel was carried 
out to determine the purity of the LPS.  
 
Indirect ELISA 
Levels of B. neotomae LPS-specific immunoglobulin G (total IgG), as well as selected IgG 
isotypes and IgM were determined by indirect ELISA [15]. Level of serum IgG with 
specificity to heat-killed RB51 total antigens was lso determined. In the intestinal 
secretions, levels of IgG, IgM and IgA with specificity to B. neotomae LPS and RB51 total 
antigens were determined. Using carbonate buffer, pH 9.6, B. neotomae LPS was diluted 
1 in 10, and the RB51 total antigens were diluted to obtain 1×109 CFU-equivalent/ml. The 
diluted antigens were used for coating wells (100 µl/well) of polystyrene plates (Nunc-
Immunoplate with maxisorp surface). The plates were incubated at 4°C for 12 hrs. They 
were subsequently washed with wash buffer (Tris-buffered saline (TBS), pH 7.4, with 
0.05% Tween 20) and blocked with 5% skim milk in TBS. Following an incubation of 1 
hr at 37°C, mouse sera with a 1:200 dilution in blocking buffer were added to the wells (50 
µl/well). All serum samples were tested in duplicates. For intestinal secretions, 1 in 10 
dilution was used. The plates were incubated for 4 hrs. Appropriately diluted mouse-
specific horseradish peroxidase-labeled immunoglobulin conjugates (Southern 




after washing the plate four times with wash buffer. After another hr of incubation at room 
temperature, the plates were washed four times and 100 µl of substrate solution (TMB 
Microwell peroxidase substrate; KPL, Gaithersburg, MD) was added to each well. 100 µl 
of stop solution (0.185 M sulfuric acid) was further added to the wells in order to stop the 
enzymatic reaction, and the absorbance (450nm) was recorded using a microplate reader 
(Molecular devices, Sunnyvale, CA). 
 
Intracellular cytokine staining and flow cytometry analysis  
Intracellular staining for IFN-γ and TNF-α was performed as previously described with 
some modifications [16]. Spleens were collected aseptically after euthanizing the mice and 
single cell suspensions of the splenocytes were prepared. ACK lysis buffer was used to 
lyse the RBCs and the splenocytes (106 per well) were seeded in 96 well flat-bottomed 
plates. They were cultured with different stimulants: 107 CFU-equiv. of gamma-irradiated 
B. neotomae and 107 CFU-equiv. of gamma-irradiated RB51. As controls, cells were 
stimulated with plain medium and 2.5 µg/ml of concanavalin (ConA). They were incubated 
in a humidified incubator with 5% CO2 for 8 hrs at 37 °C. Subsequently, brefeldin A 
(Golgistop; Pharmingen) was added to the splenocytes and the plates were incubated for 
another 8 hrs. Cells from each well were resuspended in PBS containing 1% BSA and 0.2% 
sodium azide (FACS buffer) and were incubated with PE-Cy7-conjugated anti-mouse CD8 
antibody (BD Pharmingen, clone53-6.7) and APC-conjugated anti-mouse CD4 antibody 
(BD Pharmingen, clone L3T4-RM 4.5) for surface staining. They were washed three times 
with FACS buffer and were further stained for intracellular IFN-γ and TNF-α by incubating 
with PE-conjugated rat anti-mouse IFN-γ antibody and FITC-conjugated rat anti-mouse 
TNF-α antibody using the Cytofix/Cytoperm kit (Pharminge). Cells stained with PE-
conjugated rat IgG1 and FITC-conjugated rat IgG1 antibody served as the isotype controls. 
BD FACS Canto II™ Flow cytometer (BD Biosciences, CA, USA) was used to acquire 
the data which was analyzed using BD FACSDIVA version 6 software (BD Biosciences, 






Protection experiments were performed at Virginia Tech in an ABSL-3 facility that was 
approved for work with select agents.  Female BALB/c mice of 4-6 weeks of age (Harlan 
Laboratories, USA) were used for the studies.  Mice were housed in individually ventilated 
cages with high-efficiency particulate arresting-filtered air.  Feed and water were provided 
ad libitum. Housing conditions included standard 12 hrs light/dark cycle, controlled 
humidity (55%) and room temperature (22oC).  After 1 week of acclimatization, mice were 
administered with vaccine or control formulation.  
 
Analysis of protective efficacy of the different prime-boost immunization regimens 
Groups of 5 mice were vaccinated by oral inoculation of 1×1011 CFU-equiv. of gamma-
irradiated RB51 and/or gamma-irradiated B. neotomae in a prime-boost immunization 
regimen; immunizations were performed (as as per Immunization of mice section: 
comparison of different prime-boost immunization strategies). A group (n=5) of mice 
inoculated with saline alone served as control. Two weeks p.i, each mouse was challenged 
by i.p. inoculation with 1×104 CFU of B. abortus 2308. Two weeks post challenge, the 
mice were euthanized and the number of bacterial CFUs in their spleens, lungs and livers 
were enumerated as previously described [17,18]. Briefly, two weeks post challenge, the 
mice were euthanized and their spleens, lungs and livers were collected aseptically. Organs 
were suspended in 1 ml of sterile PBS and were separately homogenized using tissue 
grinders. Ten-fold serial dilutions of the tissue homogenates were prepared in saline, and 
50 µl of each dilution was plated on TSA. After 3-5 days of incubation at 37 °C, the 
Brucella CFUs were counted and the bacterial burden per organ was calculated. 
 
Analysis of the protective efficacy of different vaccine doses of B. neotomae 
Groups of 10 mice were vaccinated by three oral inoculations on days 0, 3 and 10 with 




B. neotomae (as per Immunization of mice section: comparison of different vaccine doses 
of the B. neotomae vaccine). A group (n=10) of mice inoculated with saline alone served 
as control. Two weeks p.i. (2 weeks after the inoculation of the last booster dose), five mice 
from each group were challenged by i.p. inoculation with 5×104 CFU of B. abortus 2308, 
and the remaining five mice were challenged by i.n. inoculation with 4×106 CFU of B. 
abortus 2308. Two weeks post challenge, the mice were euthanized and the bacterial 
burden per organ was calculated. 
 
Statistical analyses 
Absorbance values of ELISA and flow cytometry data were analyzed for differences 
among different vaccinated groups by performing analysis of variance with post hoc Tukey 
for pair-wise comparison using SPSS version 21.0 (SPS  Inc., an IBM company, USA). 
Following bacterial challenge experiments, student t-test modified for unequal variances 
between groups was carried out to compare the log transformed CFU values in organs 
obtained from each vaccinated group of mice with the respective saline group. P values of 
<0.05 were considered significant. 
 
Ethics statement 
The protocols of the mice experiments conducted in th s study were approved by the 
Institutional Animal Care and Use Committees at Purdue University (Approval # 
1112000488) and Virginia Tech (Approval # CVM-10-048). The animal studies were 
carried out in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. Blood was collected from 
the retro-orbital plexus from mice under anesthesia. A commercially available rodent 
anesthesia machine that uses oxygen and an isoflurane precision-vaporizer for supplying 
regulated concentration of anesthetic mixture (Vetamac, Inc., Rossville, Indiana) was used 
for anesthetizing mice. To reduce pain following the bleeding, a drop of proparacaine 




eye. Mice infected with virulent Brucella abortus do not develop any clinical disease or 
show signs of suffering for the duration of the expriments conducted in this study.  
Therefore, no humane endpoints were utilized for the mice in this study. 
 
Results 
Persistence of gamma-irradiated B. neotomae in mice spleens and mesenteric lymph nodes 
following oral immunization 
The translocation of orally administered gamma-irradiated B. neotomae from gut lumen to 
mesenteric lymph node (MLN) and spleen was determined by extracting DNA from tissues 
and performing a quantitative real-time PCR specific to Brucella. Following oral 
inoculation of 1011 CFU-equivalent of gamma-irradiated B. neotomae, the bacterial DNA 
could be detected in mesenteric lymph nodes and in spleens by day 1 and persisted there 
for at least three days (Fig. 6.1). 
 
Induction of antigen-specific antibody immune responses following oral prime-boost 
immunization with gamma-irradiated B. neotomae and/or gamma-irradiated B. abortus 
RB51 
Levels of antibodies specific to B. neotomae-smooth LPS and RB51 total antigens in serum 
samples collected at 1 and 2 weeks p.i. (1 and 2 weeks after the inoculation of the last 
booster dose, respectively)  were determined by indirect ELISA. Immunization of mice 
with IRBn, IRBn/RB51 and IRRB51/Bn resulted in the induction of significantly higher 
levels of serum IgG and IgM antibodies specific to LPS when compared with the saline 
inoculated mice and the group of mice vaccinated with IRRB51 (Fig. 6.2A). However, 
there was no significant differences among the three vaccination groups (Fig. 6.2A). 
Significantly higher levels of LPS-specific IgG2a, IgG2b and IgG3 were present in the 




(Fig. 6.2A). Also, mice vaccinated with IRBn and IRBn/RB51 had higher levels of LPS-
specific IgG1 antibodies at 2 weeks p.i.; however, only mice vaccinated with IRBn had 
significantly increased levels of serum IgG1 antibodies specific to LPS at 1 week p.i. (Fig. 
6.2A). In contrast, vaccination of mice with IRRB51/Bn did not lead to the induction of 
significant levels of LPS-specific IgG1 antibodies (Fig. 6.2A). Furthermore, significantly 
higher levels of LPS-specific IgG2a, IgG2b and IgG3 antibodies were detected in the serum 
of mice vaccinated with IRRB51/Bn only at 2-weeks p.i. (Fig. 6.2A).  
Oral immunization of mice with IRBn, IRRB51/Bn and IRBn/RB51 led to the induction 
of significantly higher levels of LPS-specific IgG antibodies in the intestinal secretions 
when compared with the saline inoculated control and the IRRB51 vaccinated group (Fig. 
6.3A). Only vaccination of mice with IRBn resulted in the induction of significantly 
increased levels of LPS-specific IgM and IgA antibodies in the intestinal secretions when 
compared to the other vaccinated groups (Fig. 6.3A).  
All four vaccinated groups of mice had significantly higher levels of IgG serum antibodies 
specific to RB51 total antigens (Fig. 6.2B), as well as significantly higher levels of RB51-
specific IgG, IgM and IgA antibodies in the intestinal secretions (Fig. 6.3B) than the saline 
inoculated control mice. There was no difference in the levels of RB51-specific antibodies 
among the different groups (Fig. 6.2B and 6.3B). 
 
Induction of antigen-specific cell-mediated immune responses following oral prime-boost 
immunization with gamma-irradiated B. neotomae and/or gamma-irradiated B. abortus 
RB51 
Significantly higher proportions of antigen-specific IFN-γ-and TNF-α-secreting CD4+ and 
CD8+ T cells were detected in all vaccinated groups when compared to the respective 
unstimulated controls and the saline inoculated control group (Fig. 6.4A and B). 
Stimulation of the splenocytes with irradiated RB51 resulted in the induction of 
significantly increased proportions of RB51-specific CD4+ T cells secreting IFN-γ and 
TNF-α in mice immunized with IRRB51 than the other vaccinated groups (Fig. 6.4A and 




CD8+ T cells specific to RB51 and those that were specific to B. neotomae among the 
different vaccinated groups (Fig. 6.4A and B).  
 
Protective efficacy against intra-peritoneal challenge with virulent B. abortus 2308 
following oral prime-boost immunization with gamma-irradiated B. neotomae and/or 
gamma-irradiated B. abortus RB51 
Immunization with IRBn and IRBn/RB51 resulted in a significant reduction in the number 
of bacterial CFUs of the virulent Brucella in the spleen after i.p. challenge with virulent B. 
abortus 2308 (Table. 6.2). In contrast, the bacterial burden in the spleen of mice immunized 
with IRRB51 was not significantly different from that of the saline inoculated control group 
(Table. 6.2). All three vaccinations resulted in reduced bacterial load of virulent strain in 
livers (Table. 6.2). The bacterial loads in lungs of the vaccinated mice were not statistically 
different from that of the saline group (Table. 6.2). 
 
Induction of antigen-specific antibody immune responses following oral homologous 
prime-boost immunization with different vaccine doses of gamma-irradiated B. neotomae  
We examined the effect of different doses of gamma-irradiated B. neotomae vaccine on 
induction of specific immune responses and protection against parenteral and mucosal 
challenge with virulent B. abortus.  Three different doses, 1×109 CFU-equiv. or 1×1010 
CFU-equiv. or 1×1011 CFU-equiv. of gamma-irradiated B. neotomae were tested in a 
prime-boost immunization strategy, consisting of a priming dose and two booster doses. 
Significantly increased levels of LPS-specific IgG antibodies at 1 and 2 weeks p.i. and 
LPS-specific IgM antibodies at 1 week p.i. were detected in the serum of the three 
vaccinated groups when compared to the saline inoculated control group (Fig. 6.5). In 
addition, mice vaccinated with the 1011 CFU-equiv. dose developed significantly increased 
levels of LPS-specific IgG antibodies in the serum at 1 week p.i. when compared to the 




Significantly higher levels of LPS-specific IgG and IgM antibodies in the intestinal 
secretions were present in all vaccinated mice (Fig. 6.6). Mice vaccinated with the 1011 
CFU-equiv. dose contained the highest levels of IgG, I M and IgA antibodies (Fig. 6.6).  
 
Induction of antigen-specific CMI following oral homologous prime-boost immunization 
with different vaccine doses of gamma-irradiated B. neotomae  
Upon in vitro stimulation of splenocytes with irradi ted B. neotomae and irradiated RB51, 
significantly higher proportions of IFN-γ secreting CD4+ and CD8+ T cells were detected 
in all vaccinated groups (Fig. 6.7A). Stimulation of splenocytes with irradiated RB51 
resulted in induction of significantly increased pro ortions of CD4+ and CD8+ T cells 
secreting IFN-γ in mice immunized with the 1011 CFU equiv. dose than the other groups 
(Fig. 6.7A). Significantly increased proportion of TNF-α secreting CD4+ and CD8+ T cells 
were detected upon stimulation of splenocytes of vaccin ted mice with specific antigens 
(Fig. 6.7B).  
 
Protective efficacy against intra-peritoneal and intra-nasal challenge with virulent B. 
abortus 2308 following oral homologous prime-boost immunization with different vaccine 
doses of gamma-irradiated B. neotomae  
Upon i.p. challenge with B. abortus 2308, significantly reduced bacterial loads were 
detected in spleens and livers of all vaccinated mice (Table. 6.3); mice immunized with the 
1011 CFU-equiv. dose showed the highest resistance with an average of 2.61 log and 2.49 
log reduction in spleens and livers, respectively.  Although the lung bacterial burden in all 
vaccinated groups was lower than that of the saline inoculated control group, the difference 
was not statistically significant (Table. 6.3); again, mice immunized with the 1011 CFU-
equiv. dose showed the highest resistance in lungs with a 1.47 log difference in bacterial 
load compared to those of the saline control group.  
Following intranasal challenge with B. abortus 2308, the bacterial CFUs in lungs and 




those of mice inoculated with saline (Table. 6.4). Reduced bacterial burden was also 
detected in the livers of mice immunized with the 1011 CFU-equiv. dose, though the 
reduction was not statistically significant from the saline group (Table. 6.4). 
 
Discussion  
Vaccination by oral route is a desirable method to induce acquired immunity against 
infectious diseases in humans as well as animals. In most human brucellosis cases, the 
infection is acquired through mucosal routes. However, human brucellosis is a systemic 
disease, where the bacteria penetrate the epithelial barrier, spread to mononuclear 
phagocytic system, and affect different organ system  [19]. Therefore, an effective oral 
brucellosis vaccine must induce systemic immunity. Several research groups previously 
used live attenuated Brucella strains as oral vaccines [18,20,21]. The inherent safety risks 
associated with bacterial replication may preclude the use of attenuated Brucella strains as 
live vaccines for human brucellosis. Our previous re earch demonstrated that gamma-
irradiated B. abortus strain RB51 and B. neotomae cannot replicate, but can induce 
protective antibody and CMI responses when used as vaccines to immunize mice by 
intraperitoneal route [11,12]. In this study, we asked if these vaccines can be administered 
by oral route to immunize mice against a challenge i fection with virulent B. abortus.  Our 
empirical selection to give multiple doses of the vaccine was driven by the currently 
recommended oral vaccination regimen for Salmonella typhi, the only oral bacterial 
vaccine in human use at present, which consists of 4 d ses at 1-day intervals [22]. We first 
examined the effect of prime-boost strategy on induction of immune responses and 
protection. Contrary to our initial hypothesis, priming with B. neotomae and boosting with 
B. abortus RB51, or vice versa, did not significantly change th ype of antibody and CMI 
responses. The only notable difference was that the mic  primed with B. abortus RB51 and 
boosted with B. neotomae did not develop significant levels of IgG1 antibodies specific to 
smooth LPS even at 2 weeks p.i. (Fig. 6.2A). It is interesting that priming with B. neotomae 
and boosting with B. abortus RB51 did not dampen the overall antibody response to mooth 




higher levels of smooth LPS-specific IgG2a and IgG2b antibodies at 1 week p.i., but the 
difference disappeared by 2 weeks p.i. (Fig. 6.2A). Majority of the surface proteins of 
Brucella spp. are highly conserved [23]. Therefore, it is not surprising that all tested 
vaccination regimens induced similar levels of RB51-specific antibodies in serum and 
intestinal secretions (Fig. 6.2B and 6.3B).   
Our detection of smooth LPS- and RB51-specific antibod es in the intestinal secretions of 
the vaccinated mice is suggestive of induction of amucosal immune response. However, 
the role of mucosal immunity in protection against brucellosis remains to be determined.  
A recent study demonstrated that mice orally vaccinated with live attenuated strains B. 
abortus RB51 or B. melitensis ∆znuA developed both systemic and mucosal Th1 as well 
as Th17 responses, but the Th17 responses played a role only in the B. abortus RB51-
induced protection [21]. The important role of Th1 responses in protection against 
brucellosis is well-documented in the literature [4]. All the vaccines tested in our study 
induced antigen-specific CD4+ and CD8+ T cells that secrete IFN-γ or TNF-α in spleens, 
suggesting the generation of a systemic Th1 response.     
In mouse brucellosis models, reduced bacterial loadin spleens, livers or both, of the 
vaccinated mice compared to those of the unvaccinated nimals is the generally used 
criterion for determining the vaccine-induced protective responses [24-26]. Based on this 
standard, only mice vaccinated with B. neotomae and IRBn/RB51, but not RB51, 
developed significant protection against intraperitoneal challenge with B. abortus 2308  
(Table 6.2). This was corroborated by the reduced bacterial burden in lungs also, though 
the reduction was not significantly different from the unvaccinated mice. This observation 
suggests that oral vaccines that elicit antibodies to smooth LPS are effective in affording 
protection in mouse brucellosis models. Since the protection induced by the IRBn/RB51 
vaccination regimen was not different from that of the IRBn vaccine, we then examined 
the effect of reduced dose of B. neotomae vaccine on induction of protection. All tested 
vaccine doses induced significant protection against the intraperitoneal challenge.  
However, only the highest dose provided significant protection against the intranasal 
challenge. Why the lower doses of vaccine could not pr vide protection against the 




was a trend of reduced serum and mucosal antibody levels to smooth LPS with reduced 
vaccine dose, which could have contributed to this difference. A thorough analysis of T 
cell responses in lungs following immunization and challenge may reveal important 
differences between the different vaccination doses. Additionally, determining the effect 
of different vaccine doses on the persistence of the vaccine bacteria in lymphoid organs 
may also yield information relevant to understanding the magnitude of immune responses 
induced at different mucosal sites. Our preliminary study indicates that following oral 
inoculation of  mice with 1011 CFU-equivalent of gamma-irradiated B. neotomae, the 
bacterial DNA could be detected in mesenteric lymph nodes and in spleens by day 1 and 
persisted there for at least three days (Fig. 6.1).     
In conclusion, these studies demonstrate the feasibility of using gamma-irradiated B. 
neotomae as oral vaccine to induce protection against both parenteral and mucosal 
challenge with virulent Brucella spp. This type of vaccine is a safer alternative to live 
vaccines for human brucellosis.  Future studies should f cus on formulating the vaccine to 
bypass the acidic conditions of human stomach, assessing the shelf-life of the vaccines and 
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Table 6.1. Immunization schedule. 







Day 3, 7 and 10 
IRRB51 Irradiated RB51 Irradiated RB51 
IRBn Irradiated B. neotomae Irradiated B. neotomae 
IRRB51/Bn Irradiated RB51 Irradiated B. neotomae 






Table 6.2. Protection against intra-peritoneal challenge with virulent B. abortus 2308 
following oral prime-boost immunization of mice with gamma-irradiated B. neotomae 
and/or gamma-irradiated B. abortus RB51. 
 Vaccine 
 (gamma-irradiated) 
Bacterial load in 
log
10







 CFU in 
spleen 
None (saline) 4.66 ± 0.77 - 
RB51 4.03 ± 0.93** 0.63 
B. neotomae 2.55 ± 0.21* 2.11 




 CFU in 
liver 
None (saline) 3.61 ± 0.11 - 
RB51 2.82 ± 0.32* 0.79 
B. neotomae 2.53 ± 0.21* 1.08 




 CFU in 
lung 
None (saline) 2.59 ± 1.18 - 
RB51 2.71 ± 0.53 - 
B. neotomae 1.85 ± 0.46** 0.74 
B. neotomae/RB51 1.70 ± 0.28** 0.89 
 
a  Units of protection were calculated by subtracting the mean log10 CFU for a vaccinated 
group from the mean log10 CFU of the corresponding saline control group. 
* Significantly different from the corresponding saline group (P < 0.05). 





Table 6.3. Protection against intra-peritoneal challenge with virulent B. abortus 2308 
following oral homologous prime-boost immunization of mice with multiple vaccine doses 
of gamma-irradiated B. neotomae. 
 Vaccine 
 (gamma-irradiated) 
Bacterial load in 
log
10







 CFU in 
spleen 
None (saline) 6.53 ± 0.03 - 
B. neotomae 10
9
 5.27 ± 0.53* 1.26 
B. neotomae 10
10
 5.18 ± 0.50* 1.35 
B. neotomae10
11




 CFU in 
liver 
None (saline) 4.48 ± 0.19 - 
B. neotomae 10
9
 3.47 ± 0.27* 1.01 
B. neotomae 10
10
 3.69 ± 0.61* 0.79 
B. neotomae10
11




 CFU in 
lung 
None (saline) 3.61 ± 0.88 - 
B. neotomae 10
9
 3.47 ± 0.32** 0.14 
B. neotomae 10
10
 3.16 ± 0.28** 0.45 
B. neotomae10
11
 2.14 ± 1.15** 1.47 
 
a  Units of protection were calculated by subtracting the mean log10 CFU for a vaccinated 
group from the mean log10 CFU of the corresponding saline control group. 
* Significantly different from the corresponding saline group (P < 0.05). 





Table 6.4. Protection against intra-nasal challenge with virulent B. abortus 2308 following 
oral homologous prime-boost immunization of mice with multiple vaccine doses of 
gamma-irradiated B. neotomae. 
 Vaccine 
 (gamma-irradiated) 
Bacterial load in 
log
10







 CFU in 
spleen 
None (saline) 5.10 ± 0.61 - 
B. neotomae 10
9
 5.23 ± 0.74 - 
B. neotomae 10
10
 5.34 ± 0.39 - 
B. neotomae10
11




 CFU in 
liver 
None (saline) 3.33 ± 0.65 - 
B. neotomae 10
9
 3.36 ± 0.48 - 
B. neotomae 10
10
 3.25 ± 0.63** 0.08 
B. neotomae10
11




 CFU in 
lung 
None (saline) 5.30 ± 0.12 - 
B. neotomae 10
9
 5.40 ± 0.21 - 
B. neotomae 10
10
 4.67 ± 0.94** 0.63 
B. neotomae10
11
 4.08 ± 0.91* 1.22 
 
a  Units of protection were calculated by subtracting the mean log10 CFU for a vaccinated 
group from the mean log10 CFU of the corresponding saline control group. 
* Significantly different from the corresponding saline group (P < 0.05). 







Figure 6.1. Persistence of gamma-irradiated B. neotomae in mouse spleens and mesenteric 
lymph nodes as detected by real-time quantitative PCR. A group of 8 female BALB/c mice 
were orally administered with 1×1011 CFU-equivalent of gamma-irradiated B. neotomae.  
On days 1 and 3 post-vaccination, 4 mice from the group were euthanized and their spleens 
and mesenteric lymph nodes were collected aseptically.  The organs were homogenized in 
PBS and DNA from the homogenates were extracted using a commercial kit (DNeasy 
Blood and Tissue Kit, Qiagen Inc.). Quantification f B. neotomae DNA in the samples 







Figure 6.2. ELISA detection of (A) B. neotomae-specific antibodies, and (B) RB51-specific 
IgG antibody in serum of mice vaccinated with gamma-irradiated prime-boost regimens. 
Mice were vaccinated with gamma-irradiated RB51, B. neotomae, RB51/B. neotomae and 




weeks after the last booster vaccination, were diluted 1 in 200 and assayed for the presence 
of (A) LPS-specific IgG, IgM, IgG1, IgG3, IgG2a and IgG2b and (B) RB51-specific 
antibodies. Results are shown as mean ± standard deviation (n = 4) of absorbance at 450 nm 
of the color developed. *Significantly different from the corresponding saline group at 
week 1 (P < 0.05). **Significantly different from the corresponding saline group at week 
2 (P < 0.05). ff Significantly different from the corresponding vaccination groups at week 









Figure 6.3. ELISA detection of IgG, IgM, IgA antibodies specific to (A) B. neotomae LPS, 
and (B) RB51 total antigens in the intestinal secretions of mice vaccinated with gamma-
irradiated prime-boost regimens.  Mice were vaccinated with gamma-irradiated RB51, B. 
neotomae, RB51/B. neotomae and B. neotomae/RB51, or inoculated with saline. Intestinal 
secretions were collected at 2 weeks after the last booster vaccination, were diluted 1 in 10 
and assayed for the presence of (A) LPS-specific and (B) RB51-specific antibodies. Results 
are shown as mean ± standard deviation (n = 4) of absorbance at 450 nm of the color 
developed. *Significantly different from the corresponding saline group (P < 0.05). ff 






Figure 6.4. Flow cytometric analysis showing the percentage of (A) interferon-γ secreting, 
and (B) tumor necrosis factor-α secreting CD4+ and CD8+ T cells in the spleens of BALB/c 
mice immunized with gamma-irradiated prime-boost regimens. Mice were vaccinated 
with RB51, B. neotomae, RB51/B. neotomae and B. neotomae/RB51, or inoculated with 
saline. Splenocytes from the vaccinated mice were stimulated with media (unstimulated), 
gamma-irradiated B. neotomae and gamma-irradiated RB51 and the percentage of IFN-γ 
secreting and TNF-α secreting CD4+ and CD8+ T cells were analyzed by flow-cytometry. 
*Significantly different from the corresponding unstimulated control (P < 0.05). ff 
Significantly different from the corresponding vaccination groups with irradiated RB51 





Figure 6.5. ELISA detection of IgG and IgM antibodies specific to B. neotomae LPS in 
serum of mice vaccinated with different doses of gamma-irradiated B. neotomae. Mice 
were vaccinated with 109 CFU-equivalent or 1010 CFU-equivalent or 1011 CFU-equivalent 
of gamma-irradiated B. neotomae, or inoculated with saline.Serum samples were colle ted 
at 1 and 2 weeks after the last booster vaccination, were diluted 1 in 200 and assayed for 
the presence of LPS-specific antibodies. Results are shown as mean ± standard deviation 
(n = 4) of absorbance at 450 nm of the color developed. *Significantly different from the 
corresponding saline group at week 1 (P < 0.05). **Significantly different from the 
corresponding saline group at week 2 (P < 0.05). ff Significantly different from the 







Figure 6.6. ELISA detection of IgG, IgM and IgA antibodies specific to B. neotomae LPS 
in the intestinal secretions of mice vaccinated with different doses of gamma-irradiated B. 
neotomae. Mice were vaccinated with 109 CFU-equivalent or 1010 CFU-equivalent or 1011 
CFU-equivalent of gamma-irradiated B. neotomae, or inoculated with saline. Intestinal 
secretions were collected at 2 weeks after the last booster vaccination, were diluted 1 in 10 
and assayed for the presence of LPS-specific antibodies. Results are shown as 
mean ± standard deviation (= 4) of absorbance at 450 nm of the color developed. 
*Significantly different from the corresponding saline group (P < 0.05). ff Significantly 







Figure 6.7. Flow cytometric analysis showing the percentage of (A) interferon-γ secreting, 




mice immunized with different doses of gamma-irradiated B. neotomae. Mice were 
immunized with 109 CFU-equivalent or 1010 CFU-equivalent or 1011 CFU-equivalent of 
gamma-irradiated B. neotomae, or inoculated with saline. Splenocytes from the vaccinated 
mice were stimulated with media (unstimulated), gamma-irradiated B. neotomae and 
gamma-irradiated RB51 and the percentage of IFN-γ secreting and TNF-α secreting CD4+ 
and CD8+ T cells were analyzed by flow-cytometry. (C) Representative figure of the flow 
cytometric analysis. *Significantly different from the corresponding unstimulated control 
within a vaccination group (P < 0.05). aa Significantly different from the corresponding 
vaccination groups with irradiated B. neotomae stimulation (P < 0.05). ff Significantly 
different from the corresponding vaccination groups with irradiated RB51 stimulation 





CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS 
Research conducted in this dissertation was aimed at developing improved vaccines for 
brucellosis using B. abortus RB51 and B. neotomae.  Th1 type of cell-mediated immunity 
is crucial for vaccine-induced protection against brucellosis.  In addition, antibodies to the 
O-polysaccharide (O-PS) of the lipopolysaccharide (LPS) play a protective role against 
infections with B. abortus, B. melitensis and B. suis. B. abortus RB51, an attenuated rough 
strain, is used as a live vaccine in the control of bovine brucellosis. Animals do not produce 
antibodies to the O-PS in response to the RB51 vaccin tion. We asked if engineering RB51 
to synthesize O-PS and smooth LPS would enhance its vaccine efficacy. In this regard, we 
first tested whether overexpression of two glycosyltransferases WbkA and WbkE, which 
are essential for O-PS synthesis in Brucella, in RB51 results in O-PS synthesis and confers 
it a smooth phenotype. Quite unexpectedly, we found that overexpression of wbkA in RB51 
leads to an extreme clumpy phenotype and synthesis of an exopolysaccharide (EPS). Our 
study, for the first time, demonstrates the novel role of wkbA in EPS synthesis. This finding 
extends the growing evidence for the genetic competenc  of Brucella to synthetize EPS. 
Lectin binding studies demonstrated that the exopolysaccharide contains mannose, 
galactose, N-acetylglucosamine and N-acetylgalactosmine. The EPS production resulted 
in enhanced adherence of the bacteria to polystyrene matrices. However, EPS did not 
change the attenuation characteristic of strain RB51WbkA. Also, our results indicate that 
EPS has minimal, if any, role in modulating immune responses in mice; the RB51WbkA 
vaccine induced a similar level of protective response against virulent B. abortus challenge 
as strain RB51. Future studies should focus on the translational implication of this finding; 
studies to determine how EPS affects bacterial fitness under different environmental 




Purification and structural characterization of the EPS would also aid in the understanding 
of its possible function during infection. Lastly, aswbkA gene is a target of quorum sensing 
(QS)-regulators, it would be interesting to investiga e the role of QS-regulators in altering 
the expression of wbkA under specific conditions and the effect on EPS synthesis. From 
practical point of view, it would be interesting to examine if EPS production has any benefit 
to RB51 vaccine manufacturing, such as increased stability during lyophilization or 
increased shelf-life of the vaccine. 
The second objective was to determine whether increasing the amount of bactoprenol 
primed molecules in strain RB51WboA would increase the expression of O-PS and restore 
the smooth phenotype. Gene wbkF encodes undecaprenyl-glycosyltransferase enzyme that 
catalyzes the transfer of an acetyl-aminosugar to undecaprenylphosphate leading to the 
priming of this carrier for O-PS polymerization. Interestingly, B. ovis contains a non-
functional wbkF while B. canis carries a deletion in the region encompassing wbkF and 
wbkD. In our study (Chapter 5), we overexpressed the wbkF gene in strain RB51WboA to 
generate strain RB51WboAKF. Our study indicates that strain RB51WboAKF produces 
smooth LPS but does not exhibit smooth colony phenotype or increased virulence. 
Immunization with strain RB51WboAKF induces enhanced antigen-specific antibody as 
well as cell-mediated responses, primarily of Th1 type, in mice. Also, strain 
RB51WboAKF confers a superior level of protection against virulent B. abortus 2308 and 
B. melitensis 16M than strain RB51 and RB51WboA in mice.  These results are extremely 
promising and suggest that strain RB51WboAKF could be a more efficacious vaccine than 
its parent strain in natural hosts.  Future studies should focus on determining the vaccine 
efficacy of RB51WboAKF in cattle and small ruminants against infections with virulent 
Brucella spp. An important consideration is that safety concer s may preclude the use of 
antibiotic resistant plasmids in vaccines. Alternate strategies to ensure plasmid 
maintenance need to be exploited for increasing the saf ty profile of the vaccine. One way 
to engineer an antibiotic resistance-marker free system is to construct an auxotrophic 
bacterial strain by mutating an essential gene. The growth of this strain will be restored by 
complementation or introduction of a plasmid carrying the deleted gene. Another important 




antibodies. Most of the serodiagnostic assays for brucellosis are based on the detection of 
anti-O-PS antibodies. To prevent confounding serology, we will need alternate methods 
for differentiation of vaccinated animals from animals infected with wild-type Brucella 
spp. Previously, efforts have been directed towards modifying the O-PS of Brucella to 
express a distinct immunogenic epitope that does not react with the antibodies from 
naturally infected animals. Also, recent unpublished data proposes that O-PS of Brucella 
is capped by a M-specific tetrasaccharide sequence. Therefore, it is feasible to designing 
appropriate assays that utilize specific oligosacchride antigens for the detection of 
antibodies in animals infected with wild-type Brucella. Our present study also suggests 
that, in addition to wboA gene, mutations affecting expression of several other genes 
involved in the synthesis of O-PS and smooth LPS contribute to rough phenotype of strain 
RB51.  Identification of the other contributing mutations in RB51 will help to fully reveal 
the biosynthetic pathway of Brucella smooth LPS and its regulation in response to different 
microenvironments. 
Human brucellosis is a major public health concern in several developing countries. 
Emergence of new foci of zoonotic Brucella spp. around the world has significantly 
changed the epidemiology of human brucellosis. There is a need to develop a safe and 
effective vaccine for use in humans. The third objectiv  of the current study was to test the 
ability of orally inoculated gamma-irradiated B. neotomae and B. abortus RB51 in a prime-
boost immunization approach to induce antigen-specific humoral and cell mediated 
immunity and protection against challenge with virulent B. abortus 2308. Our results 
indicated that heterologous prime-boost vaccination with B. abortus RB51 and B. 
neotomae and homologous prime-boost vaccination of mice with B. neotomae led to the 
production of serum and mucosal antibodies specific to the smooth LPS. Also, all oral 
vaccination regimens induced antigen-specific CD4+ and CD8+ T cells capable of secreting 
IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated with B. neotomae 
showed the highest level of resistance against virulent B. abortus 2308 colonization in 
spleen and liver. The next set of experiments with different doses of B. neotomae showed 
that all tested doses of 109, 1010 and 1011 CFU-equivalent conferred significant protection 




equivalent of B. neotomae was required for affording protection against intra asal 
challenge as shown by the reduced bacterial colonization in spleens and lungs. Future 
studies should focus on a comprehensive analysis of T cell responses in lungs following 
immunization and challenge to reveal any important differences between the different 
booster-dose combinations. Additionally, determining the persistence of gamma-irradiated 
bacteria in lymphoid organs will be important to enha ce our understanding of the 
magnitude of immunity induced at different mucosal ites following vaccination with 
different doses. An equally important future direction would be to study the effect of the 
number of boosters of the highest tested dose on the protective efficacy against mucosal 
and systemic challenge. Also, efforts should be focused on the formulation of vaccine to 
overcome the physiological barriers at mucosal routes including the acidic conditions of 
human stomach, and determination of the shelf-life of the gamma-irradiated vaccine and 
the duration of the vaccine-induced immune response.  
Taken together, our studies discovered the novel rol  of wbkA in EPS synthesis in Brucella. 
Also, the recombinant strain RB51WboAKF is more effective than its parent strain in 
inducing protection in mice. The last part of the present research demonstrates the 
feasibility of using gamma-irradiated B. neotomae as an effective and safe oral vaccine to 
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